{
    "results": [
        [
            0,
            "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"lab findings\"],\n  \"FREQUENCY\": [\"progressive mobilization\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            1,
            "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.",
            [
                " {\n  \"DRUGS\": [\"trabectedin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"toxicity\", \"rhabdomyolysis\"],\n  \"FREQUENCY\": [\"fourth course\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patient with retroperitoneal liposarcoma\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"heavy toxicity\", \"rhabdomyolysis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "rhabdomyolysis",
                        "retroperitoneal liposarcoma",
                        "adverse event"
                    ],
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            2,
            "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"abdominal mass\", \"surgical removal\", \"complete margin negative (R0) resection\"],\n  \"FREQUENCY\": [\"In May 2009\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"he\"],\n  \"DURATION\": [\"In May 2009\"],\n  \"SEX\": [\"he\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            3,
            "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"lesion size\", \"pre-aortic seat of the retro-peritoneum space\"],\n  \"FREQUENCY\": [\"in spite of chemotherapy\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"lesion progressed rapidly\", \"extending\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            4,
            "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.",
            [
                " {\n  \"DRUGS\": [\"trabectedin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"The patient\",\n  \"DURATION\": [\"during treatment\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            5,
            "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"drug interactions\", \"number and types of chemotherapeutic drugs\", \"narrow therapeutic index\", \"prolonged life expectancy\", \"ancillary medications\", \"cancer-related syndromes\", \"treatment-induced toxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"cancer patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"drug interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer",
                        "cancer-related syndromes",
                        "treatment-induced toxicity"
                    ]
                }
            ]
        ],
        [
            6,
            "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"chokeberry\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"juice\"],\n  \"COHORT\": [\"Male, 65-year-old patient\"],\n  \"DURATION\": [\"Chronic use\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"65-year-old\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Hypertension, hyperlipidemia, type 2 diabetes mellitus, and chronic kidney disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Commercial preparation of chokeberry juice\"]\n}",
                {
                    "Extraction process": [
                        "chokeberry juice"
                    ]
                }
            ]
        ],
        [
            7,
            "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"medicinal cannabis\"],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"complexity, health risks\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            8,
            "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.",
            [
                " {\n  \"DRUGS\": [\"cannabis\"],\n  \"HERB NAME\": [\"cannabis\"],\n  \"STUDY\": \"Pharmacogenomics test\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patient\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"chronic back pain\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "chronic back pain"
                    ]
                }
            ]
        ],
        [
            9,
            "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].",
            [
                " {\n  \"DRUGS\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"],\n  \"STUDY\": \"Treatment strategies for PD\",\n  \"PARAMETER\": [\"neuronal death\", \"dopamine concentrations\", \"movement control\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"PD\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD"
                    ],
                    "Drug": [
                        "carbidopa-levodopa",
                        "ropinirole",
                        "entacapone"
                    ]
                }
            ]
        ],
        [
            10,
            "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"cannabis\"],\n  \"STUDY\": \"case studied\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"a patient\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "adverse drug events"
                    ]
                }
            ]
        ],
        [
            11,
            "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a patient's medical history\",\n  \"PARAMETER\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"history of nicotine and alcohol dependence\", \"mild kidney disease\", \"chronic neck, back, and shoulder pain\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"A single patient\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"spinal stenosis\", \"vitamin D deficiency\", \"nicotine and alcohol dependence\", \"mild kidney disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD",
                        "spinal stenosis",
                        "vitamin D deficiency",
                        "frequent falls",
                        "mild kidney disease",
                        "chronic neck, back, and shoulder pain"
                    ]
                }
            ]
        ],
        [
            12,
            "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).",
            [
                " {\n  \"DRUGS\": [\"carbidopa-levodopa\"],\n  \"PARAMETER\": [\"tremors\"],\n  \"FREQUENCY\": [\"early in the morning\"]\n}",
                {
                    "Drug": [
                        "carbidopa-levodopa"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            13,
            "However, his PCP determined that additional medication for pain control was warranted.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"pain control\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"this patient\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            14,
            "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"study results\",\n  \"PARAMETER\": [\"discrepancies\", \"pain models\", \"healthy subjects\", \"patients\", \"routes of administration\", \"sources of the product\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "pain",
                        "healthy"
                    ]
                }
            ]
        ],
        [
            15,
            "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational\",\n  \"PARAMETER\": [\"dopamine levels\", \"neurotransmitter levels\"],\n  \"FREQUENCY\": [\"when CB1Rs are activated\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CB1Rs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CB1Rs"
                    ],
                    "Parameter": [
                        "dopamine levels"
                    ]
                }
            ]
        ],
        [
            16,
            "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a patient's case\",\n  \"PARAMETER\": [\"PGx results\", \"dopamine levels\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"one patient\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COMT\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            17,
            "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].",
            [
                " {\n  \"DRUGS\": [\"cannabis\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"previous study\",\n  \"PARAMETER\": [\"reactions to cannabis use\", \"hallucinations\"],\n  \"FREQUENCY\": [\"one out of five patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with PD\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hallucinations\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PD",
                        "hallucinations"
                    ],
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            18,
            "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].",
            [
                " {\n  \"DRUGS\": [\"morphine\"],\n  \"PARAMETER\": [\"genetic results\", \"pain status\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Pathology": [
                        "pain"
                    ],
                    "Drug": [
                        "morphine"
                    ]
                }
            ]
        ],
        [
            19,
            "The authors want to thank Katie Meyer for her assistance.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"nitric oxide production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            20,
            "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"increased rate of conventional medicines integrated with CAM for treatment\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"the world\",\n  \"DURATION\": [\"during the past two decades\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "the past two decades"
                    ]
                }
            ]
        ],
        [
            21,
            "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CAM\"],\n  \"STUDY\": \"Survey\",\n  \"PARAMETER\": [\"Cancer patients\", \"93.4%\"],\n  \"FREQUENCY\": [\"2009-2010\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Cancer patients\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            22,
            "In South Korean population reported a range from 29% to 83% [5].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Reported range in South Korean population\",\n  \"PARAMETER\": [\"Range\", \"29%\", \"83%\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"South Korean population\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"South Korean\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "South Korean"
                    ]
                }
            ]
        ],
        [
            23,
            "An important fact is that most of these affected drugs have very narrow therapeutic indices.",
            [
                " {\n  \"DRUGS\": [\n    \"ibuprofen\",\n    \"celecoxib\",\n    \"rofecoxib\",\n    \"naproxen\",\n    \"diclofenac\",\n    \"phenylbutazone\",\n    \"tenoxicam\",\n    \"ketoprofen\",\n    \"etodolac\",\n    \"tolmetin\",\n    \"aspirin\",\n    \"acetaminophen\",\n    \"ibuprofen lysine\",\n    \"celecoxib sodium\"\n  ],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\n    \"cyclooxygenase-1 (COX-1)\",\n    \"cyclooxygenase-2 (COX-2)\",\n    \"lipid peroxidation\",\n    \"reduced glutathione (GSH)\",\n    \"malondialdehyde (MDA)\",\n    \"nitric oxide (NO)\",\n    \"prostaglandin E2 (PGE2)\",\n    \"prostaglandin F2\u03b1 (PGF2\u03b1)\",\n    \"interleukin-1\u03b2 (IL-1\u03b2)\",\n    \"interleukin-6 (IL-6)\",\n    \"tumor necrosis factor-\u03b1 (TNF-\u03b1)\",\n    \"nitrite\",\n    \"nitrate\"\n  ],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\n    \"cyclooxygenase-1 (COX-1)\",\n    \"cyclooxygenase-2 (COX-2)\",\n    \"lipid peroxidase\",\n    \"reduced glutathione reductase\",\n    \"nitric oxide synthase (iNOS)\",\n    \"cyclooxygenase-2 (COX-2) mRNA\"\n ",
                {}
            ]
        ],
        [
            24,
            "To date an increasing number of studies in evaluating HDIs have been reported [11].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"studies in evaluating HDIs\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            25,
            "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"some important herb products\"],\n  \"STUDY\": [\"pharmacogenomics studies\", \"clinic studies\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "pharmacogenomics studies",
                        "clinic study"
                    ]
                }
            ]
        ],
        [
            26,
            "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).",
            [
                " {\n  \"DRUGS\": [\"thiopurine\"],\n  \"STUDY\": \"associated study\",\n  \"PARAMETER\": [\"hypoglycemic effect\"],\n  \"FREQUENCY\": [\"P = 0.001, FDR P = 0.043\"],\n  \"TARGET\": [\"thiopurine S-methyltransferase (TPMT) gene\"]\n}",
                {
                    "Parameter": [
                        "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            27,
            "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"traditional hypoglycemic herbs\"],\n  \"STUDY\": \"association study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"clinical effect\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "rs1142345"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            28,
            "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe given text does not contain any information about herbs, cohort, durations, frequencies, sexes, ages, ethnic groups, pathologies, or extraction processes. It only mentions specific drugs and their interaction with COX-1 and COX-2 enzymes.",
                {
                    "Parameter": [
                        "AUC: concentration-time curve"
                    ]
                }
            ]
        ],
        [
            29,
            "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"increase in utilization of herbal remedies over the last decade\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"no information provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            30,
            "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Faangum\", \"Sasanemasa/Sesemasa or Esisimansa\", \"Lifui\", \"Akoko\"],\n  \"STUDY\": \"Description of local names for a shrub\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Faangum",
                        "Sasanemasa/Sesemasa",
                        "Esisimansa",
                        "Lifui",
                        "Akoko"
                    ]
                }
            ]
        ],
        [
            31,
            "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [\"about 70% of xenobiotics and other endogenous substances\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP450 family of enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "cytochrome P450 (CYP450)"
                    ]
                }
            ]
        ],
        [
            32,
            "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Newbouldia laevis\", \"Cassia abbreviata\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19 activities\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"]\n}",
                {
                    "Extraction process": [
                        "extracts"
                    ],
                    "Herb name": [
                        "Newbouldia laevis",
                        "Cassia abbreviata"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9",
                        "CYP2C19"
                    ]
                }
            ]
        ],
        [
            33,
            "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Linear regression analysis\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": \"Non-targeted approach\"\n}",
                {}
            ]
        ],
        [
            34,
            "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal extracts\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"intestinal absorption\", \"plasma concentration\", \"% yield\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"weight of original starting material\", \"weight extracted powdered material\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"soluble extract available in the GIT tract\"]\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            35,
            "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"public interest in herbal medicinal remedies\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "DDI studies"
                    ]
                }
            ]
        ],
        [
            36,
            "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"these herbals\"],\n  \"STUDY\": \"no specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"chronically\"],\n  \"HERB PART\": [\"not specified\"],\n  \"COHORT\": \"consumers\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"deleterious\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            37,
            "Extraction was performed using water to mimic the indigenous mode of extraction.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"water\"],\n  \"STUDY\": \"extraction process\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"water\"]\n}",
                {}
            ]
        ],
        [
            38,
            "[44].",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"400 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            39,
            "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Phytochemical analysis\",\n  \"PARAMETER\": [\"regeneration system\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"serial dilutions\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"NADP Phytofingerprinting\", \"Waters Acquity UPLC system\", \"Acquity BEH C18 column\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector\", \"ESI probe\"]\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "extracts"
                    ],
                    "Target": [
                        "NADP"
                    ]
                }
            ]
        ],
        [
            40,
            "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Discussion\",\n  \"PARAMETER\": [\"HDI\", \"In vitro-in vivo-extrapolation\", \"Drug-Drug Interaction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            41,
            "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of study about SLC22 family members\",\n  \"PARAMETER\": [\"SLC22 family members\", \"OATs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"SLC22 family members\", \"OATs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "SLC22",
                        "OATs"
                    ]
                }
            ]
        ],
        [
            42,
            "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research study\",\n  \"PARAMETER\": [\"Oat1\", \"Oat3\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Oat1\", \"Oat3\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Oat1",
                        "Oat3"
                    ]
                }
            ]
        ],
        [
            43,
            "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Discussion of pharmacokinetic profile of Danshen components\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"families: SLC22 and SLC21, OATs\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "transporter families",
                        "the OATs"
                    ],
                    "Herb name": [
                        "Danshen components"
                    ]
                }
            ]
        ],
        [
            44,
            "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.",
            [
                " {\n  \"DRUGS\": [\"gliclazide\"],\n  \"HERB NAME\": [\"St John's wort\"],\n  \"STUDY\": \"No specific study mentioned in the given text\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description of the cohort in the given text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"type 2 diabetes\"],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "gliclazide"
                    ],
                    "Herb name": [
                        "St John's wort"
                    ],
                    "Target": [
                        "CYP2C9"
                    ],
                    "Pathology": [
                        "type 2 diabetes"
                    ]
                }
            ]
        ],
        [
            45,
            "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"alternative medicines\"],\n  \"STUDY\": \"report\",\n  \"PARAMETER\": [\"31%\", \"diabetic patients\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"diabetic patients\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            46,
            "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Retrospective study\",\n  \"PARAMETER\": [\"urinary recovered dose\", \"percentage of urinary recovered dose\"],\n  \"FREQUENCY\": [\"96 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n\"Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96 hours after dose, respectively.\"\n\nHere, the study is about the identification and percentage of metabolites found in urine after a dose was administered. The parameters mentioned are \"urinary recovered dose\" and \"percentage of urinary recovered dose\". The frequency of the event is given as \"96 hours after dose\". There is no information about the herb name, drugs used, herb parts, cohort, duration, sex, age, amount, ethnic group, pathology, or target. Also, there is no information about the extraction process.",
                {}
            ]
        ],
        [
            47,
            "Elliot et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nAccording to Elliot et al., an in vitro study was conducted to investigate the binding affinity and IC50 values of a compound against the serotonin transporter. No information about drugs, herbs, frequencies, cohort, durations, ages, amounts, ethnic groups, or pathologies was provided in the given text. Additionally, no information about the extraction process of the compound was mentioned.",
                {}
            ]
        ],
        [
            48,
            "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic study\",\n  \"PARAMETER\": [\"CYP2C9*2\", \"CYP2C9*3\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9*2",
                        "CYP2C9*3"
                    ]
                }
            ]
        ],
        [
            49,
            "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"PCR study\",\n  \"PARAMETER\": [\"final reaction volume\", \"2.5 \u00d7 HotMasterMix\", \"human genomic DNA\", \"primer pairs\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcl\", \"20 \u03bcl\", \"approximately 250 ng\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            50,
            "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.",
            [
                " {\n  \"DRUGS\": [\"gliclazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"participants' diet (caffeine and grapefruit)\"],\n  \"FREQUENCY\": [\"day before until 2 days after taking gliclazide\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"participants\"],\n  \"DURATION\": [\"clinical trial\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "caffeine",
                        "grapefruit"
                    ],
                    "Drug": [
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            51,
            "(2003).",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"etodolac\", \"tenoxicam\", \"meloxicam\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"diclofenac sodium\", \"piroxicam sodium\", \"etodolac sodium\", \"tenoxicam sodium\", \"meloxicam sodium\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled trials\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"leukocyte count\", \"body temperature\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\", \"three times daily\", \"four times daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers and patients with osteoarthritis or rheumatoid arthritis\",\n  \"DURATION\": [\"4-6 weeks\", \"12 weeks\", \"24 weeks\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"Adults\", \"Elderly\"],\n  \"AMOUNT\": [\"200-400 mg\", \"400 mg\", \"200 mg\", \"100 mg\", \"50 mg\", \"10 mg\", \"20 mg\", \"5 mg\", \"10 mg\", \"2.5 mg\", \"1000 mg\", \"2000 mg\", \"400 mg\", \"100 mg\", \"50 mg\", \"20 mg\", \"5 mg\", \"10 mg\"],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"Asian\", \"Middle Eastern\"],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Rheumatoid arthritis\"],\n  \"TARGET\": [\"Cyclooxy",
                {}
            ]
        ],
        [
            52,
            "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.",
            [
                " {\n  \"DRUGS\": [\"glipizide\", \"tolbutamide\"],\n  \"STUDY\": \"clinical studies\",\n  \"PARAMETER\": [\"CL/Fs\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"carriers of the CYP2C9*3 allele\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9*3 allele"
                    ],
                    "Parameter": [
                        "CL/Fs"
                    ],
                    "Drug": [
                        "glipizide",
                        "tolbutamide"
                    ]
                }
            ]
        ],
        [
            53,
            "Park et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"AChE activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Acetylcholinesterase (AChE)\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nAccording to the provided text, the study was conducted in vitro, focusing on the acetylcholinesterase (AChE) enzyme as the target. No information about drugs, herbs, frequencies, herb parts, cohort, durations, sex, age, amounts, ethnic groups, or pathologies was mentioned in the text.",
                {}
            ]
        ],
        [
            54,
            "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Diagnostic study\",\n  \"PARAMETER\": [\"Serological titers\", \"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "acute cytomegalovirus (CMV",
                        "Epstein Barr virus (EBV"
                    ]
                }
            ]
        ],
        [
            55,
            "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Diagnostic test\",\n  \"PARAMETER\": [\"Antinuclear antibody (ANA)\", \"Smooth muscle antibody\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Modestly elevated smooth muscle antibody\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Antinuclear antibody (ANA",
                        "smooth muscle antibody"
                    ],
                    "Amount": [
                        "1 : 40",
                        "1 : 80"
                    ]
                }
            ]
        ],
        [
            56,
            "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"liver histology examination\",\n  \"PARAMETER\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"plasma cell rich interface hepatitis\", \"periportal hepatocyte apoptosis\", \"cholangiolar proliferation\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "chronic hepatitis",
                        "interface hepatitis"
                    ],
                    "Parameter": [
                        "periportal hepatocyte"
                    ]
                }
            ]
        ],
        [
            57,
            "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"clinicopathological features\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Case 1\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            58,
            "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"],\n  \"FREQUENCY\": [\"by the time of her presentation\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"asymptomatic\", \"abdominal pain\", \"fatigue\", \"lower extremity edema\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "right upper quadrant abdominal pain",
                        "fatigue",
                        "lower extremity edema"
                    ]
                }
            ]
        ],
        [
            59,
            "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"black cohosh\"],\n  \"STUDY\": [\"included\"],\n  \"PARAMETER\": [\"vasomotor symptoms of menopause\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"The American College of Obstetrics and Gynecology\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "American"
                    ],
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "menopause"
                    ]
                }
            ]
        ],
        [
            60,
            "This case culminated in liver failure despite discontinuation of the herbal supplement [4].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal supplement\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"liver failure\"],\n  \"FREQUENCY\": [\"despite discontinuation\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver failure\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "liver failure"
                    ]
                }
            ]
        ],
        [
            61,
            "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Immunology study\",\n  \"PARAMETER\": [\"immune mechanism\", \"hapten\", \"host cellular protein\", \"autoimmune response\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"autoimmune response\"],\n  \"TARGET\": [\"host cellular protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            62,
            "Naranjo [8] Causality Scale for Adverse Drug Reactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Discussion\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Adverse Drug Reactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Adverse Drug Reactions"
                    ]
                }
            ]
        ],
        [
            63,
            "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"black cohosh\"],\n  \"STUDY\": [\"case studies\", \"comparison\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients\", \"women\", \"postmenopausal women\"],\n  \"DURATION\": [\"long-term use\", \"chronic use\"],\n  \"SEX\": [\"women\"],\n  \"AGE\": [\"postmenopausal\"],\n  \"AMOUNT\": [\"high doses\", \"standard doses\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatotoxicity\", \"liver damage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "hepatotoxicity"
                    ]
                }
            ]
        ],
        [
            64,
            "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].",
            [
                " {\n  \"DRUGS\": [\"Levofloxacin\"],\n  \"STUDY\": \"used to treat\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bacterial infections\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Levofloxacin (LVFX)",
                        "third-generation fluoroquinolone antibiotic"
                    ]
                }
            ]
        ],
        [
            65,
            "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.",
            [
                " {\n  \"DRUGS\": [\"Relinqing\u00ae\"],\n  \"HERB NAME\": [\"Polygonum capitatum\"],\n  \"STUDY\": \"No study mentioned in text\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"usually\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with urinary system infection\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"urinary system infection\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "urinary system infection"
                    ],
                    "Herb name": [
                        "Relinqing\u00ae granule",
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            66,
            "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo distribution studies\",\n  \"PARAMETER\": [\"pharmacokinetic features of a drug\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vivo distribution studies"
                    ]
                }
            ]
        ],
        [
            67,
            "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.",
            [
                " {\n  \"DRUGS\": [\"puerarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\", \"20 ng/mL\", \"methanol\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"IS solution\", \"puerarin\", \"2% formic acid\", \"rat tissue homogenate\"]\n}",
                {
                    "Herb name": [
                        "puerarin"
                    ]
                }
            ]
        ],
        [
            68,
            "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).",
            [
                " {\n  \"DRUGS\": [\"42 mg\u00b7kg\"],\n  \"PARAMETER\": [\"mean\", \"standard deviation (SD)\"],\n  \"FREQUENCY\": []\n}",
                {}
            ]
        ],
        [
            69,
            "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"acceptable and accurate for analyzing LVFX in complex matrices\",\n  \"PARAMETER\": [\"LVFX\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            70,
            "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis\",\n  \"PARAMETER\": [\"integrities\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            71,
            "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Polygonum capitatum\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"LVFX distribution rate in tissue\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"LVFX\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            72,
            "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"at the pharmacokinetic level\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"our current studies\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            73,
            "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.",
            [
                " {\n  \"DRUGS\": [\n    \"celecoxib\",\n    \"ibuprofen\",\n    \"acetaminophen\",\n    \"diclofenac\",\n    \"naproxen\",\n    \"aspirin\",\n    \"ibuprofen lysine\",\n    \"celecoxib lysine\"\n  ],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and molecular docking studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\", \"pain\", \"arthritis\"],\n  \"TARGET\": [\"COX-2\", \"COX-1\", \"5-LOX\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article does not mention any herbs, but it does discuss several drugs and their interactions with COX-2, COX-1, and 5-LOX. The study type is in vitro and molecular docking studies. There is no mention of any specific parameters, frequencies, herb parts, cohorts, durations, sexes, ages, amounts, or ethnic groups.",
                {}
            ]
        ],
        [
            74,
            "KY[2017]073).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"400 mg celecoxib\", \"200 mg ibuprofen\", \"1000 mg acetaminophen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            75,
            "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.",
            [
                " {\n  \"DRUGS\": [\"people with diabetes receiving this combination\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"monitoring\",\n  \"PARAMETER\": [\"possible signs of reduced efficacy\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"people with diabetes\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            76,
            "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"KF\"],\n  \"STUDY\": [\"shown to possess\"],\n  \"PARAMETER\": [\"anticancer\", \"antioxidant\", \"anti-osteoporosis\", \"anti-inflammatory\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "the extract and constituents of KF"
                    ],
                    "Pathology": [
                        "anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"
                    ]
                }
            ]
        ],
        [
            77,
            "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"List of study materials was obtained from\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": \"\"\n}\n\n\"Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)\"\n\nNo entities were found in the given text.",
                {
                    "Extraction process": [
                        "Hanks balanced salt solution (HBSS)",
                        "HEPES",
                        "Trypsin EDTA",
                        "Sodium Pyruvate"
                    ],
                    "Drug": [
                        "Penicillin-streptomycin"
                    ]
                }
            ]
        ],
        [
            78,
            "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"STUDY\": \"assay for reversible inhibition\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Parental and transfected MDCK-II cells\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"200 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Amount": [
                        "10%",
                        "1%",
                        "1%",
                        "200 \u03bcL"
                    ],
                    "Extraction process": [
                        "FBS"
                    ],
                    "Herb name": [
                        "non-essential amino acids"
                    ]
                }
            ]
        ],
        [
            79,
            "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"roots of KF\"],\n  \"STUDY\": \"reports\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"roots\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe two major classes of compounds isolated from the roots of KF are:\n1. alkyl phenols\n2. triterpene glycosides (saponins)\n\nThis information is based on the report by Ali and Khan (2011). No further information about drugs, herbs, study type, parameters, frequencies, herb parts, cohort, durations, sexes, ages, amounts, ethnic groups, pathologies, or target enzymes/transporters was provided in the given text.",
                {
                    "Herb part": [
                        "the roots"
                    ],
                    "Herb name": [
                        "KF",
                        "alkyl phenols and triterpene glycosides (saponins)"
                    ]
                }
            ]
        ],
        [
            80,
            "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).",
            [
                " {\n  \"DRUGS\": [\"calcein-AM\", \"digoxin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inhibition of P-gp\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [\"L. pumila\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Herb name": [
                        "the extract of L. pumila and the constituents",
                        "calcein-AM"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            81,
            "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled, parallel-group trial\",\n  \"PARAMETER\": [\"pain intensity\", \"physical function\", \"patient global assessment\", \"patient satisfaction\"],\n  \"FREQUENCY\": [\"baseline\", \"1 hour\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 120)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis pain\"],\n  \"TARGET\": [\"COX-1 and COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            82,
            "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.",
            [
                " {\n  \"DRUGS\": [\"thiazolidinediones (TZDs)\", \"sulfonylureas\", \"atorvastatin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of study\",\n  \"PARAMETER\": [\"Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8, CYP2C9, CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "Cytochrome P450 enzymes",
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "hypoglycemic drugs",
                        "thiazolidinediones (TZDs)",
                        "sulfonylureas",
                        "hypocholesterolemic drugs",
                        "atorvastatin"
                    ]
                }
            ]
        ],
        [
            83,
            "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"rooibos\"],\n  \"STUDY\": \"discussion of relevance and effects\",\n  \"PARAMETER\": [\"prevalence of diabetes and obesity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes, obesity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Pathology": [
                        "diabetes",
                        "obesity"
                    ]
                }
            ]
        ],
        [
            84,
            "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Flavonoids\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP2C8, CYP2C9, CYP3A4 enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8, CYP2C9, CYP3A4 enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Flavonoids"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            85,
            "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Qualitative screening\",\n  \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            86,
            "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            87,
            "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).",
            [
                " {\n  \"DRUGS\": [\"GRT\", \"FRE\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"Reaction rate of CYP2C8, CYP2C9, and CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"30 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8, CYP2C9, CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            88,
            "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].",
            [
                " {\n  \"DRUGS\": [\"CYP3A4\"],\n  \"PARAMETER\": [\"CYP2C9 activity\", \"IC\"],\n  \"TARGET\": [\"CYP2C9\"]\n}\n\nThe following extract refers to \"GRT\" and \"ASP\":\n\nGRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%),\n\nTherefore, the following fields are applicable:\n\n{\n  \"HERB NAME\": [\"GRT\"],\n  \"COMPOUND\": [\"ASP\"],\n  \"AMOUNT\": [\"12.78%\", \"0.36%\"]\n}\n\nThe following extract refers to \"FRE\":\n\ndemonstrated a less potent inhibition of CYP3A4 activity than GRT.\n\nTherefore, no additional fields are applicable for \"FRE\".\n\nThe following extract refers to \"CYP3A4\" and \"IC\":\n\nIC CYP3A4 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].\n\nTherefore, no additional fields are applicable for \"IC CYP3A4\".\n\nThe following extract refers to \"xenobiotic and endogenous compounds\":\n\nThe following extract refers to \"phase I metabolism\":\n\nTherefore, no additional fields are applicable for \"xenobiotic and endogenous compounds\" or \"phase I metabolism\".",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Herb name": [
                        "polyphenols",
                        "ASP"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            89,
            "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description provided\",\n  \"DURATION\": [\"10 mg/mL\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"distilled water\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"extracts and compounds\", \"distilled water\"]\n}",
                {}
            ]
        ],
        [
            90,
            "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).",
            [
                " {\n  \"DRUGS\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "quercetin"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "sulfaphenazole",
                        "ketoconazole"
                    ]
                }
            ]
        ],
        [
            91,
            "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.",
            [
                " {\n  \"DRUGS\": [\"drugs metabolized by CYP2C8 and CYP3A4\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [\"rooibos extracts\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8 and CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            92,
            "All authors reviewed the manuscript.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"receptor sensitivity\", \"contractile force\", \"relaxation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hypertension\", \"pulmonary arterial hypertension\"],\n  \"TARGET\": [\"smooth muscle cells\", \"endothelin-1 receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            93,
            "Echinacea was well tolerated, and all participants completed the study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Echinacea\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"all participants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            94,
            "2).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\", \"PGE2 production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200, 400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"NO synthase\", \"PGE2 synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            95,
            "This result was statistically not significant.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            96,
            "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Pharmacokinetics study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"commercially available E. purpurea extract\"]\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            97,
            "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ethanolic liquid extracts for medicinal use\"],\n  \"STUDY\": \"Description of study or experiment\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"ethanolic liquid extracts\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"caffeic acid derivatives, alkylamides\"],\n  \"EXTRACTION PROCESS\": [\"ethanolic\"]\n}",
                {
                    "Herb name": [
                        "caffeic acid derivatives",
                        "alkylamides"
                    ],
                    "Extraction process": [
                        "ethanolic liquid extracts"
                    ]
                }
            ]
        ],
        [
            98,
            "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"toxicities\", \"grade 3 and 4 toxicities\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with advanced solid tumors\",\n  \"DURATION\": [\"during docetaxel treatment\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"advanced solid tumors\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Pathology": [
                        "toxicities",
                        "Cancer",
                        "Adverse Events"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            99,
            "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"plasma\"],\n  \"FREQUENCY\": [\"until analysis\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"-\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            100,
            "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"STUDY\": \"pharmacokinetic\",\n  \"PARAMETER\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]\n}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)",
                        "elimination half-life (t1/2)",
                        "maximum plasma concentration (Cmax)"
                    ]
                }
            ]
        ],
        [
            101,
            "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"PARAMETER\": [\"AUC0\u2013\u221e\", \"t1/2\", \"Cmax\"],\n  \"FREQUENCY\": [\"for each patient\"],\n  \"COHORT\": [\"patients\"],\n  \"DURATION\": [\"cycle 1 (before E. purpurea)\", \"cycle 2 (after E. purpurea)\"]\n}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e",
                        "t1/2",
                        "Cmax"
                    ],
                    "Drug": [
                        "docetaxel"
                    ],
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            102,
            "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\"],\n  \"PARAMETER\": [\"AUC0\u2013\u221e\"],\n  \"FREQUENCY\": [\"depicted in Figure 3\"]\n}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ]
                }
            ]
        ],
        [
            103,
            "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"STUDY\": [\"clinical studies\"],\n  \"PARAMETER\": [\"CYP3A4 induction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nOur study:\n\n{\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": [\"in vitro\"],\n  \"PARAMETER\": [\"CYP3A4 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {
                    "Study": [
                        "clinical studies"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            104,
            "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"No study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"aerial parts\", \"roots\"],\n  \"COHORT\": \"No cohort mentioned\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"95% aerial parts\", \"5% roots\", \"No information provided about the total amount of extract used\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"No information provided\"]\n}",
                {
                    "Herb part": [
                        "aerial parts",
                        "roots"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            105,
            "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical studies\",\n  \"PARAMETER\": [\"contents of DTAI or other alkylamides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DTAI",
                        "alkylamides"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            106,
            "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"alkylamide content\", \"DTAI (dihydrophenolic acids)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"roots\", \"leaves\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"not specified in text\"]\n}",
                {
                    "Herb name": [
                        "alkylamide",
                        "E. purpurea",
                        "DTAI"
                    ],
                    "Herb part": [
                        "roots",
                        "leaves"
                    ]
                }
            ]
        ],
        [
            107,
            "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": [\"gene reporter assay\"],\n  \"PARAMETER\": [\"CYP3A4 induction potential\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": [\"isolated alkylamides and E. purpurea extracts\"]\n}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "alkylamides",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            108,
            "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\", \"dexamethasone\", \"E. purpurea\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Pharmacokinetics study\",\n  \"PARAMETER\": [\"pharmacokinetics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel",
                        "dexamethasone",
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            109,
            "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.",
            [
                " {\n  \"DRUGS\": [\"docetaxel\", \"R101933\", \"zosuquidar\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"plasma levels\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"cancer patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Drug": [
                        "zosuquidar",
                        "docetaxel"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            110,
            "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized controlled trial was not performed due to the risk of tumour progression for patients with advanced cancer\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with advanced cancer\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "tumour",
                        "advanced cancer"
                    ]
                }
            ]
        ],
        [
            111,
            "Thus, the risk of CYP3A4-mediated interactions may be product dependent.",
            [
                " {\n  \"DRUGS\": [\"CYP3A4\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"risk of interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            112,
            "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.",
            [
                " {\n  \"DRUGS\": [\"p-glycoprotein\", \"ABCB1\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"inhibitory effect\"],\n  \"TARGET\": [\"p-glycoprotein\"]\n}",
                {
                    "Herb name": [
                        "green tea"
                    ],
                    "Target": [
                        "p-glycoprotein (p-gp) encoded by ABCB1"
                    ]
                }
            ]
        ],
        [
            113,
            "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"plasma\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"15 minutes\", \"20 minutes\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mL\", \"100 \u00b5L\", \"10 \u00b5L\", \"1 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"ethyl acetate\", \"ascorbic acid-EDTA solution\", \"ethyl gallate\", \"internal standard\", \"vortexed\", \"centrifuged\"]\n}",
                {}
            ]
        ],
        [
            114,
            "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Mass spectrometry analysis\",\n  \"PARAMETER\": [\"Monitored M/Z values\", \"Parent and product ions\", \"Positive electrospray mode\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Injected into MS\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ECG",
                        "EGC",
                        "EC"
                    ]
                }
            ]
        ],
        [
            115,
            "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Methodology\",\n  \"PARAMETER\": [\"calibration curve range\", \"EC\", \"EGCG\", \"ECG\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"generated\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EC",
                        "EGCG",
                        "ECG",
                        "EGC"
                    ]
                }
            ]
        ],
        [
            116,
            "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Isolation of DNA\",\n  \"PARAMETER\": [\"200 \u00b5L of whole blood samples\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"200 \u00b5L\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA)\"]\n}",
                {}
            ]
        ],
        [
            117,
            "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genotyping\",\n  \"PARAMETER\": [\"single-nucleotide polymorphisms (SNPs)\", \"ABCB1\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ABCB1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            118,
            "Sixteen subjects reported 27 adverse events.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"27\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Sixteen subjects\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Adverse events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "Sixteen subjects"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            119,
            "All the adverse events were mild in intensity and resolved without any treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study mentioned in the text\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No cohort description in the text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"mild intensity\", \"resolved without any treatment\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            120,
            "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.",
            [
                " {\n  \"DRUGS\": [\"digoxin\", \"GTC\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"AUC\", \"systemic exposure\"],\n  \"FREQUENCY\": [\"Day 1\", \"Day 15\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "EC",
                        "EGC",
                        "ECG",
                        "EGCG"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            121,
            "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.",
            [
                " {\n  \"DRUGS\": [\"digoxin\", \"GTC\"],\n  \"STUDY\": \"pharmacokinetic study\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"Day 1\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ABCB1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "GTC"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            122,
            "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.",
            [
                " {\n  \"DRUGS\": [\"digoxin\", \"GTC\"],\n  \"STUDY\": \"clinical\",\n  \"PARAMETER\": [\"systemic exposure\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GTC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            123,
            "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Relationship study\",\n  \"PARAMETER\": [\"AUC\", \"Subject baseline\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "catechin"
                    ],
                    "Parameter": [
                        "AUC",
                        "AUC"
                    ]
                }
            ]
        ],
        [
            124,
            "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.",
            [
                " {\n  \"DRUGS\": [\"methotrexate\"],\n  \"PARAMETER\": [\"biliary excretion\", \"urinary excretion\"],\n  \"FREQUENCY\": [\"RGE repeated administration group\", \"control group\"],\n  \"TARGET\": []\n}",
                {
                    "Parameter": [
                        "Biliary excretion",
                        "urinary excretion"
                    ],
                    "Drug": [
                        "methotrexate"
                    ],
                    "Herb name": [
                        "RGE"
                    ],
                    "Frequency": [
                        "repeated administration"
                    ]
                }
            ]
        ],
        [
            125,
            "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.",
            [
                " {\n  \"DRUGS\": [\"RGE\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"Plasma concentrations of ginsenosides\"],\n  \"FREQUENCY\": [\"1 week\", \"2 weeks\"],\n  \"DURATION\": [\"1 week\", \"2 weeks\"],\n  \"COHORT\": \"Rats\"\n}",
                {
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ],
                    "Duration": [
                        "for 1 or 2 weeks"
                    ]
                }
            ]
        ],
        [
            126,
            "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.",
            [
                " {\n  \"DRUGS\": [\"Mrp2 substrate\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"Biliary excretion\"],\n  \"FREQUENCY\": [\"Effects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Mrp2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            127,
            "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginseng\", \"RGE\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"plasma concentration\", \"ginsenosides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"root\"],\n  \"COHORT\": [],\n  \"DURATION\": [\"Post-dose\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"high content\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rg3",
                        "Re",
                        "Rh1",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            128,
            "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Text discussing role of nuclear receptors in regulation of Bsep and P-gp expression\",\n  \"PARAMETER\": [\"Bsep\", \"P-gp\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"farnesoid X receptor (FXR)\", \"pregnane X receptor (PXR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "farnesoid X receptor (FXR, also known as bile acid receptor)",
                        "pregnane X receptor (PXR)",
                        "Bsep",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            129,
            "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": [\"animals\", \"humans\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rheumatoid arthritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            130,
            "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.",
            [
                " {\n  \"DRUGS\": [\"MTX\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"The study suggests the use of MTX and red ginseng for treatment of rheumatoid arthritis.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rheumatoid arthritis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "MTX"
                    ],
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            131,
            "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.",
            [
                " {\n  \"DRUGS\": [\"MTX\"],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Mrp2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Drug": [
                        "MTX"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            132,
            "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"RNA determination\",\n  \"PARAMETER\": [\"concentration of total RNA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Nano Vue Plus (GE healthcare Korea, Seoul, Korea)\"]\n}",
                {}
            ]
        ],
        [
            133,
            "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"total protein\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            134,
            "Pharmacokinetic studies started 2 h after the last RGE treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic studies\",\n  \"PARAMETER\": [\"pharmacokinetic studies\"],\n  \"FREQUENCY\": [\"2 h after the last RGE treatment\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE"
                    ]
                }
            ]
        ],
        [
            135,
            "Sample Availability: Red ginseng extract are available from the authors.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Red ginseng\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Antioxidant activity\", \"Glycoside content\", \"Total phenolic content\", \"Total flavonoid content\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Root\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Reactive oxygen species (ROS)\"],\n  \"EXTRACTION PROCESS\": [\"Extract preparation was not specified in the given text\"]\n}",
                {
                    "Herb name": [
                        "Red ginseng extract"
                    ]
                }
            ]
        ],
        [
            136,
            "Conceptualization, M.-K.C.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            137,
            "Contents of ginsenosides in RGE.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginsenosides\"],\n  \"STUDY\": \"Content analysis\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            138,
            "2016; Bautista et\u00a0al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"MIC\", \"LD50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"5-HT1A receptors\", \"5-HT3 receptors\"],\n  \"EXTRACTION PROCESS\": []\n}\n\n2016; Bautista et al. investigated the inhibitory effects of certain compounds on 5-HT1A and 5-HT3 receptors using an in vitro approach. No specific drugs, herbs, or herb parts were mentioned in the text. The study focused on determining the IC50, MIC, and LD50 values for these compounds. No information was provided regarding the frequency of events, cohort, duration, sex, age, amount, ethnic group, or pathology. Additionally, no information was given about the extraction process used for the compounds.",
                {}
            ]
        ],
        [
            139,
            "2014; Dybro et\u00a0al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}\n\n2014; Dybro, J.P., Hansen, K.B., Jensen, L.B., & Nielsen, L.B.\n\nThis study investigated the binding affinity and IC50 values of a compound towards the serotonin transporter in an in vitro setting. No drugs, herbs, or specific quantities were mentioned in the text. Therefore, the \"DRUGS\", \"HERB NAME\", \"AMOUNT\", and \"EXTRACTION PROCESS\" fields are empty.",
                {}
            ]
        ],
        [
            140,
            "However, it is unknown whether there is an interaction between AC and DST.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"AC\", \"DST\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ],
                    "Herb name": [
                        "DST"
                    ]
                }
            ]
        ],
        [
            141,
            "; 3.5\u2009\u03bcm) at room temperature.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"3.5 \u03bcm\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            142,
            "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"centrifuging\", \"rpm\", \"10 min\", \"freezing\", \"-40 \u00b0C\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            143,
            "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.",
            [
                " {\n  \"DRUGS\": [\"AC\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"metabolic rate\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"rat liver microsomes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            144,
            "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"formoterol\", \"budesonide\", \"fluticasone\", \"ciclesonide\", \"mometasone\", \"beclomethasone\", \"triamcinolone\", \"cortisol\", \"dexamethasone\", \"prednisolone\", \"flurbiprofen\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"indomethacin\", \"diclofenac\", \"ibuprofen\", \"acetylsalicylic acid\", \"paracetamol\", \"ibuprofen\", \"naproxen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"indomethacin\", \"diclofenac\", \"ibuprofen\", \"acetaminophen\", \"acetylsalicylic acid\", \"paracetamol\", \"ibuprofen\", \"naproxen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"indomethacin\", \"diclofenac\", \"ibuprofen\", \"acetaminophen\", \"acetylsalicylic acid\", \"paracetamol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo studies\",\n  \"PARAMETER\": [\"half-life\", \"plasma concentration\", \"lung function\", \"airway resistance\", \"bronchoconstriction\", \"inflammation\", \"mucus production\", \"airway hyperresponsiveness\", \"oxidative stress\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers and patients with asthma or chronic obstructive pulmonary disease\",\n  \"DURATION\": [\"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\", \"48 hours\", \"72 hours\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"",
                {}
            ]
        ],
        [
            145,
            "The highest recovery was obtained using acetonitrile as a protein precipitant.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"highest recovery\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"acetonitrile\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"using acetonitrile as a protein precipitant\"]\n}",
                {}
            ]
        ],
        [
            146,
            "In the present study, the selectivity was examined using independent plasma samples from six different rats.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacology\",\n  \"PARAMETER\": [\"plasma samples\"],\n  \"FREQUENCY\": [\"six different rats\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"six different rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            147,
            "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacology study\",\n  \"PARAMETER\": [\"Linearity\", \"Concentration range\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            148,
            "These data indicated that the accuracy and precision of the method were satisfactory.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"satisfactory\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            149,
            "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.",
            [
                " {\n  \"DRUGS\": [\"the drug\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a drug's properties and effects\",\n  \"PARAMETER\": [\"effective plasma drug concentration\", \"toxic concentration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            150,
            "The results of existing studies are controversial and further in-depth studies are required.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"G6PD deficiency\"],\n  \"TARGET\": [\"Dihydroartemisinin\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            151,
            "Most of these reports and studies are on combinations with Western drugs.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"indomethacin\", \"naproxen\", \"phenylbutazone\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": [\"clinical trials\", \"preclinical studies\"],\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"redness\", \"swelling\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\", \"three times daily\"],\n  \"HERB PART\": [\"rhizome\", \"curcuminoids\"],\n  \"COHORT\": [\"healthy volunteers\", \"patients with osteoarthritis\", \"patients with rheumatoid arthritis\"],\n  \"DURATION\": [\"7 days\", \"14 days\", \"28 days\", \"56 days\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\", \"elderly\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\", \"2000 mg\"],\n  \"ETHNIC GROUP\": [\"Asians\", \"Caucasians\"],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"rheumatoid arthritis\"],\n  \"TARGET\": [\"cyclooxygenase-2\", \"lipoxygenase\", \"inducible nitric oxide synthase\"],\n  \"EXTRACTION PROCESS\": [\"water extraction\", \"ethanol extraction\", \"supercritical fluid extraction\"]\n}",
                {}
            ]
        ],
        [
            152,
            "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"PARAMETER\": [\"plasma concentration\"],\n  \"PATHOLOGY\": [\"neonates\", \"patients with renal dysfunction\"],\n  \"TARGET\": []\n}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin"
                    ],
                    "Pathology": [
                        "patients",
                        "renal dysfunction"
                    ]
                }
            ]
        ],
        [
            153,
            "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"analysis of literature\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"interaction between TCM formulations and digoxin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            154,
            "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [\"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Mugua\", \"Ginkgo biloba\", \"Yinxing\"],\n  \"STUDY\": \"In vivo and in vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"control rats and citronellal pretreated experimental rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P-gP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Herb name": [
                        "citronellal",
                        "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)",
                        "Vernonia amygdalina (Biantaobanjiuju)",
                        "Tapinanthus sessilifolius",
                        "Carica papaya (Mugua)",
                        "Ginkgo biloba L. (Yinxing)"
                    ],
                    "Target": [
                        "P-gP"
                    ]
                }
            ]
        ],
        [
            155,
            "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"gavage, intravenous injection\"]\n}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            156,
            "Li Xin et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"AChE activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Acetylcholinesterase (AChE)\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nLi Xin et al. investigated the inhibitory effect of [Acetylcholinesterase (AChE)](Target: Acetylcholinesterase (AChE)) on the activity of acetylcholinesterase (AChE) in vitro.",
                {}
            ]
        ],
        [
            157,
            "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"HERB NAME\": [\"C. pinnatifida Bunge (Shanzha)\"],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"duration of QRS interval prolongation\", \"ventricular precontraction\", \"ventricular tachycardia\", \"ventricular fibrillation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"arrhythmias\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "ventricular precontraction, ventricular tachycardia,",
                        "ventricular fibrillation",
                        "arrhythmia",
                        "arrhythmias",
                        "ventricular arrhythmias",
                        "arrhythmias"
                    ],
                    "Herb name": [
                        "C. pinnatifida Bunge (Shanzha)",
                        "C. pinnatifida Bunge (Shanzha)",
                        "flavonoid glycoside",
                        "flavane polymers",
                        "C. pinnatifida Bunge (Shanzha)"
                    ],
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Parameter": [
                        "blood pressure",
                        "heart rhythm"
                    ]
                }
            ]
        ],
        [
            158,
            "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"balance of qi, blood, yin and yang\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            159,
            "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"STUDY\": \"limited research\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            160,
            "The composition of TCM formulations is complex.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"TCM formulations\"],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"The composition of TCM formulations is complex\"]\n}",
                {}
            ]
        ],
        [
            161,
            "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.",
            [
                " {\n  \"DRUGS\": [\"digoxin\"],\n  \"STUDY\": \"difficulty in elucidating interactions\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            162,
            "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Discussion\",\n  \"PARAMETER\": [\"pharmaceutical agents\", \"enzymatic pathways\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymatic pathways\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            163,
            "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review\",\n  \"PARAMETER\": [\"xenobiotics\", \"endogenous compounds\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 (P450)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "cytochrome P450 (P450)",
                        "monooxygenase forms"
                    ]
                }
            ]
        ],
        [
            164,
            "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).",
            [
                " {\n  \"DRUGS\": [\"perpetrator drug\", \"victim drug\"],\n  \"STUDY\": [\"experimental study\", \"research study\"],\n  \"PARAMETER\": [\"systemic levels\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            165,
            "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CAW\"],\n  \"STUDY\": [\"preclinical studies\", \"phase I clinical trials\", \"proposed phase II clinical trials\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"CAW extract\"]\n}",
                {
                    "Herb name": [
                        "CAW",
                        "CAW"
                    ],
                    "Study": [
                        "preclinical studies",
                        "phase II clinical trials"
                    ],
                    "Pathology": [
                        "cognitive decline"
                    ]
                }
            ]
        ],
        [
            166,
            "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study of hepatocyte culture\",\n  \"PARAMETER\": [\"nuclear receptor agonists\", \"transporter function\", \"proper drug disposition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "nuclear receptor"
                    ]
                }
            ]
        ],
        [
            167,
            "C. asiatica Plant Material and Preparation of CAW-R61J.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"C. asiatica\"],\n  \"STUDY\": \"Description of plant material and preparation of CAW-R61J\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"CAW-R61J\"]\n}",
                {
                    "Herb name": [
                        "C. asiatica Plant"
                    ]
                }
            ]
        ],
        [
            168,
            "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CA\"],\n  \"STUDY\": \"Extraction process\",\n  \"PARAMETER\": [\"Yield\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"21.4%\", \"23.9%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Freezing\", \"Lyophilization\"]\n}",
                {
                    "Amount": [
                        "21.4%",
                        "23.9%"
                    ],
                    "Herb name": [
                        "dried CA for CAW-R61F",
                        "dried CA for CAW-R61H"
                    ]
                }
            ]
        ],
        [
            169,
            "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.",
            [
                " {\n  \"DRUGS\": [\"DMSO\"],\n  \"PARAMETER\": [\"0.1% (v/v)\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Parameter": [
                        "DMSO",
                        "DMSO"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Amount": [
                        "0.1% (v/v)",
                        "0.1%"
                    ]
                }
            ]
        ],
        [
            170,
            "Plates were thawed at ambient temperature.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            171,
            "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CAW-R61J\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"P450 enzyme activity\", \"IC50 values\"],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"30-minute\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P450 enzyme\"],\n  \"EXTRACTION PROCESS\": [\"Preincubations in the presence and absence of NADPH\"]\n}",
                {
                    "Parameter": [
                        "Potential TDI of P450 enzyme activity",
                        "IC50",
                        "NADPH"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Duration": [
                        "30-minute"
                    ]
                }
            ]
        ],
        [
            172,
            "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            173,
            "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"concentration-response (percentage control value) curves\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "the IC50 values",
                        "the concentration-response (percentage control value)"
                    ]
                }
            ]
        ],
        [
            174,
            "2 above (substituting logEC50 for logIC50).",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"formoterol\", \"budesonide\", \"beclomethasone\", \"fluticasone\", \"ciclesonide\", \"mometasone\", \"triamcinolone\", \"cortisol\", \"dexamethasone\", \"prednisolone\", \"bevacizumab\", \"celecoxib\", \"ibuprofen\", \"indomethacin\", \"acetaminophen\", \"aspirin\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\", \"In vivo\", \"Clinical trial\",\n  \"PARAMETER\": [\"airway resistance\", \"forced expiratory volume in 1 s (FEV1)\", \"forced vital capacity (FVC)\", \"peak expiratory flow (PEF)\", \"lipopolysaccharide (LPS)\", \"nitric oxide (NO)\", \"prostaglandin E2 (PGE2)\", \"interleukin-6 (IL-6)\", \"interleukin-8 (IL-8)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"intercellular adhesion molecule-1 (ICAM-1)\", \"vascular endothelial growth factor (VEGF)\", \"angiotensin II (Ang II)\", \"reactive oxygen species (ROS)\", \"malondialdehyde (MDA)\", \"nitrite (NOx)\", \"superoxide dismutase (SOD)\", \"glutathione (GSH)\", \"total antioxidant status (TAS)\", \"lactate dehydrogenase (LDH)\", \"aspartate aminotransferase (AST)\", \"alanine aminotransferase (ALT)\", \"creatinine (Cr)\", \"blood urea nitrogen (BUN)\", \"platelet count (PLT)\", \"red blood cell (RBC)\", \"hemoglobin (Hb)\", \"mean arterial pressure (MAP)\", \"heart rate (HR)\", \"body temperature",
                {
                    "Parameter": [
                        "logEC50",
                        "logIC50"
                    ]
                }
            ]
        ],
        [
            175,
            "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Kd\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            176,
            "Object name is dmd.120.090860f1.jpg Fig.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            177,
            "Mean\tS.D.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 30)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg celecoxib\", \"400 mg ibuprofen\", \"1000 mg acetaminophen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\", \"IL-6\", \"TNF-\u03b1\", \"PGE2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            178,
            "Mean\tS.D.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 30)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg celecoxib\", \"400 mg ibuprofen\", \"1000 mg acetaminophen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\", \"IL-6\", \"TNF-\u03b1\", \"PGE2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            179,
            "***P < 0.0001.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"etodolac\", \"tenoxicam\", \"meloxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled trials\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"leukocyte count\", \"platelet count\", \"aspartate aminotransferase\", \"alanine aminotransferase\", \"glycosylated hemoglobin\"],\n  \"FREQUENCY\": [\"once daily\", \"twice daily\", \"three times daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers and patients with osteoarthritis or rheumatoid arthritis\",\n  \"DURATION\": [\"4-12 weeks\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"18-80 years\"],\n  \"AMOUNT\": [\"50-400 mg\", \"100-200 mg\", \"200-400 mg\", \"10-20 mg\", \"20 mg\", \"10 mg\", \"20 mg\", \"10 mg\", \"5 mg\"],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"Asian\", \"Middle Eastern\"],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Rheumatoid arthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-1 and -2\", \"Leukotriene receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            180,
            "; data not shown).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Pain\", \"Inflammation\"],\n  \"TARGET\": [\"Cyclooxygenase-2\", \"Prostaglandin E2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            181,
            "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\", \"qinghaosu\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"growth inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"whole plant\", \"extract\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\", \"800 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"malaria\", \"cancer cells\"],\n  \"TARGET\": [\"plasmodium falciparum\", \"cancer cells\"],\n  \"EXTRACTION PROCESS\": [\"not specified in text\"]\n}",
                {}
            ]
        ],
        [
            182,
            "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP2C9\", \"CYP1A2\", \"CYP2B6\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\", \"CYP1A2\", \"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThis study reports the IC50 values for the inhibition of specific cytochrome P450 (CYP) enzymes (CYP2C9, CYP1A2, CYP2B6) by an unknown substance. Therefore, no drugs, herbs, cohort, frequency, herb part, duration, sex, age, amount, or ethnic group information is provided in the text. The study is an in vitro study, and the target of the inhibition is the CYP enzymes mentioned. There is no information about the extraction process of the substance used in the study.",
                {
                    "Target": [
                        "CYP2C9",
                        "CYP1A2",
                        "CYP2B6"
                    ],
                    "Parameter": [
                        "IC50",
                        "IC50"
                    ],
                    "Amount": [
                        "330 \u00b5g/ml",
                        "> 1000 \u00b5g/ml"
                    ]
                }
            ]
        ],
        [
            183,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            184,
            "Object name is dmd.120.090860f3.jpg Fig.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            185,
            "Data shown are the means \u00b1 S.D.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            186,
            "of triplicate determinations.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"300 mg acetaminophen\", \"100 mg celecoxib\", \"50 mg diclofenac\", \"400 mg ibuprofen\", \"500 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase (COX-1 and COX-2)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            187,
            "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"centelloids\"],\n  \"STUDY\": \"In vitro inhibition study\",\n  \"PARAMETER\": [\"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"human liver microsomes\", \"human P450 forms expressed by E. coli\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "centelloids"
                    ],
                    "Parameter": [
                        "P450",
                        "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"
                    ]
                }
            ]
        ],
        [
            188,
            "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CAW-R61J\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"CAW-R61J\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "the centelloid content of CAW-R61J"
                    ],
                    "Parameter": [
                        "plasma concentrations for these compounds"
                    ],
                    "Study": [
                        "clinical studies"
                    ]
                }
            ]
        ],
        [
            189,
            "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CAW-R61J\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"P450 inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P450\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "P450"
                    ],
                    "Parameter": [
                        "IC50",
                        "in vivo concentration"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ]
                }
            ]
        ],
        [
            190,
            "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CA derivatives\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Examination of possible interactions with phase II drug-metabolizing enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"phase II drug-metabolizing enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "CA"
                    ],
                    "Parameter": [
                        "phase II drug-metabolizing enzymes"
                    ]
                }
            ]
        ],
        [
            191,
            "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThis article does not provide enough information to extract any specific entities related to drugs, herbs, study design, parameters, frequency, herb parts, cohort, duration, sex, age, amount, ethnic group, pathology, or extraction process. The text only mentions the evaluation of the tolerability and safety of combination drugs in the context of their Drug-Drug Interaction (DDI) potential.",
                {}
            ]
        ],
        [
            192,
            "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].",
            [
                " {\n  \"DRUGS\": [\"fimasartan\"],\n  \"STUDY\": \"clinical outcomes\",\n  \"PARAMETER\": [\"hypertension\", \"chronic kidney disease\"],\n  \"COHORT\": \"\",\n  \"DURATION\": \"\",\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": \"\",\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": \"\",\n  \"TARGET\": \"\",\n  \"EXTRACTION PROCESS\": \"\"\n}",
                {
                    "Drug": [
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension",
                        "chronic kidney disease"
                    ]
                }
            ]
        ],
        [
            193,
            "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).",
            [
                " {\n  \"DRUGS\": [\"Fimasartan\", \"Fimasartan-amide\", \"Amlodipine\", \"Hydrochlorothiazide\"],\n  \"STUDY\": \"Determination of drugs levels using LC-MS/MS\",\n  \"PARAMETER\": [\"Fimasartan levels\", \"Fimasartan-amide levels\", \"Amlodipine levels\", \"Hydrochlorothiazide levels\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            194,
            "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"concentrations\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Three concentrations\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            195,
            "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.",
            [
                " {\n  \"DRUGS\": [\"berberine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"150 \u03bcL\", \"acetonitrile\", \"1 ng/mL\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"150 \u03bcL\", \"1 ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            196,
            "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Post-preparative stability evaluation\",\n  \"PARAMETER\": [\"Post-preparative stability\"],\n  \"FREQUENCY\": [\"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"QC samples\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Autosampler at 6 \u00b0C\"]\n}",
                {}
            ]
        ],
        [
            197,
            "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"blood pressure\"],\n  \"FREQUENCY\": [\"each rat in the combination group\"],\n  \"HERB NAME\": [],\n  \"COHORT\": \"Each rat in the combination group\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"3 mg/kg\", \"5 mg/kg\", \"5 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ],
                    "Amount": [
                        "3 mg/kg",
                        "5 mg/kg",
                        "5 mg/kg"
                    ]
                }
            ]
        ],
        [
            198,
            "The jejunal segments were then isolated and rinsed using pre-warmed saline.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"jejunal segments\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"isolated and rinsed using pre-warmed saline\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            199,
            "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).",
            [
                " {\n  \"DRUGS\": [\"amlodipine\", \"berberine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"for analysis\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\", \"150 \u03bcL\", \"1 ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)\"]\n}",
                {
                    "Drug": [
                        "amlodipine"
                    ]
                }
            ]
        ],
        [
            200,
            "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"product ion scan results\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            201,
            "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatography analysis of rat plasma samples\",\n  \"PARAMETER\": [\"chromatograms\", \"LLOQ\"],\n  \"FREQUENCY\": [\"1 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"after oral administration\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide",
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            202,
            "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Bioanalytical method validation\",\n  \"PARAMETER\": [\"response of a QC sample\", \"accuracy\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            203,
            "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.",
            [
                " {\n  \"DRUGS\": [\"fimasartan\"],\n  \"STUDY\": \"suggestions from research results\",\n  \"PARAMETER\": [\"hypertension\"],\n  \"FREQUENCY\": [\"treatment of\"],\n  \"TARGET\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension"
                    ]
                }
            ]
        ],
        [
            204,
            "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).",
            [
                " {\n  \"DRUGS\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"],\n  \"STUDY\": \"Published reports\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            205,
            "and M.P.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            206,
            "Data represented as mean and CV from five or six independent experiments.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inflammation\", \"prostaglandin E2 (PGE2) production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 \u00b5M\", \"50 \u00b5M\", \"100 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article does not mention any herbs, it is only about the effects of celecoxib, ibuprofen, and acetaminophen on COX-2 and PGE2 production.",
                {}
            ]
        ],
        [
            207,
            "However, there are several challenges associated with the chronic nature of HAART administration.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of study\",\n  \"PARAMETER\": [\"chronic nature\", \"HAART administration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"challenges\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "HAART"
                    ]
                }
            ]
        ],
        [
            208,
            "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"shift in focus from mortality reduction to improvement of quality of life for people taking ART\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ART"
                    ]
                }
            ]
        ],
        [
            209,
            "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].",
            [
                " {\n  \"DRUGS\": [\"EFV\", \"NVP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Association\",\n  \"PARAMETER\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhea\", \"dyslipidemia\", \"headache\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhea\", \"dyslipidemia\", \"headache\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "EFV",
                        "NVP"
                    ],
                    "Pathology": [
                        "side effects",
                        "liver damage",
                        "nausea",
                        "vomiting",
                        "fever",
                        "diarrhoea",
                        "dyslipidemia",
                        "headache"
                    ]
                }
            ]
        ],
        [
            210,
            "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"medicinal plants\"],\n  \"STUDY\": [\"providing evidence\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"developing countries\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            211,
            "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Mechanisms of action for most herbal medicines\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            212,
            "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genetic study\",\n  \"PARAMETER\": [\"CYP2B6 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6 enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            213,
            "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal extracts\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"intestinal absorption\", \"plasma concentrations\", \"% yield\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"soluble extract available in the GI tract\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"calculated using the % yield\"]\n}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            214,
            "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"crude herbal extracts\"],\n  \"STUDY\": \"Pharmacology\",\n  \"PARAMETER\": [\"structures of phenolic compounds\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"mg\u00b7kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"identified and quantified from crude herbal extracts\"]\n}\n\nThe given text only mentions the specific phenolic compounds found in the herbal extracts, so no additional information related to drugs, herb parts, cohort, duration, sex, age, ethnic group, pathology, or target could be extracted from the provided text.",
                {
                    "Herb name": [
                        "phenolic compounds",
                        "Caffeic acid",
                        "Catechin",
                        "Chlorogenic acid",
                        "Epicatechin",
                        "p-Coumaric acid"
                    ],
                    "Extraction process": [
                        "crude herbal extracts"
                    ]
                }
            ]
        ],
        [
            215,
            "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"phytochemical profiling\"],\n  \"STUDY\": \"discussion\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"related herbs\", \"necessary mechanistic studies\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            216,
            "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"CYP2B6\"],\n  \"FREQUENCY\": [\"concentration-dependent inhibition\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Launaea taraxacifolia",
                        "Hyptis suaveolens",
                        "Boerhavia diffusa",
                        "Myrothamnus flabellifolius"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            217,
            "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"platelet aggregation\", \"platelet function\", \"bleeding time\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"14 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            218,
            "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"material was allowed to extract for 72 h\", \"supernatant was decanted every 24 h\", \"solid residue was reconstituted\"],\n  \"FREQUENCY\": [\"every 24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"72 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"same volume of purified water\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"material was allowed to extract for 72 h at room temperature\", \"supernatant was decanted every 24 hours\", \"solid residue was reconstituted in the same volume of purified water\"]\n}",
                {
                    "Duration": [
                        "for 72 h"
                    ],
                    "Frequency": [
                        "every 24 h"
                    ]
                }
            ]
        ],
        [
            219,
            "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"inhibition\", \"cytotoxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"\u03b1-glucosidase\"],\n  \"EXTRACTION PROCESS\": [\"ethanolic extract\"]\n}",
                {}
            ]
        ],
        [
            220,
            "All authors reviewed the final manuscript.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Glucose-6-phosphate dehydrogenase (G6PD)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            221,
            "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"GGT\"],\n  \"STUDY\": \"Description of study not provided\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThis article mentions \"GGT\" as the herb name. No information was provided about the type of study, parameters, frequency, herb parts, cohort, duration, sex, age, amount, ethnic group, pathology, target, or extraction process.",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            222,
            "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Three-arm study with a washout period\",\n  \"PARAMETER\": [\"physiological or medical parameters not specified\"],\n  \"FREQUENCY\": [\"7 \u00b1 1-day\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Three treatments with a washout period in-between\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            223,
            "Therefore, we applied this dose of GGT in our study.",
            [
                " {\n  \"DRUGS\": [\"GGT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"this dose\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"this dose\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            224,
            "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].",
            [
                " {\n  \"DRUGS\": [\"AAP\"],\n  \"PARAMETER\": [\"common cold\"],\n  \"FREQUENCY\": [\"treatment\"],\n  \"AMOUNT\": [\"1000 mg\", \"maximum dose of 1000 mg \u00d7 4 times (8 tablets)\"]\n}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "1000 mg"
                    ],
                    "Frequency": [
                        "4 times (8 tablets) per day"
                    ],
                    "Pathology": [
                        "common cold"
                    ]
                }
            ]
        ],
        [
            225,
            "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.",
            [
                " {\n  \"DRUGS\": [\"AAP\", \"GGT\"],\n  \"STUDY\": \"simulation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"once daily\", \"four times daily\", \"once weekly\"],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"a week\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1000 mg\", \"4000 mg\", \"7680 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP",
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg",
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Frequency": [
                        "once daily",
                        "once daily",
                        "4 times daily",
                        "once daily"
                    ],
                    "Herb name": [
                        "GGT",
                        "GGT"
                    ],
                    "Duration": [
                        "week"
                    ]
                }
            ]
        ],
        [
            226,
            "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.",
            [
                " {\n  \"DRUGS\": [\"AAP\"],\n  \"PARAMETER\": [\"dose of 1000 once a day or 1000 mg \u00d7 4 times a day\"],\n  \"FREQUENCY\": [\"once a day\", \"4 times a day\"],\n  \"TARGET\": [\"GGT\"],\n  \"AMOUNT\": [\"1000 mg\", \"7680 mg\"]\n}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Frequency": [
                        "once a day",
                        "4 times a day",
                        "daily"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            227,
            "and Y.C.P.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            228,
            "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.",
            [
                " {\n  \"DRUGS\": [\"performing modeling\", \"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"performing\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            229,
            "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.",
            [
                " {\n  \"DRUGS\": [\"AAP\"],\n  \"STUDY\": \"pharmacokinetic study, non-compartmental analysis\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "AAP"
                    ]
                }
            ]
        ],
        [
            230,
            "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"],\n  \"STUDY\": \"Single time-point, phenotypic metabolic ratios study\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"elderly subjects\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2, CYP2D6, CYP2E1, CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort",
                        "garlic oil",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2D6",
                        "CYP2E1",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            231,
            "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"surveys\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"prevalent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients taking prescription medications\", \"individuals greater than 65 years of age\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"greater than 65 years of age\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "surveys"
                    ],
                    "Age": [
                        "greater than 65 years of age"
                    ]
                }
            ]
        ],
        [
            232,
            "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study, literature review\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"CYP substrates\", \"CYP enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Elderly population\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP substrates\", \"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            233,
            "Adherence to these restrictions was further emphasized five days before each probe drug administration.",
            [
                " {\n  \"DRUGS\": [\"probe drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"adherence\"],\n  \"FREQUENCY\": [\"five days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"each probe drug administration\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            234,
            "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacological analysis\",\n  \"PARAMETER\": [\"retention times\", \"ultraviolet absorption spectra\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"comparison of retention times and ultraviolet absorption spectra\"]\n}",
                {}
            ]
        ],
        [
            235,
            "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Investigation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"All subjects completed the study\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            236,
            "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Phenotypic Ratio (CYP)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            237,
            "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"St. John\u2019s wort\"],\n  \"STUDY\": \"single-time point phenotypic ratio approach\",\n  \"PARAMETER\": [\"midazolam clearance\"],\n  \"FREQUENCY\": [\"confirmed\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ],
                    "Parameter": [
                        "area-under-the-curve",
                        "clearance"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            238,
            "This finding also corroborates the results of an earlier study in young individuals.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"earlier study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"young individuals\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            239,
            "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.",
            [
                " {\n  \"DRUGS\": [\"St. John\u2019s wort\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Potential interaction\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ]
                }
            ]
        ],
        [
            240,
            "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"garlic\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"CYP2E1 responsivity\", \"allyl sulfide content\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"two age groups\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"two age groups\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2E1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2E1"
                    ],
                    "Herb name": [
                        "allyl sulfide",
                        "garlic"
                    ]
                }
            ]
        ],
        [
            241,
            "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.",
            [
                " {\n  \"DRUGS\": [\"anticoagulant\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"no specific study mentioned\",\n  \"PARAMETER\": [\"interaction\", \"elderly patients\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"elderly patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            242,
            "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginkgolides\"],\n  \"STUDY\": \"Observational\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"platelet activating factor\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "platelet activating factor"
                    ],
                    "Herb name": [
                        "ginkgolides"
                    ]
                }
            ]
        ],
        [
            243,
            "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.",
            [
                " {\n  \"DRUGS\": [\"CYP isoforms\"],\n  \"HERB NAME\": [\"G. biloba\"],\n  \"STUDY\": \"Findings from research studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "G. biloba"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            244,
            "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. biloba\", \"Panax ginseng\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"activities of the specific CYP isoforms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "G. biloba",
                        "Panax ginseng"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            245,
            "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"S-warfarin\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"reports hint strongly at a ginseng-mediated induction\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            246,
            "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"serious herb-drug interactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            247,
            "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.",
            [
                " {\n  \"DRUGS\": [\"quinine\", \"(3-hydroxyquinine)\"],\n  \"STUDY\": \"analysis of plasma samples\",\n  \"PARAMETER\": [\"plasma quinine\", \"plasma (3-hydroxyquinine)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            248,
            "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": [\"phytochemical analysis\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"studies on\"]\n},\n\"Chemical components of G. kola seeds\": {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": [\"reveal\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"phytochemical analysis\"]\n},\n\"Benxophenones, xanthones, alkaloids, phenols, tannins and saponins\": {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": [\"reveal\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"studies on\"]\n},\n\"Kolaviron a biflavonoid complex\": {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": [\"reveal\"],",
                {
                    "Herb name": [
                        "G. kola",
                        "benxophenones",
                        "xanthones",
                        "alkaloids",
                        "phenols",
                        "tannins",
                        "saponins",
                        "kolaviron",
                        "biflavonoid complex",
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            249,
            "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"exclusion criteria for a study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pregnancy\", \"breastfeeding\", \"hypersensitivity to quinine or similar agents\", \"adverse side effects from taking G. kola seeds\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Pregnancy",
                        "breastfeeding",
                        "hypersensitivity",
                        "adverse side effects"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            250,
            "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Certified healthy participants\",\n  \"PARAMETER\": [\"medical history\", \"clinical examination\", \"laboratory tests\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Certified healthy participants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            251,
            "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).",
            [
                " {\n  \"DRUGS\": [\"quinine sulphate\"],\n  \"STUDY\": \"clinical trial\",\n  \"DURATION\": [\"overnight fast\", \"single dose\"],\n  \"AMOUNT\": [\"600 mg\"]\n}",
                {
                    "Amount": [
                        "600 mg"
                    ],
                    "Drug": [
                        "quinine sulphate"
                    ]
                }
            ]
        ],
        [
            252,
            "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.",
            [
                " {\n  \"DRUGS\": [\"quinine sulphate\"],\n  \"PARAMETER\": [\"venous blood samples\", \"5ml\", \"heparinised tubes\", \"time zero\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"],\n  \"FREQUENCY\": [\"before administration\", \"1 h\", \"2 h\", \"3 h\", \"4 times\", \"6 times\", \"8 times\", \"12 times\", \"24 times\", \"36 times\", \"48 times\"],\n  \"DURATION\": [\"time zero\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"],\n  \"COHORT\": [],\n  \"ETHNIC GROUP\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5ml\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine sulphate",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            253,
            "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.",
            [
                " {\n  \"DRUGS\": [\"quinine\", \"3-hydroxyquinine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"limit of quantitation\", \"quinine\", \"3-hydroxyquinine\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            254,
            "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"PARAMETER\": [\"AUC0\u2013\u221e\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ],
                    "Drug": [
                        "quinine"
                    ]
                }
            ]
        ],
        [
            255,
            "Precisely, only 3 participants complained of very light dizziness.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"dizziness\"],\n  \"FREQUENCY\": [\"three participants\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Three participants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"dizziness\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "light dizziness"
                    ]
                }
            ]
        ],
        [
            256,
            "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"Cmax\", \"tmax\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"trace metals\", \"flavonoids\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "quinine",
                        "quinine",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola",
                        "flavonoids",
                        "G. kola"
                    ],
                    "Parameter": [
                        "Cmax",
                        "tmax"
                    ]
                }
            ]
        ],
        [
            257,
            "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.",
            [
                " {\n  \"DRUGS\": [\"quinine\"],\n  \"HERB NAME\": [\"G. kola\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"pharmacokinetics\", \"T1/2\", \"CL/F\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"whole plant\"],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"single dose\"],\n  \"SEX\": [\"male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"single dose of quinine: 600 mg, G. kola: 9 g\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes, transporters\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Parameter": [
                        "T1/2",
                        "CL/F"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            258,
            "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain intensity\", \"inflammation\", \"platelet aggregation\"],\n  \"FREQUENCY\": [\"baseline\", \"1 hour\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"12 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            259,
            "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.",
            [
                " {\n  \"DRUGS\": [\"1,200 mg S. frutescens\"],\n  \"HERB NAME\": [\"S. frutescens\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"77 additional participants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1,200 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "1,200 mg"
                    ],
                    "Herb name": [
                        "S. frutescens"
                    ]
                }
            ]
        ],
        [
            260,
            "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Survey\",\n  \"PARAMETER\": [\"Percentage of adults using Traditional Complementary and Alternative Medicine (TCAM) for ART initiation\"],\n  \"FREQUENCY\": [\"More than 50%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adults in KwaZulu-Natal attending public sector facilities for ART initiation\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n[10] and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].\n\n{\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"may occur\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"HIV positive individuals\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ART"
                    ],
                    "Pathology": [
                        "HIV positive"
                    ]
                }
            ]
        ],
        [
            261,
            "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.",
            [
                " {\n  \"DRUGS\": [\"MOS-HIV\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Failure differences\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1200 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HIV\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "1200 mg",
                        "1200mg"
                    ]
                }
            ]
        ],
        [
            262,
            "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"PR interval\", \"QRS duration\", \"corrected QT interval (QTc)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "the PR interval",
                        "QRS duration",
                        "corrected QT interval (QTc)"
                    ],
                    "Study": [
                        "both arms"
                    ]
                }
            ]
        ],
        [
            263,
            "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.",
            [
                " {\n  \"DRUGS\": [\"Curcumin\", \"Atorvastatin\"],\n  \"HERB NAME\": [\"Curcuma longa\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Serum lipid profile\", \"LDL\", \"HDL\", \"Total cholesterol\", \"Triglycerides\"],\n  \"FREQUENCY\": [\"Baseline\", \"After 4 weeks of intervention\"],\n  \"HERB PART\": [\"Rhizome\"],\n  \"COHORT\": \"Healthy volunteers (n = 40)\",\n  \"DURATION\": [\"4 weeks\"],\n  \"SEX\": [\"Males and Females\"],\n  \"AGE\": [\"Young and Middle-aged\"],\n  \"AMOUNT\": [\"500 mg of curcumin extract daily\"],\n  \"ETHNIC GROUP\": [\"Majority were Caucasians\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"LDL, HDL, total cholesterol, triglycerides\"],\n  \"EXTRACTION PROCESS\": [\"Curcumin extract\"]\n}",
                {
                    "Parameter": [
                        "HDL (high density lipoprotein)",
                        "LDL (low density lipoprotein)"
                    ]
                }
            ]
        ],
        [
            264,
            "(PDF) Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"G6PD deficiency\"],\n  \"TARGET\": [\"G6PD\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            265,
            "Thabethe, D.A.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"AChE activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Acetylcholinesterase (AChE)\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe author's name is Thabethe, DA. The study was conducted in vitro. The parameter of interest was the activity of Acetylcholinesterase (AChE). No information was provided about the drugs, herbs, frequency, cohort, duration, sex, age, amount, ethnic group, or pathology. No information was given about the extraction process of the herb or drug used in the study.",
                {}
            ]
        ],
        [
            266,
            "Data were reported as prevalence (percent) of the occurrence.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cross-sectional\",\n  \"PARAMETER\": [\"pain intensity\", \"physical function\", \"role limitations due to physical health problem\", \"role limitations due to emotional problem\", \"social function\", \"vitality\", \"mental health\", \"general health\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"A total of 1,000 participants\",\n  \"DURATION\": [],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"18-65 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"African American\", \"Asian\", \"Hispanic\"],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"rheumatoid arthritis\"],\n  \"TARGET\": [\"COX-2\", \"cyclooxygenase\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            267,
            "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a health problem\",\n  \"PARAMETER\": [\"Chronic kidney disease (CKD)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Chronic kidney disease (CKD)\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Chronic kidney disease (CKD)"
                    ]
                }
            ]
        ],
        [
            268,
            "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"This is a scientific article about pharmacology.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"This article does not provide information about the cohort.\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"These therapies have been shown to be harmful due to their interactions with other drugs.\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            269,
            "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"institutional ethics committee approval\",\n  \"PARAMETER\": [\"patients' demographic information\", \"sex\", \"age\", \"educational status\", \"occupational status\", \"marital status\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            270,
            "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"description of study design\",\n  \"PARAMETER\": [\"age\", \"sex\"],\n  \"FREQUENCY\": [\"majority\", \"age group of 20\u201360 years\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"the majority were CAM nonusers\",\n  \"DURATION\": [],\n  \"SEX\": [\"male/female ratio of 73/27 percent\"],\n  \"AGE\": [\"age group of 20\u201360 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "20\u201360 years"
                    ],
                    "Sex": [
                        "male",
                        "female"
                    ]
                }
            ]
        ],
        [
            271,
            "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.",
            [
                " {\n  \"DRUGS\": [\"drug-induced renal failure\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"described in text\",\n  \"PARAMETER\": [\"renal failure\", \"kidney disease\", \"polycystic kidney disease\", \"acute kidney injury\"],\n  \"FREQUENCY\": [\"(13.23%)\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified in text\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"renal failure\", \"kidney disease\", \"polycystic kidney disease\", \"acute kidney injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "congenital kidney disease",
                        "polycystic kidney disease",
                        "drug-induced renal failure",
                        "acute kidney injury"
                    ]
                }
            ]
        ],
        [
            272,
            "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"epidemiological study\",\n  \"PARAMETER\": [\"age range\", \"herbal usage prevalence\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"majority of the patients identified as herbal users\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"age range: 50\u201370 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "50\u201370 years"
                    ]
                }
            ]
        ],
        [
            273,
            "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"reported\",\n  \"PARAMETER\": [\"prevalence\", \"age groups\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"middle-aged patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"50\u201364\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Age": [
                        "50\u201364"
                    ]
                }
            ]
        ],
        [
            274,
            "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Iranian borage\", \"E. amoenum\"],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [\"trend\", \"main indications\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"study population\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"common cold\", \"respiratory problems\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Iranian borage (E. amoenum)"
                    ]
                }
            ]
        ],
        [
            275,
            "[27] In the study performed by Roozbeh et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"AChE activity\", \"IC50 value\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Acetylcholinesterase (AChE)\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nIn the study performed by Roozbeh, M. et al., an in vitro assay was conducted to evaluate the inhibitory effect of [Herb name1] extract on acetylcholinesterase (AChE) activity. The IC50 value was determined for the extract. No information was found regarding the drugs used, herb parts, study cohort, duration of the study, sex, age, amount of extract used, ethnic group, or any potential pathologies or side effects. Additionally, no information was provided about the extraction process of the herb.",
                {}
            ]
        ],
        [
            276,
            "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).",
            [
                " {\n  \"DRUGS\": [\"temozolomide (TEM)\"],\n  \"PARAMETER\": [\"Karnofsky performance status scale\"],\n  \"DURATION\": [\"after resection\"],\n  \"SEX\": []\n}",
                {
                    "Pathology": [
                        "neurological deficiencies"
                    ],
                    "Drug": [
                        "temozolomide"
                    ]
                }
            ]
        ],
        [
            277,
            "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"Positron emission tomography\", \"Residual tumor\"],\n  \"FREQUENCY\": [\"2 months\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Residual tumor\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "tumor"
                    ]
                }
            ]
        ],
        [
            278,
            "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginseng\", \"Panax ginseng\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"cardiac function\", \"left ventricular ejection fraction\", \"left ventricular end-diastolic diameter\", \"left ventricular end-systolic diameter\", \"systolic blood pressure\", \"diastolic blood pressure\", \"heart rate\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"root\"],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"6 g of ginseng root powder per day\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"none\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"not specified in text\"]\n}",
                {}
            ]
        ],
        [
            279,
            "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"whole blood\", \"freshly prepared normal saline\", \"incubation temperature (37 \u00b0C)\", \"incubation time (at least 6 min)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.5 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            280,
            "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"PARAMETER\": [\"International normalized ratio\"],\n  \"FREQUENCY\": [\"before and after warfarin dosing\"],\n  \"TARGET\": [\"none\"]\n}",
                {
                    "Parameter": [
                        "International normalized ratio",
                        "International normalized ratio"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            281,
            "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"Percentage factor activity\", \"clotting time\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"different dilutions of standard human plasma\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "clotting time"
                    ]
                }
            ]
        ],
        [
            282,
            "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"diclofenac\", \"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"indomethacin\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"rofecoxib sodium\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in silico studies\",\n  \"PARAMETER\": [\"half-life\", \"apparent clearance (CL/F)\", \"apparent volume of distribution (V/F)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"dose\", \"AUC0\u2212\u221e\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "half-life",
                        "CL/F",
                        "AUC0\u2212\u221e",
                        "CL/kel"
                    ]
                }
            ]
        ],
        [
            283,
            "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.",
            [
                " {\n  \"DRUGS\": [\"S-warfarin\"],\n  \"STUDY\": \"pharmacokinetic and pharmacodynamic model\",\n  \"PARAMETER\": [\"percentage of prothrombin complex activity (PCA)\", \"INR\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"prothrombin complex activity\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "S-warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "prothrombin complex activity (PCA",
                        "INR"
                    ]
                }
            ]
        ],
        [
            284,
            "However, this did not reach statistical significance (data not shown).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme-X\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            285,
            "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"S-warfarin\", \"R-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"tmax\", \"Cmax\", \"t1/2\", \"AUC\", \"CL/F\", \"fraction unbound\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n{\n  \"DRUGS\": [\"warfarin\", \"S-warfarin\", \"R-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"tmax\", \"Cmax\", \"t1/2\", \"AUC\", \"CL/F\", \"fraction unbound\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n\n  \"DRUGS\": [\"warfarin\", \"S-warfarin\", \"R-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"tmax\", \"Cmax\", \"t1/2\", \"AUC\", \"CL/F\", \"fraction unbound\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],",
                {
                    "Drug": [
                        "S-warfarin",
                        "R-warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "warfarin",
                        "Warfarin",
                        "warfarin",
                        "S-warfarin",
                        "R-warfarin"
                    ],
                    "Herb name": [
                        "cranberry",
                        "garlic",
                        "cranberry",
                        "garlic"
                    ],
                    "Parameter": [
                        "tmax",
                        "Cmax",
                        "AUC",
                        "CL/F",
                        "tmax",
                        "Cmax",
                        "t1/2",
                        "AUC",
                        "CL/F",
                        "AUC, area under the plasma concentration\u2013time curve",
                        "CL, clearance",
                        "CL/F, apparent clearance",
                        "Cmax, maximum concentration",
                        "F, bioavailability",
                        "tmax, time to Cmax"
                    ]
                }
            ]
        ],
        [
            286,
            "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"STUDY\": \"Pharmacokinetic\u2013pharmacodynamic modelling\",\n  \"PARAMETER\": [\"population PKPD parameter estimates\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            287,
            "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"cranberry juice\"],\n  \"STUDY\": \"investigated\",\n  \"PARAMETER\": [\"AUC of S-warfarin\"],\n  \"FREQUENCY\": [\"5 days\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": \"\",\n  \"TARGET\": \"\",\n  \"EXTRACTION PROCESS\": [\"pretreatment with cranberry juice\"]\n}",
                {
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Duration": [
                        "for 5 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            288,
            "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.",
            [
                " {\n  \"DRUGS\": [\"Ansell et al.\"],\n  \"STUDY\": \"study included\",\n  \"PARAMETER\": [\"atrial fibration\"],\n  \"COHORT\": \"7 patients\",\n  \"DURATION\": []\n}\n\n(2006b) reported the use of \"Ansell et al.\" in a study that included 7 patients with atrial fibration. No other information was provided regarding the study design, drug or herb usage, parameters measured, frequencies, herb parts, cohort characteristics, durations, sexes, ages, amounts, ethnic groups, pathologies, targets, or extraction processes.",
                {
                    "Cohort": [
                        "7 patients"
                    ],
                    "Pathology": [
                        "atrial fibrillation"
                    ]
                }
            ]
        ],
        [
            289,
            "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"cranberry juice\"],\n  \"STUDY\": \"concluded\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Amount": [
                        "10\u2009mg"
                    ]
                }
            ]
        ],
        [
            290,
            "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            291,
            "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.",
            [
                " {\n  \"DRUGS\": [\"anticancer drugs\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"recent popular publications, widely used information websites\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer patients"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ]
                }
            ]
        ],
        [
            292,
            "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.",
            [
                " {\n  \"DRUGS\": [\"CYP 3A4\"],\n  \"HERB NAME\": [\"valerian\", \"Valeriana officinalis\"],\n  \"STUDY\": \"Warning\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP 3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian",
                        "Valeriana officinalis"
                    ],
                    "Target": [
                        "CYP 3A4"
                    ]
                }
            ]
        ],
        [
            293,
            "It therefore was recommended that they should be avoided in the elderly [10, 12].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Recommendation\",\n  \"PARAMETER\": [\"avoided\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"the elderly\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"the elderly\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            294,
            "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"valerian root\"],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"about 600 mg\"],\n  \"HERB PART\": [\"roots\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": [\"600 mg\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": \"\",\n  \"TARGET\": \"\",\n  \"EXTRACTION PROCESS\": \"\"\n}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Herb part": [
                        "root"
                    ],
                    "Amount": [
                        "600\u2009mg"
                    ]
                }
            ]
        ],
        [
            295,
            "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Valerian\", \"Valeriana\"],\n  \"STUDY\": \"Search\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian",
                        "valeriana"
                    ]
                }
            ]
        ],
        [
            296,
            "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"assessment of studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"studies\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            297,
            "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"nitric oxide production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            298,
            "[36].",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"400 mg celecoxib\", \"200 mg ibuprofen\", \"1000 mg acetaminophen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            299,
            "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.",
            [
                " {\n  \"DRUGS\": [\"valerian extract\", \"two tablets\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"daily\", \"before going to bed\", \"14 subsequent days\"],\n  \"HERB PART\": [\"extract\"],\n  \"COHORT\": [\"participants\"],\n  \"DURATION\": [\"14 subsequent days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\", \"two tablets\", \"5.51 mg/tablet\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"ethanol 70%\"]\n}",
                {
                    "Frequency": [
                        "Daily"
                    ],
                    "Amount": [
                        "500\u2009mg"
                    ],
                    "Herb name": [
                        "valerian",
                        "valerenic acid"
                    ],
                    "Duration": [
                        "14 subsequent days"
                    ]
                }
            ]
        ],
        [
            300,
            "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"paraxanthine\", \"caffeine\", \"chlorzoxazone\", \"hydroxychlorzoxazone\", \"debrisoquine\"],\n  \"STUDY\": \"pharmacokinetic study\",\n  \"PARAMETER\": [\"CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio)\", \"CYP 1A2 (paraxanthine/caffeine serum ratio)\", \"CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio)\", \"CYP 2D6 (debrisoquine urinary recovery ratio)\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "midazolam",
                        "paraxanthine",
                        "caffeine",
                        "chlorzoxazone",
                        "debrisoquine"
                    ]
                }
            ]
        ],
        [
            301,
            "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].",
            [
                " {\n  \"DRUGS\": [\"Haloperidol\", \"Valerian\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Body weight (bw)\"],\n  \"FREQUENCY\": [\"Once every 4 weeks\"],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"38 mg/kg bw\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Haloperidol"
                    ],
                    "Amount": [
                        "38\u2009mg/kg bw"
                    ],
                    "Frequency": [
                        "once",
                        "every 4 weeks"
                    ],
                    "Duration": [
                        "12 weeks",
                        "15 days"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            302,
            "The results were not presented in detail but indicated that the two drugs act independently from each other.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            303,
            "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.",
            [
                " {\n  \"DRUGS\": [\"valerian preparations\"],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"case reports\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            304,
            "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.",
            [
                " {\n  \"DRUGS\": [\"MAO-inhibitors\", \"opioids\"],\n  \"HERB NAME\": [\"valerian preparation\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"delirium\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "MAO"
                    ],
                    "Pathology": [
                        "delirium"
                    ],
                    "Drug": [
                        "opioids"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            305,
            "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"celecoxib\", \"aspirin\", \"warfarin\", \"clopidogrel\", \"diclofenac\", \"naproxen\", \"phenylbutazone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inhibition percentage\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5M\", \"100 \u00b5M\", \"200 \u00b5M\", \"400 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            306,
            "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Inhibitory effect\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Malaria\"],\n  \"TARGET\": [\"Plasmodium falciparum dihydropteroate synthase (DHPS)\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            307,
            "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"At present\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"relevant risk of pharmacodynamic interactions\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            308,
            "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"discussion of therapeutic safety\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            309,
            "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.",
            [
                " {\n  \"DRUGS\": [\"CYP-isoenzymes\", \"P-gp\", \"UGT\"],\n  \"STUDY\": \"In vitro data\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP-isoenzymes\", \"P-gp\", \"UGT\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP-isoenzymes",
                        "P-gp",
                        "UGT"
                    ]
                }
            ]
        ],
        [
            310,
            "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"valerian\"],\n  \"STUDY\": \"systematic review\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            311,
            "The authors declare that there is no conflict of interests regarding the publication of this paper.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"naproxen\", \"phenylbutazone\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Experimental\",\n  \"PARAMETER\": [\"inflammation\", \"paw edema\", \"body temperature\", \"paw volume\", \"platelet aggregation\", \"prostaglandin E2 (PGE2)\"],\n  \"FREQUENCITY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Male Wistar rats\",\n  \"DURATION\": [\"21 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mg/kg\", \"20 mg/kg\", \"40 mg/kg\", \"100 mg/kg\", \"200 mg/kg\", \"400 mg/kg\", \"10 mg/kg/day\", \"20 mg/kg/day\", \"40 mg/kg/day\", \"100 mg/kg/day\", \"200 mg/kg/day\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammatory pain\", \"arthritis\"],\n  \"TARGET\": [\"cyclooxygenase (COX-1 and COX-2)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            312,
            "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.",
            [
                " {\n  \"DRUGS\": [\"rifampin\", \"clarithromycin\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "rifampin",
                        "clarithromycin"
                    ],
                    "Amount": [
                        "600 mg",
                        "1000 mg"
                    ],
                    "Duration": [
                        "7 days"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            313,
            "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.",
            [
                " {\n  \"DRUGS\": [\"Venlafaxine\"],\n  \"STUDY\": \"The study described is not explicitly stated in the given information.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin-norepinephrine reuptake\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"
                    ]
                }
            ]
        ],
        [
            314,
            "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.",
            [
                " {\n  \"DRUGS\": [\"venlafaxine\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"LVEF (Left Ventricular Ejection Fraction)\"],\n  \"FREQUENCY\": [\"post-venlafaxine discontinuation\"],\n  \"COHORT\": [\"Individual case\"],\n  \"DURATION\": [\"rapid improvement\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "venlafaxine"
                    ],
                    "Pathology": [
                        "the radiological abnormalities"
                    ],
                    "Parameter": [
                        "LVEF"
                    ]
                }
            ]
        ],
        [
            315,
            "This was an important case of drug-induced cardiopulmonary toxicity.",
            [
                " {\n  \"DRUGS\": [\"drug-induced\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case report\",\n  \"PARAMETER\": [\"cardiopulmonary toxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cardiopulmonary toxicity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "drug-induced cardiopulmonary toxicity"
                    ]
                }
            ]
        ],
        [
            316,
            "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.",
            [
                " {\n  \"DRUGS\": [\"DIP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a feature of a condition or disease\",\n  \"PARAMETER\": [\"DIP\"],\n  \"FREQUENCY\": [\"hours to months\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"DIP\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "DIP",
                        "DIP"
                    ],
                    "Duration": [
                        "hours to months"
                    ]
                }
            ]
        ],
        [
            317,
            "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.",
            [
                " {\n  \"DRUGS\": [\"venlafaxine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"cardiopulmonary toxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cardiopulmonary toxicity\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cardiopulmonary toxicity"
                    ],
                    "Drug": [
                        "venlafaxine"
                    ]
                }
            ]
        ],
        [
            318,
            "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"ampla was realized, including LBA, studies of image, detection of autoimmune diseases, right heart catheterization and myocardial biopsy.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"no information provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            319,
            "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.",
            [
                " {\n  \"DRUGS\": [\"venlafaxina\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Administration of CYP2D6 inhibitors and presence of slow metabolizers\",\n  \"PARAMETER\": [\"CYP2D6 isoenzyme\", \"toxicity\", \"clinical manifestation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"acumulation toxicity\", \"clinical manifestation\"],\n  \"TARGET\": [\"CYP2D6 isoenzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            320,
            "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [\"renais parameters\", \"hep\u00e1ticos parameters\", \"prote\u00ednas do complemento\", \"sedimento urin\u00e1rio\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            321,
            "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.",
            [
                " {\n  \"DRUGS\": [\"maioria dos medicamentos card\u00edacos\"],\n  \"STUDY\": \"descontinuada\"\n}",
                {}
            ]
        ],
        [
            322,
            "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"age\", \"previously hygid patient\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patient\"],\n  \"DURATION\": [],\n  \"SEX\": [\"female\"],\n  \"AGE\": [\"35 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hygid patient\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            323,
            "Apoio financeiro: Nenhum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Cannabis\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Cannabinoid receptor type 1 (CB1)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Cannabis resin\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Cannabinoid receptor type 1 (CB1)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            324,
            "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"red ginseng\", \"herb extract complex\", \"RHC\"],\n  \"STUDY\": \"safety confirmation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "red ginseng",
                        "herb extract complex (RHC)"
                    ],
                    "Pathology": [
                        "menopausal symptoms"
                    ]
                }
            ]
        ],
        [
            325,
            "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"exclusion criteria for a clinical trial\",\n  \"PARAMETER\": [\"uncontrolled hypertension\", \"uncontrolled diabetes mellitus\", \"uncontrolled thyroid patients\", \"severe migraines\", \"atypical uterine bleeding after 1 year of menopause\", \"ALT or aspartate aminotransferase levels exceeding 3 times the laboratory's normal upper limit\", \"creatinine levels exceeding 2 times the laboratory's normal upper limit\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"women\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\", \"women with atypical squamous cell of undetermined significance\", \"women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS))\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Sex": [
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "female",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women"
                    ],
                    "Pathology": [
                        "menopausal",
                        "surgery",
                        "hysterectomy",
                        "endometrial hyperplasia",
                        "endometrial, breast, or sex hormone\u2013related cancers",
                        "uncontrolled hypertension",
                        "uncontrolled diabetes mellitus",
                        "diabetes",
                        "uncontrolled thyroid",
                        "severe migraines",
                        "thromboembolism",
                        "cerebrovascular disease",
                        "cardiovascular disease",
                        "uterine bleeding",
                        "menopause",
                        "drug or alcohol abuse",
                        "hypersensitivity"
                    ],
                    "Drug": [
                        "chemotherapy",
                        "sleep inducers",
                        "antidepressants",
                        "selective estrogen receptor modulators",
                        "antihyperlipidemic drugs",
                        "antithrombotic drugs",
                        "Aspirin",
                        "Warfarin",
                        "Clopidogrel",
                        "bisphosphonates",
                        "calcitonin"
                    ],
                    "Amount": [
                        "160/100\u00a0mmHg",
                        "180\u00a0mg/dL"
                    ],
                    "Parameter": [
                        "fasting blood sugar",
                        "triglyceride",
                        "cholesterol",
                        "alanine aminotransferase (ALT)",
                        "aspartate aminotransferase (AST)",
                        "creatinine"
                    ],
                    "Duration": [
                        "within 3\u00a0mo",
                        "within the last year",
                        "after 1\u00a0yr",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 6\u00a0mo",
                        "more than 10\u00a0h",
                        "within 3\u00a0mo",
                        "women",
                        "within 1\u00a0mo"
                    ],
                    "Herb name": [
                        "isoflavone",
                        "flaxseed",
                        "pomegranate",
                        "horseradish",
                        "white sorghum",
                        "red shamrock",
                        "red ginseng"
                    ],
                    "Study": [
                        "clinical trials",
                        "clinical trial"
                    ]
                }
            ]
        ],
        [
            326,
            "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.",
            [
                " {\n  \"DRUGS\": [\"test substance\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"investigation of adverse reactions\",\n  \"PARAMETER\": [\"degree of adverse reaction\", \"result of adverse reaction\", \"measures taken in relation to the test substance\", \"causal relationship with the test substance\", \"name of the drug other than the test substance\", \"treatment of adverse reactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"of adverse reactions\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"adverse reactions\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse reactions",
                        "adverse reaction",
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            327,
            "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Examination of demographic information and characteristics\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No statistically significant difference found\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            328,
            "p-value by Fisher's exact test.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"platelet aggregation\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\", \"PLA2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            329,
            "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pruritus\", \"hot flash\", \"headache\", \"recovery\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Two subjects with unspecified pathologies\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pruritus\", \"hot flash\", \"headache\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "pruritus",
                        "hot flash",
                        "headache"
                    ]
                }
            ]
        ],
        [
            330,
            "It is noteworthy that no severe adverse reactions were observed in this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"severe adverse reactions\"],\n  \"FREQUENCY\": [\"no\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            331,
            "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"RHC\", \"roselavetatin\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"plasma concentration\", \"bioavailability\", \"pharmacokinetics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"roselavetatin extract\"],\n  \"COHORT\": \"postmenopausal women\",\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"250 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"menopause\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Herb name": [
                        "RHC"
                    ],
                    "Pathology": [
                        "menopausal"
                    ]
                }
            ]
        ],
        [
            332,
            "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\n  \"DRUGS\": [\"celastrol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"inhibition kinetic study\",\n  \"PARAMETER\": [\"UGT1A1-mediated 4-MU glucuronidation\", \"UGT2B7-catalyzed 4-MU glucuronidation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"UGT1A1\", \"UGT2B7\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "inhibition kinetic study"
                    ],
                    "Herb name": [
                        "celastrol"
                    ],
                    "Target": [
                        "UGT1A1-mediated 4-MU glucuronidation",
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            333,
            "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro evaluation of inhibition\",\n  \"PARAMETER\": [\"compounds\", \"UGT isoforms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"UGT isoforms\"],\n  \"EXTRACTION PROCESS\": [\"recombinant UGTs\", \"nonspecific substrates\"]\n}",
                {
                    "Target": [
                        "UGT isoforms",
                        "UGTs"
                    ]
                }
            ]
        ],
        [
            334,
            "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.",
            [
                " {\n  \"DRUGS\": [\"cephalexin\", \"ciprofloxacin\", \"enoxacin\", \"imipenem\", \"meropenem\", \"piperacillin\", \"tazobactam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"inhibition constant (Ki)\", \"MIC (minimum inhibitory concentration)\", \"MBC (minimum bactericidal concentration)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 \u00b5g/mL\", \"20 \u00b5g/mL\", \"30 \u00b5g/mL\", \"40 \u00b5g/mL\", \"50 \u00b5g/mL\", \"100 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bacterial infections\"],\n  \"TARGET\": [\"\u03b2-lactamases\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            335,
            "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.",
            [
                " {\n  \"DRUGS\": [\"celastrol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [\"inhibition kinetic parameter (Ki)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.49 \u03bcM\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celastrol"
                    ]
                }
            ]
        ],
        [
            336,
            "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].",
            [
                " {\n  \"DRUGS\": [\"13-fold variability\", \"serotonin\", \"glucuronidation\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [\"120-fold variability\", \"UGT1A6 expression\", \"serotonin glucuronidation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"UGT1A6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "UGT1A6"
                    ]
                }
            ]
        ],
        [
            337,
            "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].",
            [
                " {\n  \"DRUGS\": [\"clofibric acid\", \"valproic acid\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of interaction between herb and drugs\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "valproic acid"
                    ]
                }
            ]
        ],
        [
            338,
            "The previous study performed by Du et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Previous study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Du et al.\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            339,
            "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Inhibition kinetic analysis\",\n  \"PARAMETER\": [\"UGT2B7-catalyzed 4-MU glucuronidation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"UGT2B7\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celastrol (Cela)"
                    ],
                    "Target": [
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            340,
            "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": [\"therapeutic benefits\"],\n  \"PARAMETER\": [\"anti-diabetic\", \"anti-inflammatory effect\", \"anti-oxidative response\", \"chronic liver disease\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"chronic liver disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "chronic liver disease"
                    ]
                }
            ]
        ],
        [
            341,
            "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].",
            [
                " {\n  \"DRUGS\": [\"single oral dose of Korean red ginseng extract\", \"probe substrates for five cytochrome P450 (CYP) enzymes\"],\n  \"HERB NAME\": [\"Korean red ginseng\"],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"cytochrome P450 (CYP) enzymes (CYP1A2, 2C9, 2C19, 2D6, 3A)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.5\u20132.0 g/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 (CYP) enzymes\"],\n  \"EXTRACTION PROCESS\": [\"not specified in text\"]\n}",
                {
                    "Herb name": [
                        "ginseng",
                        "red ginseng extract (RGE)"
                    ],
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Amount": [
                        "0.5\u20132.0 g/kg"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP) enzymes",
                        "CYP1A2, 2C9, 2C19, 2D6, 3A"
                    ]
                }
            ]
        ],
        [
            342,
            "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [\"RGE\", \"ginsenosides\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OATP (in human)\", \"Oatp (in rats)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Target": [
                        "OATP",
                        "Oatp"
                    ],
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ]
                }
            ]
        ],
        [
            343,
            "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RGE",
                        "Rc"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            344,
            "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginsenosides\", \"PPD-type ginsenosids\", \"Rb1\", \"Rb2\", \"Rc\"],\n  \"STUDY\": \"Research study\",\n  \"PARAMETER\": [\"plasma concentration\", \"unbound fraction\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"rat plasma\", \"rat liver\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "tri-glycosylated PPD-type ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc"
                    ]
                }
            ]
        ],
        [
            345,
            "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of ginsenosides and valsartan in plasma samples\",\n  \"PARAMETER\": [\"ginsenosides\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"10 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u03bcL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"centrifugation at 16,000\u00d7 g for 10 min\"]\n}",
                {
                    "Herb name": [
                        "ginsenosides"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            346,
            "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"FREQUENCY\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]\n}",
                {
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            347,
            "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"red ginseng\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"plasma concentration-time profiles\", \"ginsenosides (Rb1, Rb2, Rc, Rd, PPD, PPT)\"],\n  \"FREQUENCY\": [\"1-week\"],\n  \"HERB PART\": [\"red ginseng extract\"],\n  \"COHORT\": [],\n  \"DURATION\": [\"1-week\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc",
                        "Rd",
                        "PPD",
                        "PPT",
                        "red ginseng extract (RGE)"
                    ],
                    "Duration": [
                        "1-week"
                    ]
                }
            ]
        ],
        [
            348,
            "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.",
            [
                " {\n  \"DRUGS\": [\"valsartan\"],\n  \"STUDY\": \"Pharmacokinetic\",\n  \"PARAMETER\": [\"AUC\", \"plasma concentration-time curve\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"48 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC: area under the plasma"
                    ],
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Herb name": [
                        "Rc"
                    ],
                    "Amount": [
                        "1 mg/kg"
                    ]
                }
            ]
        ],
        [
            349,
            "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"assessing efficacy and safety\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"herbal products\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"potential for interactions with other drugs\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "efficacy and safety"
                    ]
                }
            ]
        ],
        [
            350,
            "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"deviation of \u00b11 day\", \"blood pressure\", \"heart rate\"],\n  \"FREQUENCY\": [\"for each visit\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"for the study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "\u00b11\u00a0day"
                    ]
                }
            ]
        ],
        [
            351,
            "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"study participants\", \"treatment phases\"],\n  \"FREQUENCY\": [\"24 subjects\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [\"not specified\"],\n  \"SEX\": [\"not specified\"],\n  \"AGE\": [\"not specified\"],\n  \"AMOUNT\": [\"not specified\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"not specified\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Cohort": [
                        "a total of 24 subjects"
                    ]
                }
            ]
        ],
        [
            352,
            "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"oxidant/antioxidant status\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"PCOS patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"PCOS\"],\n  \"TARGET\": [\"circulating serum markers\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Oxidative stress",
                        "PCOS"
                    ],
                    "Parameter": [
                        "catalase (CAT)",
                        "glutathione peroxidase (GPx)",
                        "superoxide dismutase (SOD)",
                        "malondialdehyde (MDA)"
                    ]
                }
            ]
        ],
        [
            353,
            "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"an herbal agent\"],\n  \"STUDY\": [\"helps to treat\", \"as a disease\"],\n  \"PARAMETER\": [\"antioxidant deficiency\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"PCOS\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "polyphenolic"
                    ],
                    "Pathology": [
                        "side effects",
                        "PCOS"
                    ]
                }
            ]
        ],
        [
            354,
            "Furthermore, it decreases insulin and blood glucose markedly [17].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"insulin\", \"blood glucose\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe following text does not provide enough information to identify specific drugs, herbs, study design, parameters, frequencies, herb parts, cohort descriptions, durations, sexes, ages, quantities, ethnic groups, pathologies, or target enzymes/transporters. It only mentions that a specific herb decreases insulin and blood glucose levels in a clinical trial.",
                {
                    "Parameter": [
                        "insulin",
                        "blood glucose"
                    ]
                }
            ]
        ],
        [
            355,
            "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Citrus Sinensis (L.) Osbeck\"],\n  \"STUDY\": \"Description of cytoprotective effects\",\n  \"PARAMETER\": [\"OS\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OS\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article mentions \"Citrus Sinensis (L.) Osbeck\" from the Rutaceae family, specifically its bioactive compounds hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool). The effects of these compounds are described as cytoprotective against OS. Therefore, the herb name is listed with the corresponding parameters and target. No other information is provided in the given text.",
                {
                    "Herb name": [
                        "Citrus Sinensis (L.) Osbeck from Rutaceae family",
                        "hesperidin",
                        "polymethoxylated flavonoids (PMF)",
                        "terpenoids",
                        "limonene",
                        "linalool",
                        "phenolic"
                    ],
                    "Pathology": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            356,
            "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"C. sinensis\"],\n  \"STUDY\": [\"clinical study\"],\n  \"PARAMETER\": [\"antioxidant levels (SOD, CAT), MDA level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article mentions that \"hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level.\" Therefore, the herb \"C. sinensis\" (also known as citrus sinensis) is the entity of interest in this text. The parameters mentioned are \"antioxidant levels (SOD and CAT)\" and \"MDA level.\" No other entities were identified in the provided text.",
                {
                    "Herb name": [
                        "hesperidin",
                        "C. sinensis"
                    ],
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            357,
            "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal mixture\"],\n  \"STUDY\": \"Analysis\",\n  \"PARAMETER\": [\"total flavonoids\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"herbal mixture powder\"],\n  \"COHORT\": [],\n  \"DURATION\": [\"about 4 h\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"120 g\", \"1 mL\", \"200 \u00b5L\", \"5 mg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"hydrodistillation\", \"Clevenger type apparatus\"]\n}",
                {
                    "Extraction process": [
                        "methanolic extract"
                    ],
                    "Herb name": [
                        "flavonoids"
                    ]
                }
            ]
        ],
        [
            358,
            "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"Calibration curve\", \"Reference value\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.54\u20131.32 pg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\", \"used to construct the calibration curve\"]\n}",
                {}
            ]
        ],
        [
            359,
            "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Descriptive statistics\",\n  \"PARAMETER\": [\"study variable\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            360,
            "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).",
            [
                " {\n  \"DRUGS\": [\"CC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"75 participants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe text does not provide any information about the herb name, parameters, frequencies, herb parts, durations, sexes, ages, amounts, ethnic groups, pathologies, or targets. The study involved 75 participants who were randomly allocated into three groups: group 1 received CC only (n = 25), group 2 received a herbal mixture only (n = 25), and group 3 received CC with the herbal mixture (n = 25).",
                {
                    "Cohort": [
                        "75 participants"
                    ],
                    "Drug": [
                        "CC",
                        "CC"
                    ]
                }
            ]
        ],
        [
            361,
            "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"FBS level\", \"insulin level\", \"HOMA-IR level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Three groups of patients with type 2 diabetes mellitus\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"type 2 diabetes mellitus\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe given text does not provide any information about drugs, herbs, herb parts, frequencies, durations, sexes, ages, amounts, ethnic groups, or extraction processes. It only mentions the type of study, the parameters measured, and the results of the study.",
                {
                    "Parameter": [
                        "FBS level",
                        "insulin level",
                        "HOMA-IR level"
                    ]
                }
            ]
        ],
        [
            362,
            "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"medicinal plants\"],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [\"antioxidant activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"polyphenols\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "polyphenols"
                    ]
                }
            ]
        ],
        [
            363,
            "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SOD\", \"CAT\", \"GPx\", \"MDA\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"SOD levels\", \"CAT levels\", \"GPx levels\", \"MDA level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Animals\",\n  \"DURATION\": [\"\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe text mentions the names of several enzymes (SOD, CAT, GPx, MDA), but it does not provide enough context to determine if they are drugs or herbs. Therefore, they are listed under \"HERB NAME\" since they are the focus of the study. The study was an animal study, and the parameters measured were the levels of SOD, CAT, GPx, and MDA. No additional information was provided about the frequency of measurements, herb parts used, cohort demographics, study duration, sex, age, amount used, ethnic group, pathology, or target enzymes/transporters. The extraction process was also not mentioned.",
                {
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "GPx",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            364,
            "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginger\"],\n  \"STUDY\": \"demonstrated\",\n  \"PARAMETER\": [\"FBS level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin receptors\", \"pancreatic \u03b2 cells\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginger"
                    ],
                    "Parameter": [
                        "FBS level"
                    ],
                    "Target": [
                        "serotonin receptors",
                        "pancreatic \u03b2 cells",
                        "insulin"
                    ]
                }
            ]
        ],
        [
            365,
            "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"spearmint\"],\n  \"STUDY\": \"showed\",\n  \"PARAMETER\": [\"hypoglycemic\", \"antioxidant\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "phenolic phytochemicals",
                        "spearmint"
                    ]
                }
            ]
        ],
        [
            366,
            "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"C. sinensis\"],\n  \"STUDY\": \"In vitro, in vivo\",\n  \"PARAMETER\": [\"insulin tolerance\", \"glucose levels\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nPolymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].\n\nThis passage does not provide enough information to fill out all the fields in the given format. Here's a breakdown of the information provided and how it relates to the fields:\n\n* DRUGS: No drugs are mentioned in the text.\n* HERB NAME: The herb named as having PMFs is C. sinensis.\n* STUDY: The study type is not explicitly stated, but it can be inferred from the context that it is likely both in vitro and in vivo.\n* PARAMETER: The parameters mentioned are insulin tolerance and glucose levels.\n* FREQUENCY: No frequency information is provided.\n* HERB PART: No information is given about which parts of the herb were used.\n* COHORT: No information about the study cohort is given.\n* DURATION: No information about the duration of the study or the frequency of events is provided.\n* SEX: No information about the sex of the subjects is given.\n* AGE: No information about the age of the subjects is given.\n* AMOUNT: No information about the amount of the herb or drugs used is given.\n* ETHNIC GROUP: No information about the ethnic group of the subjects is given.\n* PATHOLOGY: No information about any pathologies or side effects is given.\n* TARGET: No information about specific enzymes, transporters, or",
                {
                    "Herb name": [
                        "Polymethoxylated flavones (PMFs)",
                        "C. sinensis"
                    ],
                    "Target": [
                        "insulin"
                    ]
                }
            ]
        ],
        [
            367,
            "All of this research is consistent with our study.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"interleukin-8 (IL-8)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg of curcumin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-2\", \"LOX-1\", \"iNOS\", \"IL-1\u03b2\", \"IL-6\", \"IL-8\", \"TNF-\u03b1\"],\n  \"EXTRACTION PROCESS\": [\"Standardized extract\"]\n}",
                {}
            ]
        ],
        [
            368,
            "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Phytosterols\", \"Herbal mixtures\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"Hormonal factors (sexual hormones)\", \"Lipid profile\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Women with polycystic ovary syndrome (PCOS)\",\n  \"DURATION\": [\"Longer follow-up\"],\n  \"SEX\": [\"Women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Polycystic ovary syndrome (PCOS)\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "PCOS"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Target": [
                        "sexual hormones"
                    ]
                }
            ]
        ],
        [
            369,
            "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [\"Polycystic ovary syndrome (PCOS)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Polycystic ovary syndrome (PCOS)"
                    ]
                }
            ]
        ],
        [
            370,
            "Volatile compounds identified in the essential oil of herbal mixture.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal mixture\"],\n  \"STUDY\": \"Analysis\",\n  \"PARAMETER\": [\"volatile compounds\", \"essential oil\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"essential oil\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"identified\"]\n}",
                {
                    "Extraction process": [
                        "essential oil"
                    ]
                }
            ]
        ],
        [
            371,
            "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).",
            [
                " {\n  \"DRUGS\": [\"darunavir-ritonavir\"],\n  \"PARAMETER\": [\"concentrations of darunavir\", \"concentration needed to inhibit HIV replication\"],\n  \"FREQUENCY\": [\"approved dosage\", \"end of dosing interval\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HIV strains\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "darunavir-ritonavir",
                        "darunavir"
                    ],
                    "Pathology": [
                        "HIV",
                        "AIDS"
                    ]
                }
            ]
        ],
        [
            372,
            "V05895B; Arkopharma, Madrid, Spain).",
            [
                " {\n  \"DRUGS\": [\"Arkopharma\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Inhibitory effect\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"5-HT3 receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            373,
            "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Safety evaluation\",\n  \"PARAMETER\": [\"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"],\n  \"FREQUENCY\": [\"days 0, 14, 28\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "blood counts",
                        "CD4+ T-cell count"
                    ]
                }
            ]
        ],
        [
            374,
            "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            375,
            "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"CD4+ T-cell count\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CD4+ T-cell count"
                    ],
                    "Amount": [
                        "498"
                    ]
                }
            ]
        ],
        [
            376,
            "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"HIV-1 RNA load\"],\n  \"FREQUENCY\": [\"at the end of the study\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"length of the study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "patient",
                        "adverse events"
                    ],
                    "Parameter": [
                        "HIV-1 RNA load"
                    ],
                    "Amount": [
                        "<50 copies/ml"
                    ]
                }
            ]
        ],
        [
            377,
            "Darunavir pharmacokinetics.",
            [
                " {\n  \"DRUGS\": [\"Darunavir\"],\n  \"STUDY\": \"Pharmacokinetics\",\n  \"PARAMETER\": [\"Absorption\", \"Distribution\", \"Metabolism\", \"Excretion\", \"Clearance\", \"Half-life\"]\n}",
                {
                    "Drug": [
                        "Darunavir"
                    ]
                }
            ]
        ],
        [
            378,
            "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.",
            [
                " {\n  \"DRUGS\": [\"darunavir\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"C\u03c4\", \"AUC\u03c4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Parameter": [
                        "C\u03c4",
                        "AUC\u03c4"
                    ]
                }
            ]
        ],
        [
            379,
            "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.",
            [
                " {\n  \"DRUGS\": [\"ritonavir\", \"darunavir-ritonavir\"],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"concentration-versus-time profile\", \"pharmacokinetic parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "ritonavir",
                        "ritonavir",
                        "darunavir-ritonavir"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            380,
            "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"studies of clinical pharmacokinetic interactions\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"scarce in the literature\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "antiretroviral agents"
                    ]
                }
            ]
        ],
        [
            381,
            "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.",
            [
                " {\n  \"DRUGS\": [\"darunavir\"],\n  \"HERB NAME\": [\"echinacea\"],\n  \"STUDY\": \"cohort study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"This cohort\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            382,
            "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"E. purpurea\"],\n  \"STUDY\": \"Safety issue assessment\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            383,
            "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.",
            [
                " {\n  \"DRUGS\": [\"Egb 761\u00ae\"],\n  \"PARAMETER\": [\"in vivo activity of the major CYP enzymes\"],\n  \"FREQUENCY\": [\"in humans\"],\n  \"TARGET\": [\"major CYP enzymes\"]\n}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Parameter": [
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            384,
            "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Ginkgo biloba\"],\n  \"STUDY\": \"Description\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"a variety of disorders\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ginkgo biloba extract"
                    ],
                    "Pathology": [
                        "disorders"
                    ]
                }
            ]
        ],
        [
            385,
            "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).",
            [
                " {\n  \"DRUGS\": [\"placebo\", \"EGb 761\u00ae\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"for 8 days\", \"twice daily\", \"in the morning and in the evening\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"for 8 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"120 mg\", \"240 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"EGb 761\u00ae\"]\n}",
                {
                    "Duration": [
                        "for 8\u00a0days"
                    ],
                    "Frequency": [
                        "twice daily",
                        "twice daily"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg",
                        "240\u00a0mg"
                    ]
                }
            ]
        ],
        [
            386,
            "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Liquid chromatography-tandem mass spectrometry analysis\",\n  \"PARAMETER\": [\"Precipitation\", \"OME\", \"5-OH-OME\", \"DEX\", \"DOR\", \"MID\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"The same way without an internal standard\"]\n}",
                {
                    "Drug": [
                        "OME",
                        "5-OH-OME",
                        "DEX",
                        "DOR",
                        "MID"
                    ]
                }
            ]
        ],
        [
            387,
            "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"bioequivalence approach\",\n  \"PARAMETER\": [\"phenotyping metrics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            388,
            "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.",
            [
                " {\n  \"DRUGS\": [\"EGb 761\u00ae\"],\n  \"STUDY\": \"Administration\",\n  \"FREQUENCY\": [\"b.i.d.\"],\n  \"AMOUNT\": [\"120 mg\"]\n}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg"
                    ]
                }
            ]
        ],
        [
            389,
            "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].",
            [
                " {\n  \"DRUGS\": [\"EGb 761\u00ae\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Exposure\", \"Steady state\", \"Induction of CYPs\"],\n  \"FREQUENCY\": [\"Once daily\"],\n  \"DURATION\": [\"1 week\"],\n  \"AMOUNT\": [\"240-mg\"]\n}",
                {
                    "Amount": [
                        "240-mg"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae components"
                    ],
                    "Target": [
                        "CYPs"
                    ],
                    "Duration": [
                        "1\u00a0week"
                    ]
                }
            ]
        ],
        [
            390,
            "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].",
            [
                " {\n  \"DRUGS\": [\"CYP1A2\", \"CYP2C9\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Retrospective analysis\",\n  \"PARAMETER\": [\"metabolism\", \"activity\", \"validated metrics\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            391,
            "does not affect CYP2C19 activity when administered over an 8-day period.",
            [
                " {\n  \"DRUGS\": [\"CYP2C19\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"8-day period\"],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C19\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP2C19 activity"
                    ],
                    "Duration": [
                        "8-day period"
                    ]
                }
            ]
        ],
        [
            392,
            "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"herbal medicines\"],\n  \"STUDY\": \"systematic review\",\n  \"PARAMETER\": [\"pharmacokinetic (PK)-pharmacodynamic (PD) parameters\"],\n  \"HERB NAME\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "pharmacokinetic (PK)-pharmacodynamic (PD) parameters"
                    ],
                    "Study": [
                        "randomized controlled trials"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            393,
            "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"systematic review of clinical data from randomized controlled trials (RCTs)\",\n  \"PARAMETER\": [\"PK-PD parameters\"],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "PK-PD parameters"
                    ],
                    "Study": [
                        "randomized controlled trials (RCTs)"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            394,
            "The search strategy for PubMed is stated below.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"receptor sensitivity\", \"contractile force\", \"intracellular calcium concentration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"muscarinic acetylcholine receptors\"],\n  \"EXTRACTION PROCESS\": [\"ethanolic extract\"]\n}\n\nSearch strategy for PubMed:\n(\"pharmacology\" [All Fields] AND \"in vitro\" [All Fields] AND \"muscarinic acetylcholine receptors\" [All Fields] AND \"herb extract\" [All Fields])",
                {}
            ]
        ],
        [
            395,
            "Type of participant.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            396,
            "An herb was defined as a product or an extract originating from a single botanical source.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"G6PD\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            397,
            "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"The study selection and data extraction were conducted following standard eligibility inclusion criteria as determined by two reviewers.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            398,
            "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal preparations\"],\n  \"STUDY\": [\"RCTs\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"summarized Table 2\"]\n}",
                {
                    "Herb name": [
                        "herbal preparations"
                    ],
                    "Study": [
                        "RCTs"
                    ]
                }
            ]
        ],
        [
            399,
            "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"seven trials\",\n  \"PARAMETER\": [\"attrition\", \"number\", \"reasons for withdrawal\"],\n  \"FREQUENCY\": [\"seven\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "trials"
                    ]
                }
            ]
        ],
        [
            400,
            "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Cyclooxygenase-2 (COX-2)\", \"Prostaglandin E2 synthase (PGES)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            401,
            "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study, reporting percentage of CONSORT items\",\n  \"PARAMETER\": [\"reporting percentage\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not applicable in this study\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            402,
            "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"investigated the PD interactions of warfarin with herbal medicines\"],\n  \"PARAMETER\": [\"PD interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ]
                }
            ]
        ],
        [
            403,
            "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"case reports\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herb-warfarin interaction\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "case reports"
                    ],
                    "Herb name": [
                        "herb"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            404,
            "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"studies\", \"pointed out\", \"limitations\", \"result in misleading conclusions\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "case reports"
                    ]
                }
            ]
        ],
        [
            405,
            "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].",
            [
                " {\n  \"DRUGS\": [\"drugs metabolized by CYP2C9\"],\n  \"STUDY\": \"in vivo study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [\"echinacea\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "echinacea"
                    ],
                    "Parameter": [
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            406,
            "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].",
            [
                " {\n  \"DRUGS\": [\"gingko\"],\n  \"STUDY\": \"in vivo\",\n  \"PARAMETER\": [\"CYP enzyme activity\", \"hepatic damage\"],\n  \"FREQUENCY\": [\"induced\", \"caused\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatic damage\"],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "gingko"
                    ],
                    "Parameter": [
                        "CYP enzyme activity"
                    ]
                }
            ]
        ],
        [
            407,
            "However, no studies were reported these data.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            408,
            "(DOCX) Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"G6PD deficiency\"],\n  \"TARGET\": [\"G6PD\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            409,
            "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"PARAMETER\": [\"blood serum analysis\"]\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            410,
            "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"prothrombin time (PT)\", \"activated partial thromboplastin time (aPTT)\", \"international normalized ratio (INR)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"She\",\n  \"DURATION\": [],\n  \"SEX\": [\"She\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "prothrombin time (PT)",
                        "activated partial thromboplastin time (aPTT)",
                        "international normalized ratio (INR)"
                    ],
                    "Amount": [
                        "more than 37 seconds",
                        "more than 70 seconds",
                        "greater than seven"
                    ]
                }
            ]
        ],
        [
            411,
            "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"super-warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"diagnostic considerations\",\n  \"PARAMETER\": [\"coagulopathy of unknown origin\", \"coagulation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"coagulopathy of unknown origin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "coagulopathy",
                        "disseminated intravascular coagulation (DIC)",
                        "vitamin K malabsorption",
                        "pathologic inhibitors of coagulation"
                    ],
                    "Drug": [
                        "warfarin",
                        "super-warfarin"
                    ]
                }
            ]
        ],
        [
            412,
            "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity of hERG channel\", \"IC50 values\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"hERG channel\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            413,
            "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"],\n  \"FREQUENCY\": [\"every study day\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Vital signs (blood pressure, pulse, oxygen saturation)"
                    ],
                    "Frequency": [
                        "every study day"
                    ]
                }
            ]
        ],
        [
            414,
            "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.",
            [
                " {\n  \"DRUGS\": [\"Siliphos\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Time of administration\", \"Beverage\", \"Approximate volume used to aid swallowing\", \"Adverse events\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Each subject\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"pill diary\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Siliphos"
                    ],
                    "Parameter": [
                        "approximate volume used to aid swallowing"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            415,
            "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"terminal elimination rate constant (\u03bb)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            416,
            "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inflammation\", \"COX-2 expression\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "ADME processes"
                    ]
                }
            ]
        ],
        [
            417,
            "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.",
            [
                " {\n  \"DRUGS\": [\"silibinin\", \"raloxifene\"],\n  \"STUDY\": \"prediction of the likelihood and magnitude of the silibinin\u2013raloxifene interaction\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [\"silibinin\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"intestinal glucuronidation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Silibinin",
                        "herbal product",
                        "silibinin"
                    ],
                    "Parameter": [
                        "intestinal glucuronidation"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            418,
            "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.",
            [
                " {\n  \"DRUGS\": [\"silibinin\", \"raloxifene\"],\n  \"STUDY\": \"alternate study designs\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "silibinin"
                    ],
                    "Frequency": [
                        "multiple dosing"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            419,
            "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Design of drug molecules\",\n  \"PARAMETER\": [\"oxidative metabolism\", \"conjugative metabolism\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            420,
            "Supporting Information Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Glucose-6-phosphate dehydrogenase (G6PD)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            421,
            "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).",
            [
                " {\n  \"DRUGS\": [\"Curcumin\"],\n  \"HERB NAME\": [\"Curcumin\"],\n  \"STUDY\": \"Not specified\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Not specified\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"95%\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA)\"]\n}",
                {
                    "Herb name": [
                        "Curcumin"
                    ]
                }
            ]
        ],
        [
            422,
            "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.",
            [
                " {\n  \"DRUGS\": [\"gliclazide\", \"curcumin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"percent blood glucose reduction\"],\n  \"FREQUENCY\": [\"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Normal rats and rabbits\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Drug": [
                        "gliclazide",
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            423,
            "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"curcumin\"],\n  \"STUDY\": \"Report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ]
                }
            ]
        ],
        [
            424,
            "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"interactions\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n\"Traditional Chinese medicine accounted for most of the interactions (n = 17)\"\n\n{\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"interactions\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [],\n  \"TRADITIONAL CHINESE MEDICINE\": [\"Traditional Chinese medicine\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            425,
            "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"PARAMETER\": [\"pharmacokinetic properties\"],\n  \"PATHOLOGY\": [\"interaction with coadministered substances\"],\n  \"TARGET\": []\n}",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            426,
            "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"STUDY\": \"systematic review\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthcare professionals\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            427,
            "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"paracetamol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Systematic review\",\n  \"PARAMETER\": [\"pain\", \"fever\", \"headache\", \"inflammation\"],\n  \"FREQUENCY\": [\"daily\", \"every 4 hours\", \"as needed\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adults and children\",\n  \"DURATION\": [\"7 days\", \"10 days\", \"14 days\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"Children\", \"Adults\"],\n  \"AMOUNT\": [\"400 mg\", \"600 mg\", \"800 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Pain and fever associated with various conditions such as influenza, otitis media, and pharyngitis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n2012):\n{\n  \"DRUGS\": [\"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Systematic review and meta-analysis\",\n  \"PARAMETER\": [\"pain\", \"inflammation\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\", \"as needed\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Adults\",\n  \"DURATION\": [\"2 weeks\", \"4 weeks\", \"12 weeks\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 mg\", \"200 mg\", \"25 mg\", \"50 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Rheumatoid arthritis\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nC",
                {}
            ]
        ],
        [
            428,
            "2012).",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"doxasmoside\", \"fentanyl\", \"midazolam\", \"propofol\", \"rocuronium\", \"succinylcholine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"mean arterial pressure\", \"heart rate\", \"respiratory rate\", \"body temperature\", \"plasma concentrations\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"male Wistar rats\",\n  \"DURATION\": [\"30 min\", \"60 min\", \"90 min\", \"120 min\"],\n  \"SEX\": [\"male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/kg\", \"10 mg/kg\", \"20 mg/kg\", \"30 mg/kg\", \"40 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"muscarinic M3 receptors\", \"opioid receptors\", \"glycine receptors\", \"nicotinic acetylcholine receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            429,
            "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [\"honey\"],\n  \"STUDY\": [\"animal study, human study\"],\n  \"PARAMETER\": [\"oral bioavailability, pharmacokinetic parameters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "oral bioavailability"
                    ],
                    "Drug": [
                        "CBZ",
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            430,
            "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"animal study\", \"case report\"],\n  \"PARAMETER\": [\"plasma level\", \"clearance\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"rats\", \"two children\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"epilepsy\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CBZ",
                        "folinic acid",
                        "CBZ",
                        "nicotinamide",
                        "CBZ"
                    ],
                    "Parameter": [
                        "clearance"
                    ],
                    "Cohort": [
                        "two children"
                    ],
                    "Pathology": [
                        "epilepsy"
                    ]
                }
            ]
        ],
        [
            431,
            "Patients on antiepileptic therapy are usually on a long-term basis.",
            [
                " {\n  \"DRUGS\": [\"antiepileptic\"],\n  \"PARAMETER\": [\"long-term basis\"],\n  \"DURATION\": [\"long-term\"]\n}",
                {
                    "Pathology": [
                        "Patients"
                    ],
                    "Drug": [
                        "antiepileptic therapy"
                    ]
                }
            ]
        ],
        [
            432,
            "In order to achieve a comprehensive literature search, a total of eleven databases were searched.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"total of eleven databases were searched\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            433,
            "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Systematic Review\",\n  \"PARAMETER\": [\"conventional databases\", \"five other English databases\", \"four Chinese databases\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            434,
            "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.",
            [
                " {\n  \"DRUGS\": [\"CBZ\"],\n  \"HERB NAME\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"plasma level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CBZ\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ispaghula husk",
                        "septilin",
                        "soybean",
                        "Xiao-cha-hu-tang"
                    ],
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            435,
            "Caution should also be paid for beverage containing alcohol.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}\n\n{\n  \"DRUGS\": [\"aspirin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"platelet aggregation\", \"platelet function\"],\n  \"FREQUENCY\": [\"daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"healthy volunteers\"],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"3 g\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n{\n  \"DRUGS\": [\"acetaminophen\"],\n  \"HERB NAME\": [\"garlic\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"acetaminophen-induced hepatotoxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"bulbs\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],",
                {}
            ]
        ],
        [
            436,
            "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.",
            [
                " {\n  \"DRUGS\": [\"CBZ\", \"Xiao-yao-san\"],\n  \"STUDY\": \"randomized double-blinded control trial\",\n  \"PARAMETER\": [\"incidence of side effects\", \"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with major depression or bipolar disorder\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"major depression or bipolar disorder\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "a randomized double-blinded control trial"
                    ],
                    "Herb name": [
                        "Xiao-yao-san"
                    ],
                    "Drug": [
                        "CBZ"
                    ],
                    "Pathology": [
                        "dizziness",
                        "blurred vision",
                        "skin rash",
                        "nausea",
                        "major depression",
                        "bipolar disorder"
                    ]
                }
            ]
        ],
        [
            437,
            "Composition of individual herbs in the included herbal formulae.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\", \"Gastrodia elata\", \"Ligusticum wallichii\", \"Panax ginseng\", \"Pogostemon cablin\"],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [\"Anti-inflammatory activity\", \"Neuroprotective effects\", \"Immunomodulatory effects\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\", \"Rhizome\", \"Root\", \"Dried root\"],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Inflammation\", \"Neurodegenerative diseases\"],\n  \"TARGET\": [\"NF-\u03baB\", \"COX-2\", \"iNOS\", \"TNF-\u03b1\", \"IL-1\u03b2\", \"IL-6\", \"IL-10\", \"IL-13\", \"IL-4\", \"IFN-\u03b3\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {}
            ]
        ],
        [
            438,
            "Fifty percent of the informants used herbal medicines alongside their prescription drugs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"fifty percent\", \"herbal medicines\"],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"fifty percent\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"informants\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            439,
            "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal medicines\"],\n  \"STUDY\": \"identifying possible interactions\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"healthcare professionals\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            440,
            "A significant relationship between variables was identified if p < 0.05.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"diclofenac\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled trial\",\n  \"PARAMETER\": [\"pain intensity\", \"physical function\", \"patient global assessment\", \"patient satisfaction\"],\n  \"FREQUENCY\": [\"baseline\", \"1 week\", \"4 weeks\", \"12 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 220)\",\n  \"DURATION\": [\"1 week\", \"4 weeks\", \"12 weeks\"],\n  \"SEX\": [\"Male\", \"Female\"],\n  \"AGE\": [\"18-65 years\"],\n  \"AMOUNT\": [\"400 mg ibuprofen\", \"500 mg acetaminophen\", \"100 mg celecoxib\", \"50 mg diclofenac\", \"220 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-1 and COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            441,
            "A summary of the background characteristics of the interviewed patients is given in Table 1.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Summary of background characteristics of interviewed patients\",\n  \"PARAMETER\": [\"interviewed patients\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"interviewed patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            442,
            "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"type-2 diabetes\"],\n  \"FREQUENCY\": [\"highest number\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients with type-2 diabetes\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [\"age group\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "type-2 diabetes"
                    ]
                }
            ]
        ],
        [
            443,
            "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.",
            [
                " {\n  \"DRUGS\": [\"hypoglycaemic agents\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"tabular summary\",\n  \"PARAMETER\": [\"pharmacological management\", \"patients' prescribed hypoglycaemic agents\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "hypoglycaemic agents"
                    ]
                }
            ]
        ],
        [
            444,
            "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"12 identified plants\"],\n  \"STUDY\": [\"pharmacological evidence\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"12 identified plants\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes management\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            445,
            "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.",
            [
                " {\n  \"DRUGS\": [\"drugs commonly prescribed to patients with diabetes\"],\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"STUDY\": \"analysis\"\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            446,
            "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbal medicines\"],\n  \"STUDY\": \"descriptive\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"healthcare practitioners\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            447,
            "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review\",\n  \"PARAMETER\": [\"herb\u2013drug interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            448,
            "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Narrative\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Herbs have been used for primary health care for thousands of years\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Herbs"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            449,
            "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study using HepaRG cell line\",\n  \"PARAMETER\": [\"liver-specific enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "carcinoma"
                    ],
                    "Parameter": [
                        "liver-specific enzymes"
                    ]
                }
            ]
        ],
        [
            450,
            "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].",
            [
                " {\n  \"DRUGS\": [\"aspirin\"],\n  \"PARAMETER\": [\"elimination half-life\"],\n  \"FREQUENCY\": [\"approximately 15 min\"]\n}",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Parameter": [
                        "an elimination half-life"
                    ],
                    "Duration": [
                        "15 min"
                    ]
                }
            ]
        ],
        [
            451,
            "A total of 22 compounds were identified or tentatively identified (Figure 1).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Identification of compounds\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n\"A total of 22 compounds were identified or tentatively identified (Figure 1).\"\n\nNo specific entities were mentioned in the text.",
                {}
            ]
        ],
        [
            452,
            "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).",
            [
                " {\n  \"DRUGS\": [\"BNPP\", \"PNS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"concentration (\u00b5g/mL)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "BNPP"
                    ],
                    "Amount": [
                        "68 \u00b5g/mL",
                        "150 \u00b5g/mL"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            453,
            "Liver drug enzymes are the common sites of drug interaction in human.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review article\",\n  \"PARAMETER\": [\"liver drug enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"liver drug enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Liver drug enzymes"
                    ]
                }
            ]
        ],
        [
            454,
            "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"notoginsenoside R\"],\n  \"STUDY\": \"UPLC-MS/MS analysis\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)\", \"LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)\"]\n}",
                {
                    "Herb name": [
                        "PNS",
                        "notoginsenoside R"
                    ]
                }
            ]
        ],
        [
            455,
            "The influence test for PON was conducted by the method of Furlong et al.",
            [
                " {\n  \"DRUGS\": [\"PON\"],\n  \"STUDY\": \"influence test\",\n  \"TARGET\": [\"PON\"]\n}",
                {
                    "Parameter": [
                        "PON"
                    ]
                }
            ]
        ],
        [
            456,
            "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"RNA extraction\",\n  \"PARAMETER\": [\"Total RNA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"2 \u00d7 10\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Trizol (CW0581, CWbio, Beijing, China)\"]\n}",
                {
                    "Amount": [
                        "2 \u00d7 10"
                    ],
                    "Parameter": [
                        "Total RNA"
                    ]
                }
            ]
        ],
        [
            457,
            "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.",
            [
                " {\n  \"DRUGS\": [\"aspirin\"],\n  \"STUDY\": \"mechanism exploration\",\n  \"TARGET\": [\"HDI (hemi-deacetylase inhibitor)\"],\n  \"PNS\": [\"peripheral nervous system\"]\n}",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            458,
            "conceived and designed the whole experiments.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"receptor affinity\", \"selectivity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"muscarinic acetylcholine receptors (mAChRs)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            459,
            "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).",
            [
                " {\n  \"DRUGS\": [\"Ibuprofen\", \"Diclofenac\", \"Acetaminophen\"],\n  \"HERB NAME\": [\"Turmeric\", \"Curcumin\"],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"Pain intensity\", \"Swelling\", \"C-reactive protein (CRP)\", \"Tumor necrosis factor-alpha (TNF-\u03b1)\", \"Interleukin-6 (IL-6)\", \"Interleukin-1\u03b2 (IL-1\u03b2)\"],\n  \"FREQUENCY\": [\"At baseline, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, and 24 hours\"],\n  \"HERB PART\": [\"Rhizome\"],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg of ibuprofen, 100 mg of diclofenac, or 1 g of acetaminophen; 1 g of turmeric rhizome powder\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase (COX-1 and COX-2)\", \"Nuclear factor-\u03baB (NF-\u03baB)\", \"Mitogen-activated protein kinase (MAPK)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the text\"]\n}",
                {}
            ]
        ],
        [
            460,
            "However, there is hardly any data on the pharmacological safety of these two herbal medicines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"two herbal medicines\"],\n  \"STUDY\": \"no information on the type of study described\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"no information on the parts of herb used\"],\n  \"COHORT\": \"no information on the description of the cohort\",\n  \"DURATION\": [\"no information on the durations of events\"],\n  \"SEX\": [\"no information on the sexes found in text\"],\n  \"AGE\": [\"no information on the ages found in text\"],\n  \"AMOUNT\": [\"no information on the quantities found in text\"],\n  \"ETHNIC GROUP\": [\"no information on the ethnic groups found in text\"],\n  \"PATHOLOGY\": [\"no information on the pathologies or side effects found in text\"],\n  \"TARGET\": [\"no information on the enzymes, transporters,... found in text\"],\n  \"EXTRACTION PROCESS\": [\"no information on the process of herb preparation found in text\"]\n}",
                {}
            ]
        ],
        [
            461,
            "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Inhibition study\",\n  \"PARAMETER\": [\"cytochrome P450 enzymes (CYPs)\", \"drug transporters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 enzymes (CYPs)\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": [\"use of commercial kits for CYPs inhibition quantification\", \"use of fluorescent probe substrates for drug transporters inhibition quantification\"]\n}",
                {
                    "Target": [
                        "cytochrome P450 enzymes (CYPs)"
                    ]
                }
            ]
        ],
        [
            462,
            "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Intracellular calcein fluorescence\", \"P-gp inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            463,
            "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).",
            [
                " {\n  \"DRUGS\": [\"Samento\", \"Banderol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro inhibition study\",\n  \"PARAMETER\": [\"CYP3A4\", \"CYP2C19\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"concentration of 1%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\", \"CYP2C19\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP2C19"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            464,
            "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).",
            [
                " {\n  \"DRUGS\": [\"omeprazole\"],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"Testing\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"aryl hydrocarbon receptor (AhR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "aryl hydrocarbon receptor (AhR)",
                        "CYP1A",
                        "AhR"
                    ],
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "omeprazole"
                    ]
                }
            ]
        ],
        [
            465,
            "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Samento\", \"Banderol\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"activity\", \"expression\", \"important drug metabolizing enzymes and drug transporters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"important drug metabolizing enzymes and drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            466,
            "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].",
            [
                " {\n  \"DRUGS\": [\"rifampicin\"],\n  \"HERB NAME\": [\"St. John\u2019s Wort\"],\n  \"STUDY\": \"Observational studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"deteriorate drug efficacy, reducing bioavailability, increasing clearance\"],\n  \"TARGET\": [\"drug metabolizing enzymes, drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "PXR"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Herb name": [
                        "John\u2019s Wort"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            467,
            "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Flow cytometry\",\n  \"PARAMETER\": [\"BCRP inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"BCRP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "BCRP",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            468,
            "Results for the positive controls rifampicin and cyclosporine A were published previously [25].",
            [
                " {\n  \"DRUGS\": [\"rifampicin\", \"cyclosporine A\"],\n  \"STUDY\": \"Results published previously\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "rifampicin",
                        "cyclosporine A"
                    ]
                }
            ]
        ],
        [
            469,
            "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Samento\", \"Banderol\"],\n  \"STUDY\": \"induction assay\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"up to a dilution of 1%\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            470,
            "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"RNA\", \"cDNA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]\n}",
                {}
            ]
        ],
        [
            471,
            "Data were evaluated as described previously [28].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Data were evaluated as described previously\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            472,
            "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Samento\", \"Banderol\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Study": [
                        "in vitro"
                    ]
                }
            ]
        ],
        [
            473,
            "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\", \"AZ-AhR\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [\"MDCKII-BCRP transport activity\", \"HEK-OATP1B1 and HEK-OATP1B3 transport activity\", \"AZ-AhR signaling\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Not specified\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"Not specified\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Not specified\"],\n  \"TARGET\": [\"MDCKII-BCRP\", \"HEK-OATP1B1 and HEK-OATP1B3\", \"AZ-AhR\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Pathology": [
                        "Cancer"
                    ]
                }
            ]
        ],
        [
            474,
            "* p < 0.05, ** p < 0.01.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"platelet aggregation\"],\n  \"FREQUENCY\": [\"at baseline\", \"after 1 week\", \"after 4 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"1 week\", \"4 weeks\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Pain\", \"Inflammation\"],\n  \"TARGET\": [\"Cyclooxygenase (COX-1 and COX-2)\", \"Nuclear factor-\u03baB (NF-\u03baB)\", \"Mitogen-activated protein kinase (MAPK)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            475,
            "Results of the reporter gene assays.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"results of reporter gene assays\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            476,
            "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.",
            [
                " {\n  \"DRUGS\": [\"rifampicin\", \"Samento\"],\n  \"STUDY\": \"concentration-dependent effect\",\n  \"PARAMETER\": [\"PXR activity\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"pregnane x receptor (PXR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "pregnane x receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            477,
            "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.",
            [
                " {\n  \"DRUGS\": [\"rifampicin\", \"Samento\", \"0.033-1%\"],\n  \"STUDY\": \"Effects on protein expression\",\n  \"PARAMETER\": [\"protein expression\", \"P-glycoprotein (P-gp)\"],\n  \"FREQUENCY\": [\"four days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"20 \u00b5M\", \"0.033-1%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"P-glycoprotein (P-gp)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)"
                    ],
                    "Duration": [
                        "after four days"
                    ]
                }
            ]
        ],
        [
            478,
            "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Samento\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP2J2 mRNA decay\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2J2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Target": [
                        "CYP2J2 mRNA"
                    ]
                }
            ]
        ],
        [
            479,
            "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Molecular study\",\n  \"PARAMETER\": [\"Expression of CYP2J2 mRNA\", \"Normalization to \u03b22mg\", \"Normalization to t = 0\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2J2 mRNA\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2J2 mRNA",
                        "\u03b22mg"
                    ]
                }
            ]
        ],
        [
            480,
            "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.",
            [
                " {\n  \"DRUGS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"],\n  \"STUDY\": \"drug interaction study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            481,
            "Its original formulation was in a tablet form.",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50 value\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1 and COX-2 isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            482,
            "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"aqueous suspension\"],\n  \"STUDY\": [\"description\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"officially listed in the Korean Pharmaceutical Codex\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"developed for convenient administration\", \"aqueous suspension\"]\n}",
                {
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Extraction process": [
                        "aqueous suspension"
                    ]
                }
            ]
        ],
        [
            483,
            "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Bovis Calculus\", \"Dioscoreae Rhizoma\", \"Glycyrrhizae Radix et Rhizoma\", \"Ginseng Radix\", \"Typhae Pollen\", \"Massa Medicata Fermentata\", \"Glycine Semen Germinatum\", \"Cinnamomi cortex\", \"Paeoniae Radix\", \"Liriopis Tuber\", \"Scutellariae Radix\", \"Angelicae Gigantis Radix\", \"Saposhnikoviae Radix\", \"Atractylodis Rhizoma Alba\", \"Bupleuri Radix\", \"Platycodonis Radix\", \"Armeniacae Semen\", \"Poria Sclerotium\", \"Cnidii Rhizoma\", \"Civet\", \"Antelopis Cornu\", \"Borneolum\"],\n  \"STUDY\": \"Description of composition of a herbal suspension\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Radix\", \"Rhizoma\", \"Pollen\", \"Sclerotium\", \"Cortex\", \"Tuber\", \"Germinatum\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Quantity in 30 ml (mg)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Description of preparation process not provided\"]\n}",
                {
                    "Herb name": [
                        "woohwangchengonsimwon suspension",
                        "Dioscoreae",
                        "Glycyrrhizae",
                        "Ginseng",
                        "Typhae",
                        "Massa Medicata Fermentata",
                        "Cinnamomi",
                        "Paeoniae",
                        "Liriopis",
                        "Scutellariae",
                        "Angelicae Gigantis",
                        "Saposhnikoviae",
                        "Atractylodis",
                        "Bupleuri",
                        "Platycodonis",
                        "Armeniacae",
                        "Poria Sclerotium",
                        "Cnidii",
                        "Civet",
                        "Borneolum",
                        "Ampelopsis",
                        "Zingiberis",
                        "Borneolum",
                        "borneol",
                        "isoborneol"
                    ],
                    "Herb part": [
                        "Rhizoma",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Pollen",
                        "cortex",
                        "Radix",
                        "Tuber",
                        "Radix",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radis",
                        "Rhizoma"
                    ]
                }
            ]
        ],
        [
            484,
            "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"subjects\"],\n  \"FREQUENCY\": [\"2 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"study period\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            485,
            "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"CYP2B6 genotyping\",\n  \"PARAMETER\": [\"CYP2B6 genotyping\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": [\"PCR products\", \"pyrosequencing\"]\n}",
                {
                    "Target": [
                        "CYP2B6",
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            486,
            "Safety monitoring was performed throughout the study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"The study description was not provided.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"The description of the cohort was not provided.\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Safety monitoring was performed throughout the study.\"]\n}",
                {}
            ]
        ],
        [
            487,
            "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of experimental setup\",\n  \"PARAMETER\": [\"5500 V\", \"500\u00b0C\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            488,
            "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"analytical data\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"analytical data\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            489,
            "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.",
            [
                " {\n  \"DRUGS\": [\"bupropion\"],\n  \"PARAMETER\": [\"AUC(0,\u221e)\", \"Cmax\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Parameter": [
                        "AUC(0,\u221e)",
                        "Cmax"
                    ],
                    "Drug": [
                        "bupropion",
                        "4-hydroxybupropion"
                    ]
                }
            ]
        ],
        [
            490,
            "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [\"within-subject data\"],\n  \"FREQUENCY\": [\"Geometric mean ratios\", \"90% confidence intervals\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            491,
            "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"blood pressure\", \"heart rate\", \"body temperature\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "blood pressure",
                        "heart rate",
                        "body temperature"
                    ]
                }
            ]
        ],
        [
            492,
            "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.",
            [
                " {\n  \"DRUGS\": [\"bupropion\", \"woohwangcheongsimwon suspension\"],\n  \"STUDY\": \"pharmacokinetics study\",\n  \"PARAMETER\": [\"CYP2B6 inhibitory effects\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2B6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2B6"
                    ],
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            493,
            "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.",
            [
                " {\n  \"DRUGS\": [\"statins\", \"grapefruit\", \"pomegranate\"],\n  \"HERB NAME\": [\"grapefruit\", \"pomegranate\"],\n  \"STUDY\": \"reaction toward different types of statins\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "statins",
                        "statins",
                        "statin"
                    ],
                    "Herb name": [
                        "grapefruit",
                        "pomegranate"
                    ]
                }
            ]
        ],
        [
            494,
            "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"tyrosine kinases\", \"malignancies\"],\n  \"FREQUENCY\": [\"overexpression\", \"somatic mutations\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"malignancies\"],\n  \"TARGET\": [\"tyrosine kinases\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "tyrosine kinases"
                    ]
                }
            ]
        ],
        [
            495,
            "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).",
            [
                " {\n  \"DRUGS\": [\"APG\", \"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"Pgp/MDR1 protein inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"APG-pretreated rats, rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Pgp/MDR1 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "Pgp",
                        "MDR1"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            496,
            "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.",
            [
                " {\n  \"DRUGS\": [\"APG\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro investigation\",\n  \"PARAMETER\": [\"BCRP/ABCG2 protein expression\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"BCRP/ABCG2 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ]
                }
            ]
        ],
        [
            497,
            "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).",
            [
                " {\n  \"DRUGS\": [\"APG\", \"DAS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"BCPR/ABCG2 protein\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"APG-pretreated rats, DAS only rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"BCPR/ABCG2 protein\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCPR",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            498,
            "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbs\"],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [\"pharmacokinetic disposition\", \"drug-metabolizing enzymes (DME)\", \"drug transporters\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"drug-metabolizing enzymes (DME)\", \"drug transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            499,
            "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.",
            [
                " {\n  \"DRUGS\": [\"APG\", \"DAS\"],\n  \"STUDY\": \"Pharmacokinetic interaction study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            500,
            "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"DURATION\": [\"not specified\"]\n}",
                {
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg"
                    ]
                }
            ]
        ],
        [
            501,
            "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"12-h light/dark cycle\", \"25 \u00b0C\", \"food and water\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Six animals per cage, total of 24 animals\",\n  \"DURATION\": [\"One week prior to experiment\", \"12 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "four groups (n = 6)"
                    ]
                }
            ]
        ],
        [
            502,
            "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.",
            [
                " {\n  \"DRUGS\": [\"DAS\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Body not specified\"],\n  \"FREQUENCY\": [\"7 days\"],\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"25 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "for 7 days"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg)"
                    ]
                }
            ]
        ],
        [
            503,
            "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.",
            [
                " {\n  \"DRUGS\": [\"APG\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"APG administration\"],\n  \"FREQUENCY\": [\"7th day, 2 hours\"],\n  \"DURATION\": [\"7 days\"],\n  \"COHORT\": [],\n  \"AGE\": [],\n  \"SEX\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "APG",
                        "APG"
                    ],
                    "Amount": [
                        "40 mg/kg",
                        "40 mg/kg"
                    ],
                    "Duration": [
                        "for 7 days"
                    ]
                }
            ]
        ],
        [
            504,
            "Electrospray ionization was used to ionize samples in a positive direction.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Ionization method\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            505,
            "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"APG\u2013DAS\"],\n  \"STUDY\": \"in vitro studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vivo studies"
                    ],
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            506,
            "and M.A.A.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            507,
            "; supervision, K.M.A.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1350 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-2\", \"IL-6\", \"TNF-\u03b1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            508,
            "All authors have read and agreed to the published version of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg\", \"200 mg\", \"1000 mg\", \"150 mg\", \"25 mg\", \"20 mg\", \"10 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Rheumatoid arthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2\", \"Prostaglandin E2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            509,
            "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen lysine\", \"indomethacin\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain intensity\", \"swelling\", \"platelet aggregation\", \"inflammatory markers (IL-6, IL-8, TNF-\u03b1, CRP)\"],\n  \"FREQUENCY\": [\"at baseline, 1, 2, 4, 7, and 14 days\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"14 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg, 1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-1 and COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            510,
            "All results are presented as the average \u00b1 SD.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            511,
            "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.",
            [
                " {\n  \"DRUGS\": [\"DAS\", \"APG\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"HEPATIC (A) AND INTESTINAL (B) BCRP/ABCG2 PROTEIN EXPRESSION\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"AFTER DAS ADMINISTRATION WITH OR WITHOUT APG PRETREATMENT\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"BCRP/ABCG2 PROTEIN\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Herb name": [
                        "APG"
                    ]
                }
            ]
        ],
        [
            512,
            "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Theory\",\n  \"PARAMETER\": [\"cytochrome P-450 (CYP) activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P-450 (CYP)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            513,
            "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            514,
            "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Warning\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"the elderly\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": \"the elderly\",\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            515,
            "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SC extract\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"quadriceps muscle strength (QMS)\", \"lactate at rest\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"adult women\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"SC extract\"]\n}",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "quadriceps muscle strength (QMS)",
                        "lactate"
                    ],
                    "Sex": [
                        "women"
                    ]
                }
            ]
        ],
        [
            516,
            "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"ANOVA\",\n  \"PARAMETER\": [\"QMS\", \"lactate level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "lactate level"
                    ]
                }
            ]
        ],
        [
            517,
            "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SC extract\"],\n  \"STUDY\": \"hypothesis\",\n  \"PARAMETER\": [\"muscle strength\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"humans\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "muscle strength"
                    ]
                }
            ]
        ],
        [
            518,
            "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].",
            [
                " {\n  \"STUDY\": \"Clinical trial or test\",\n  \"PARAMETER\": [\"angular velocity\", \"isokinetic knee extensions\", \"angular velocity of 60 degrees/second\", \"sets of measurements\", \"passive recovery\", \"2 min\"]\n}",
                {}
            ]
        ],
        [
            519,
            "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study description provided\",\n  \"PARAMETER\": [\"subject\u2019s knee joint center\", \"axis of the isokinetic dynamometer\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            520,
            "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"Plasma\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Stored at \u221280 \u00b0C\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            521,
            "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"mean SC extract supplementation\", \"placebo compliance\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"SC group: not specified\", \"placebo group: not specified\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"97.3% (90.2\u2212100%)\", \"95.8% (86.7\u2013100%)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SC extract",
                        "SC"
                    ]
                }
            ]
        ],
        [
            522,
            "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"height\", \"weight\", \"BMI\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "BMI"
                    ]
                }
            ]
        ],
        [
            523,
            "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Resting lactate level\"],\n  \"FREQUENCY\": [\"Baseline\", \"After 12 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "lactate level"
                    ],
                    "Duration": [
                        "12 weeks"
                    ]
                }
            ]
        ],
        [
            524,
            "have shown the association between high lactate production and reduced oxidative metabolism [47].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Association study\",\n  \"PARAMETER\": [\"lactate production\", \"oxidative metabolism\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "lactate"
                    ]
                }
            ]
        ],
        [
            525,
            "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"St. John's wort\"],\n  \"STUDY\": [\"clinically relevant reports\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe following text describes early reports of St. John's wort interacting with other drugs, affecting their bioavailability and efficacy. No specific drugs, herbs, parameters, frequencies, herb parts, cohorts, durations, ages, amounts, ethnic groups, pathologies, or target enzymes/transporters are mentioned in the text.",
                {
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "St. John's wort (SJW)"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            526,
            "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"pregnane-X-receptor (PXR)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"pregnane-X-receptor (PXR)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "pregnane\u2010X\u2010receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            527,
            "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\", \"ginseng\", \"ginger\", \"garlic\", \"milk thistle\", \"st. John's wort\"],\n  \"STUDY\": [\"clinical trials\", \"studies\", \"research\", \"investigation\"],\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"anxiety\", \"depression\", \"liver function\", \"cholesterol\", \"blood pressure\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\", \"root\", \"dried root\", \"powder\", \"extract\"],\n  \"COHORT\": [\"patients\", \"volunteers\", \"healthy subjects\", \"participants\"],\n  \"DURATION\": [\"8 weeks\", \"12 weeks\", \"4 weeks\", \"6 weeks\", \"3 months\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\", \"elderly\", \"middle-aged\"],\n  \"AMOUNT\": [\"500 mg\", \"1 g\", \"2 g\", \"3 g\", \"450 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"inflammatory bowel disease\", \"anxiety and depression\", \"non-alcoholic fatty liver disease\", \"hyperlipidemia\", \"hypertension\"],\n  \"TARGET\": [\"COX-2\", \"5-LOX\", \"NF-\u03baB\", \"IL-6\", \"TNF-\u03b1\", \"PPAR\u03b3\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": [\"dried and powdered\", \"extracted using ethanol\", \"standardized extract\", \"aqueous extract\"]\n}",
                {}
            ]
        ],
        [
            528,
            "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SJW\", \"hyperforin\", \"hypericin\", \"flavonoids\"],\n  \"STUDY\": \"in vitro and in vivo\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"a variety of potentially relevant targets for depression\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW extracts",
                        "hyperforin",
                        "hypericin",
                        "flavonoids"
                    ],
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ],
                    "Pathology": [
                        "depression"
                    ]
                }
            ]
        ],
        [
            529,
            "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.",
            [
                " {\n  \"DRUGS\": [\"SJW extracts\"],\n  \"STUDY\": \"tail suspension test\",\n  \"PARAMETER\": [\"time of immobility\"],\n  \"FREQUENCY\": [\"after antidepressant treatment\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "antidepressant treatment,"
                    ],
                    "Herb name": [
                        "SJW extracts"
                    ]
                }
            ]
        ],
        [
            530,
            "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of study about gene function\",\n  \"PARAMETER\": [\"xenobiotic receptor\", \"ligand binding\", \"nucleus\", \"specific PXR response elements (PXRRE)\", \"transcription\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"PXR\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "PXR",
                        "PXR response elements (PXRRE)"
                    ]
                }
            ]
        ],
        [
            531,
            "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).",
            [
                " {\n  \"DRUGS\": [\"hyperforin\"],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": [\"recently shown\", \"shown\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OATP2B1\", \"PXR\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "OATP2B1",
                        "PXR"
                    ],
                    "Herb name": [
                        "hyperforin",
                        "SJW",
                        "hyperforin"
                    ]
                }
            ]
        ],
        [
            532,
            "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).",
            [
                " {\n  \"DRUGS\": [\"test drugs\"],\n  \"HERB NAME\": [\"SJW extract\", \"St. John's wort\"],\n  \"STUDY\": \"pharmacokinetic interaction study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"concomitant application\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"low-hyperforin SJW extract\"]\n}",
                {
                    "Herb name": [
                        "low\u2010hyperforin SJW extract"
                    ]
                }
            ]
        ],
        [
            533,
            "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacoepidemiology methods and bioinformatics or data mining\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"high quality clinical data\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            534,
            "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Lingzhi\", \"Yunzhi\"],\n  \"STUDY\": [\"systematic reviews\", \"meta-analysis\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lingzhi",
                        "Yunzhi"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            535,
            "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Artemisinin content\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Plasmodium falciparum\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            536,
            "Figure\u00a01 summarizes the process of database searching and literature selection.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Literature selection\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            537,
            "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].",
            [
                " {\n\"DRUGS\": [\"5-FU\"],\n\"HERB NAME\": [],\n\"STUDY\": \"preclinical studies\",\n\"PARAMETER\": [\"T cell apoptosis\", \"caspase 3 activity\", \"Bax expression\", \"T cells count (CD4, CD4/CD8)\", \"appetite\", \"WBC (CD3+, CD4+ T cells, NK cells)\", \"platelets\", \"survival\", \"cytotoxicity\", \"metastasis\", \"phagocytic activity\", \"antibody production\", \"delayed hypersensitivity\", \"cell cycle arrest\"],\n\"FREQUENCY\": [],\n\"HERB PART\": [],\n\"COHORT\": [],\n\"DURATION\": [],\n\"SEX\": [],\n\"AGE\": [],\n\"AMOUNT\": [],\n\"ETHNIC GROUP\": [],\n\"PATHOLOGY\": [\"T cell apoptosis\", \"caspase 3 activity\", \"immunosuppression\"],\n\"TARGET\": [\"T cells\", \"Bax\"],\n\"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "T cell apoptosis",
                        "caspase 3 activity",
                        "Bax expression",
                        "cells count",
                        "CD4",
                        "CD4",
                        "CD8",
                        "WBC",
                        "CD3+",
                        "CD4+ T cells",
                        "NK cells",
                        "platelets",
                        "WBC",
                        "platelets",
                        "bone marrow cells",
                        "phagocytic activity",
                        "antibody production",
                        "caspase 3"
                    ],
                    "Study": [
                        "preclinical studies"
                    ],
                    "Pathology": [
                        "intestinal damage",
                        "metastasis"
                    ],
                    "Drug": [
                        "5-FU",
                        "5-FU"
                    ]
                }
            ]
        ],
        [
            538,
            "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].",
            [
                " {\n  \"DRUGS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"],\n  \"STUDY\": \"clinical trials\",\n  \"PARAMETER\": [\"tumor recurrence\", \"metastasis\"],\n  \"FREQUENCY\": [\"reduced\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "5-FU",
                        "carboplatin",
                        "cisplatin",
                        "cyclophosphamide",
                        "doxorubicin",
                        "etoposide",
                        "UFT"
                    ],
                    "Pathology": [
                        "tumor",
                        "metastasis"
                    ]
                }
            ]
        ],
        [
            539,
            "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro, In vivo\",\n  \"PARAMETER\": [\"antitumor effect\", \"tumor cell angiogenesis\", \"reactive oxygen species production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tumor\"],\n  \"TARGET\": [\"tumor cell angiogenesis\", \"reactive oxygen species\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            540,
            "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].",
            [
                " {\n  \"DRUGS\": [\"paclitaxel\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"recent study\",\n  \"PARAMETER\": [\"tumor metabolism\", \"Warburg-related proteins\", \"gut dysbiosis\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"tumor\"],\n  \"TARGET\": [\"Warburg-related proteins\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "gut dysbiosis"
                    ],
                    "Drug": [
                        "paclitaxel"
                    ]
                }
            ]
        ],
        [
            541,
            "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Yunzhi\"],\n  \"STUDY\": [\"could also enhance the cytotoxicity of anticancer drugs\"],\n  \"PARAMETER\": [\"cytotoxicity\", \"activity of cytotoxic and tumor-infiltrating lymphocytes\", \"activity of suppressor T cells\", \"superoxide dismutase (SOD) levels\", \"lipid peroxide levels\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ],
                    "Parameter": [
                        "suppressor T cells",
                        "superoxide dismutase (SOD)",
                        "lipid peroxide levels"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            542,
            "a.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\", \"PGE2 production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200, 400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"NO synthase\", \"PGE2 synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            543,
            "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and animal studies\",\n  \"PARAMETER\": [\"T helper cell balance\", \"Transcription factors (T-bet, GATA-3)\", \"Bax expression\", \"Caspase 3 activity\", \"T cell apoptosis\", \"Forkhead box protein 3 (Foxp3)\", \"Programmed death 1 (PD-1)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Transcription factors (T-bet, GATA-3)\", \"Bax\", \"Caspase 3\", \"Forkhead box protein 3 (Foxp3)\", \"Programmed death 1 (PD-1)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "T-box protein expressed in T cells (T-bet)",
                        "GATA-3",
                        "caspase 3",
                        "T cell",
                        "Forkhead box protein 3 (Foxp3)",
                        "programmed death 1 (PD-1)"
                    ]
                }
            ]
        ],
        [
            544,
            "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"medicinal mushrooms\"],\n  \"STUDY\": \"summary of outcomes\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            545,
            "Table S4.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Inhibition percentage\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Aldehyde oxidase (AO)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            546,
            "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": \"Healthy volunteers (n = 60)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male and Female\"],\n  \"AGE\": [\"Young and Middle-aged\"],\n  \"AMOUNT\": [\"500 mg of curcumin\"],\n  \"ETHNIC GROUP\": [\"Asian and Caucasian\"],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-2\", \"5-LOX\"],\n  \"EXTRACTION PROCESS\": [\"Standardized extract\"]\n}",
                {}
            ]
        ],
        [
            547,
            "Not applicable.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\", \"PGE2 production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\", \"800 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"NO synthase\", \"PGE2 synthase\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            548,
            "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Women diagnosed with breast cancer seek complementary and alternative treatment options\",\n  \"PARAMETER\": [\"frequency\", \"women diagnosed with breast cancer\"],\n  \"FREQUENCY\": [\"frequently\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"women diagnosed with breast cancer\"],\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"breast cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "breast cancer",
                        "side effects",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            549,
            "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"breast tumors\", \"estrogen receptor (ER)\"],\n  \"FREQUENCY\": [\"approximately 70\u201380%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"breast cancer\"],\n  \"TARGET\": [\"estrogen receptor (ER)\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nHormonal therapy plays a significant role in the treatment of early stage and metastatic ER-positive breast cancer. [\n\n{\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"hormonal therapy\", \"ER-positive breast cancer\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"breast cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe following drugs are used in hormonal therapy for ER-positive breast cancer: tamoxifen, aromatase inhibitors (anastrozole, letrozole, and exemestane), and selective estrogen receptor modulators (raloxifene and bazedoxifene). [\n\n{\n  \"DRUGS\": [\"tamoxifen\", \"anastrozole\", \"letrozole\", \"exemestane\", \"raloxifene\", \"bazedoxifene\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Descriptive study\",\n  \"PARAMETER\": [\"hormonal therapy\", \"ER-positive breast cancer\", \"drugs\"],\n  \"FREQUENCY",
                {
                    "Pathology": [
                        "breast tumors",
                        "ER-positive breast cancer"
                    ],
                    "Target": [
                        "estrogen receptor (ER)"
                    ],
                    "Drug": [
                        "hormonal therapy"
                    ]
                }
            ]
        ],
        [
            550,
            "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Viscum album\"],\n  \"STUDY\": [\"clinical studies\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"breast cancer patients\", \"other types of cancer\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"extracts\"]\n}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "Viscum album extracts (VAE)"
                    ],
                    "Pathology": [
                        "breast cancer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            551,
            "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.",
            [
                " {\n  \"DRUGS\": [\"Iscador Qu spec\"],\n  \"HERB NAME\": [\"mistletoe\", \"Malus domestica\"],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"total mistletoe lectin concentration\"],\n  \"COHORT\": [\"No description provided\"],\n  \"DURATION\": [\"No duration mentioned\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5 mg\", \"306 ng/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"No targets mentioned\"],\n  \"EXTRACTION PROCESS\": [\"No extraction process mentioned\"]\n}",
                {
                    "Amount": [
                        "5\u2009mg"
                    ],
                    "Herb name": [
                        "VAEM",
                        "Malus domestica",
                        "mistletoe lectin",
                        "Iscador Qu"
                    ]
                }
            ]
        ],
        [
            552,
            "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).",
            [
                " {\n  \"DRUGS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"\u03b2-estradiol\", \"dextrorphan-d\", \"Bioreclamation IVT\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Purchased from Bioreclamation IVT\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"50 donors, mixed gender\",\n  \"DURATION\": [],\n  \"SEX\": [\"mixed\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)",
                        "dextrorphan-d"
                    ],
                    "Target": [
                        "\u03b2-estradiol (E2)"
                    ]
                }
            ]
        ],
        [
            553,
            "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.",
            [
                " {\n  \"DRUGS\": [\"VAEM\", \"endoxifen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"proliferation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"concentration-dependent\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"proliferation\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "VAEM",
                        "VAEM"
                    ],
                    "Drug": [
                        "endoxifen"
                    ]
                }
            ]
        ],
        [
            554,
            "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Genotype classification\",\n  \"PARAMETER\": [\"enzyme phenotypes\"],\n  \"FREQUENCY\": [\"patients\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            555,
            "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"studies\",\n  \"PARAMETER\": [\"metabolic activity of CYP2D6\", \"long-term outcomes in breast cancer\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"breast cancer\"],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2D6"
                    ],
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            556,
            "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Retrospective study\",\n  \"PARAMETER\": [\"CYP2D6 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"50 donors\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            557,
            "(PDF 36 kb) Figure S2.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Curcuma longa\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Antioxidant activity\", \"Cytotoxicity\", \"Apoptosis\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200, 400, 800 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Cancer cells\"],\n  \"TARGET\": [\"Mitochondria\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            558,
            "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).",
            [
                " {\n  \"DRUGS\": [\"Dextromethorphan\", \"Quinidine\"],\n  \"STUDY\": \"in vitro inhibition profiles\",\n  \"PARAMETER\": [\"CYP2D6\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.1-1-2-5-10-100 \u03bcM\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Dextromethorphan",
                        "Quinidine"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            559,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg acetaminophen\", \"100 mg celecoxib\", \"100 mg diclofenac\", \"400 mg ibuprofen\", \"500 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"pain and inflammation\"],\n  \"TARGET\": [\"cyclooxygenase (COX-1 and COX-2)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            560,
            "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"HERB NAME\": [\"H. sabdariffa\"],\n  \"STUDY\": \"No study described\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "captopril"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ]
                }
            ]
        ],
        [
            561,
            "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.",
            [
                " {\n  \"DRUGS\": [\"Captopril\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"Plasma\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"30 minutes\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"180 \u00b5L\", \"20 \u00b5L (twice)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Plasma\"],\n  \"EXTRACTION PROCESS\": [\"2-4-dibromoacetophenone stock solution\", \"5% ammonia solution\"]\n}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            562,
            "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)",
            [
                " {\n  \"DRUGS\": [\"captopril\"],\n  \"PARAMETER\": [\"dose\", \"BW\", \"p.o.\"],\n  \"FREQUENCY\": [\"daily\", \"for two weeks\", \"morning\"]\n}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Duration": [
                        "for two weeks"
                    ],
                    "Drug": [
                        "captopril"
                    ],
                    "Amount": [
                        "4.5\u2009mg/200\u2009g BW"
                    ]
                }
            ]
        ],
        [
            563,
            "The animals were anaesthetized before blood collection process.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"blood collection\", \"anaesthetization\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            564,
            "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)",
            [
                " {\n  \"DRUGS\": [\"saline solution\"],\n  \"PARAMETER\": [\"body fluid\"],\n  \"FREQUENCY\": [\"loss\", \"administrating\"],\n  \"AMOUNT\": [\"1.0\u2009mL\"]\n}",
                {}
            ]
        ],
        [
            565,
            "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).",
            [
                " {\n  \"DRUGS\": [\"capturepril\"],\n  \"PARAMETER\": [\"within-run accuracy\", \"precision\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            566,
            "In selectivity testing, six rats plasma was used.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Selectivity testing\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"six rats\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            567,
            "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.",
            [
                " {\n  \"DRUGS\": [\"Captopril\", \"2-4-dibromoacetophenone\"],\n  \"STUDY\": \"Experiment\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"as a derivatization agent\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"sulfhydryl group in captopril\"],\n  \"EXTRACTION PROCESS\": [\"used as a derivatization agent\"]\n}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            568,
            "Ammonia was used during derivatization since the reaction is optimal at basic pH.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"pH\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Ammonia\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            569,
            "The reaction was then stopped by adding formic acid [17].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"reaction\"],\n  \"FREQUENCY\": [\"was then stopped\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"by adding formic acid\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"formic acid\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            570,
            "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"H. sabdariffa\"],\n  \"STUDY\": \"Two weeks of coadministration study\",\n  \"PARAMETER\": [\"GSH level\", \"expression of the PEPT1 transporter\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Two weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"GSH level\", \"PEPT1 transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Duration": [
                        "Two weeks"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ],
                    "Target": [
                        "GSH",
                        "PEPT1 transporter"
                    ]
                }
            ]
        ],
        [
            571,
            "2016; Eng et\u00a0al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [\"Expression of Bcl-2, Bax, and caspase-3\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Mice\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Cisplatin-induced apoptosis\"],\n  \"TARGET\": [\"Bcl-2, Bax, caspase-3\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            572,
            "2016).",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"doxasmoside\", \"fentanyl\", \"midazolam\", \"propofol\", \"rocuronium\", \"succinylcholine\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"animal study\",\n  \"PARAMETER\": [\"mean arterial pressure\", \"heart rate\", \"respiratory rate\", \"body temperature\", \"plasma concentrations\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"male Wistar rats\",\n  \"DURATION\": [\"30 min\", \"60 min\", \"90 min\", \"120 min\"],\n  \"SEX\": [\"male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/kg\", \"10 mg/kg\", \"20 mg/kg\", \"30 mg/kg\", \"40 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"muscarinic acetylcholine receptors\", \"opioid receptors\", \"glycine receptors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            573,
            "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"laboratory rodent chow\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Animal study\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"laboratory rodent chow\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            574,
            "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis performed on a liquid chromatography system\",\n  \"PARAMETER\": [\"liquid chromatography system\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            575,
            "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical\",\n  \"PARAMETER\": [\"results obtained from clinical study\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            576,
            "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.",
            [
                " {\n  \"DRUGS\": [\"GLT\", \"AC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"GLT\", \"AC\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "GLT"
                    ],
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            577,
            "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?",
            [
                " {\n  \"DRUGS\": [\"cephalosporins\", \"cephalexin\", \"cefazolin\", \"ceftriaxone\", \"cefotaxime\", \"cefepime\", \"imipenem\", \"piperacillin\", \"tazobactam\", \"gentamicin\", \"amikacin\", \"tobramycin\", \"vancomycin\", \"linezolid\", \"daptomycin\", \"colistin\", \"meropenem\", \"ertapenem\", \"doxycycline\", \"rifampicin\", \"isoniazid\", \"pyrazinamide\", \"ethambutol\", \"rifabutin\", \"clarithromycin\", \"azithromycin\", \"levofloxacin\", \"moxifloxacin\", \"ciprofloxacin\", \"ertapenem\", \"cefoperazone\", \"cefotetan\", \"cefuroxime\", \"cephalothin\", \"cephaloridine\", \"cephalexin\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephaloridine\", \"cephalothin\", \"cephalorid",
                {}
            ]
        ],
        [
            578,
            "(n\u00a0=\u00a06).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"400 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Amount": [
                        "6"
                    ]
                }
            ]
        ],
        [
            579,
            "wrote the manuscript.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-1 and COX-2 isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            580,
            "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            581,
            "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme-butyrylcholinesterase\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nS.M., Y.O., R.T., J.K., H.W., M.F., and K.S. conducted an in vitro study on the activity of an enzyme-butyrylcholinesterase. No information was provided about the drugs used, herbs mentioned, type of cohort, duration of the study, sex, age, amount, ethnic group, or pathologies or side effects. No information was given about the herb parts used or the extraction process.",
                {}
            ]
        ],
        [
            582,
            "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Eugenia jambolana\"],\n  \"STUDY\": \"Description\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Indian traditional herb\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Indian\"],\n  \"PATHOLOGY\": [\"diabetes mellitus\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Eugenia jambolana (EJ)"
                    ],
                    "Ethnic group": [
                        "Indian"
                    ],
                    "Pathology": [
                        "diabetes mellitus"
                    ]
                }
            ]
        ],
        [
            583,
            "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacodynamic\",\n  \"PARAMETER\": [\"blood glucose level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe given text does not provide enough information to extract any entities related to drugs, herbs, study type, parameters, frequencies, herb parts, cohort, durations, sexes, ages, amounts, ethnic groups, pathologies, or target enzymes/transporters. It only mentions that there is a reduction in blood glucose level during a pharmacodynamic study, but it does not specify which drugs, herbs, or extracts were used.",
                {
                    "Drug": [
                        "SITA"
                    ],
                    "Parameter": [
                        "blood glucose level"
                    ],
                    "Study": [
                        "pharmacodynamic study"
                    ]
                }
            ]
        ],
        [
            584,
            "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).",
            [
                " {\n  \"DRUGS\": [\"gliptins\"],\n  \"HERB NAME\": [\"EJE\"],\n  \"STUDY\": [\"research groups studying the protective and therapeutic effect\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetic\"],\n  \"TARGET\": [\"enzyme dipeptidyl peptidase-4 (DDP-4)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "EJ",
                        "EJE",
                        "anthocyanins",
                        "flavonoids"
                    ],
                    "Drug": [
                        "Gliptins",
                        "oral anti-diabetic agents"
                    ],
                    "Target": [
                        "enzyme dipeptidyl peptidase-4 (DDP-4)"
                    ]
                }
            ]
        ],
        [
            585,
            "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"safety and efficacy\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"diabetic patient\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetic patient\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            586,
            "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Dried seed of Eugenia jambolana\"],\n  \"STUDY\": \"Preparation of herb extract\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Dried seed\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"aqueous extract\", \"double maceration technique\"]\n}",
                {
                    "Herb part": [
                        "seed"
                    ],
                    "Herb name": [
                        "Eugenia jambolana"
                    ],
                    "Extraction process": [
                        "aqueous extract",
                        "double maceration technique"
                    ]
                }
            ]
        ],
        [
            587,
            "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"seven days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"filtering\", \"storing in refrigerator\"]\n}",
                {}
            ]
        ],
        [
            588,
            "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"filtrate\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"was filtered\", \"obtained in this step\", \"was mixed with the previous filtrate\"]\n}",
                {}
            ]
        ],
        [
            589,
            "Glucose level was determined using GOD-POD Erba diagnostic kits.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory study\",\n  \"PARAMETER\": [\"Glucose level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Glucose level"
                    ]
                }
            ]
        ],
        [
            590,
            "3a and b).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase (COX-1 and COX-2)\", \"Lipoxygenase (LOX)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            591,
            "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Analysis of mass chromatograms\",\n  \"PARAMETER\": [\"Mass chromatograms\", \"Peak for SITA at 0.642min\", \"PRM at 0.482 min\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "SITA",
                        "PRM",
                        "SITA",
                        "PRM"
                    ]
                }
            ]
        ],
        [
            592,
            "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Underlying mechanism\",\n  \"PARAMETER\": [\"diabetes\", \"oxidative stress\", \"inflammatory response\", \"liver damage\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\", \"liver damage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes",
                        "liver damage",
                        "oxidative stress",
                        "aberrant inflammatory response"
                    ]
                }
            ]
        ],
        [
            593,
            "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Binding affinity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            594,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\n  \"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"randomized controlled trial\",\n  \"PARAMETER\": [\"glycosylated hemoglobin (HbA1c)\", \"fasting blood glucose (FBG)\", \"body weight\", \"waist circumference\", \"hip circumference\", \"systolic blood pressure (SBP)\", \"diastolic blood pressure (DBP)\", \"high-density lipoprotein (HDL)\", \"triglycerides\", \"very low-density lipoprotein (VLDL)\", \"low-density lipoprotein (LDL)\", \"insulin resistance\", \"homeostasis model assessment of insulin resistance (HOMA-IR)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"1,024 participants with type 2 diabetes mellitus\",\n  \"DURATION\": \"24 weeks\",\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Asian\", \"Caucasian\", \"African American\", \"Hispanic\"],\n  \"PATHOLOGY\": [\"type 2 diabetes mellitus\"],\n  \"TARGET\": [\"insulin resistance\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe following entities were identified as drugs: metformin, rosiglitazone, pioglitazone.\n\nThe following entities were identified as parameters: glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), body weight, waist circumference, hip circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), high-density lipoprotein (HDL), triglycerides, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), insulin resistance, homeostasis model assessment of insulin resistance (HOMA-IR).\n\nThe study was identified as a randomized controlled trial.\n\nNo herbs were identified in the text.",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            595,
            "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"EJE\", \"SITA\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"BUN\"],\n  \"FREQUENCY\": [\"elevated levels\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Treatment with EJE and EJE\u202f+\u202fSITA\"]\n}",
                {
                    "Herb name": [
                        "EJE",
                        "EJE\u202f"
                    ],
                    "Drug": [
                        "\u202fSITA"
                    ],
                    "Parameter": [
                        "BUN"
                    ]
                }
            ]
        ],
        [
            596,
            "9, Table\u00a02).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg celecoxib/day\", \"200 mg ibuprofen/day\", \"1000 mg acetaminophen/day\", \"150 mg diclofenac/day\", \"500 mg naproxen/day\", \"20 mg piroxicam/day\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            597,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\n  \"DRUGS\": [\"metformin\", \"rosiglitazone\", \"pioglitazone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"randomized controlled trial\",\n  \"PARAMETER\": [\"glycosylated hemoglobin (HbA1c)\", \"fasting blood glucose (FBG)\", \"body weight\", \"waist circumference\", \"hip circumference\", \"systolic blood pressure (SBP)\", \"diastolic blood pressure (DBP)\", \"triglycerides (TG)\", \"total cholesterol (TC)\", \"high-density lipoprotein cholesterol (HDL-C)\", \"low-density lipoprotein cholesterol (LDL-C)\", \"very low-density lipoprotein cholesterol (VLDL-C)\", \"insulin resistance (IR)\", \"homeostasis model assessment of insulin resistance (HOMA-IR)\", \"quantitative insulin sensitivity check index (QUICKI)\", \"malondialdehyde (MDA)\", \"superoxide dismutase (SOD)\", \"glutathione peroxidase (GPx)\", \"total antioxidant status (TAS)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"120 patients with type 2 diabetes mellitus were enrolled in the study\",\n  \"DURATION\": \"12 weeks\",\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"type 2 diabetes mellitus\"],\n  \"TARGET\": [\"insulin resistance\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article does not mention any herbs, so the \"HERB NAME\" field is empty. The \"FREQUENCY\" field is empty because no information about the frequency of events is provided in the text. The \"HERB PART\" field is empty because no information about the parts of the herb used is provided in the text. The \"AMOUNT\" field is empty because no information about the quantities used is provided in the text. The \"",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            598,
            "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"PARAMETER\": [\"pharmacokinetic parameters\"],\n  \"FREQUENCY\": []\n}\n\nThe following passage refers to a study where oral administration of A. officinarum affected the pharmacokinetics of indomethacin. No additional information about the study type, herbs, cohort, duration, sex, age, amount, ethnic group, pathology, target, or extraction process was provided.",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            599,
            "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"excretion study\",\n  \"PARAMETER\": [\"excretions\", \"bile and feces\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "A.\u00a0Officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            600,
            "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"tissue homogenates\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"same method as plasma sample preparation\", \"dilution process not specified\"]\n}",
                {}
            ]
        ],
        [
            601,
            "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal experiment\",\n  \"PARAMETER\": [\"rats\", \"model group\", \"M-AOE group\", \"six rats\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            602,
            "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"bile\", \"time after dosing\"],\n  \"FREQUENCY\": [\"0\u20131 h\", \"1\u20132 h\", \"2\u20133 h\", \"3\u20134 h\", \"4\u20135 h\", \"5\u20136 h\", \"6\u20137 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            603,
            "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"Urine\", \"Feces\", \"Time after administration\"],\n  \"FREQUENCY\": [\"0\u20136 h\", \"6\u201318 h\", \"18\u201328 h\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            604,
            "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"bioanalytical method validation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            605,
            "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"HERB NAME\": [\"A. officinarum\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"gastric injury\"],\n  \"FREQUENCY\": [\"induced\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"gastric injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ],
                    "Pathology": [
                        "gastric injury"
                    ]
                }
            ]
        ],
        [
            606,
            "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.",
            [
                " {\n  \"DRUGS\": [\"indomethacin\"],\n  \"STUDY\": \"model group\",\n  \"PARAMETER\": [\"plasma concentration-time curves\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            607,
            "1).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"twice daily\", \"once daily\", \"daily\"],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-2\", \"LOX-1\", \"COX-1\"],\n  \"EXTRACTION PROCESS\": [\"Standardized extract\"]\n}",
                {}
            ]
        ],
        [
            608,
            "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"PARAMETER\": [\"INR\"],\n  \"FREQUENCY\": [\"daily\", \"monthly\"],\n  \"DURATION\": [\"maintenance\"]\n}",
                {
                    "Parameter": [
                        "INR",
                        "monitoring"
                    ],
                    "Amount": [
                        "1.7\u20132.5",
                        "1.875 mg"
                    ],
                    "Frequency": [
                        "daily"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            609,
            "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.",
            [
                " {\n  \"DRUGS\": [\"anticoagulant\"],\n  \"PARAMETER\": [\"thrombin times (TTs)\"],\n  \"FREQUENCY\": [\"occasionally\"],\n  \"AMOUNT\": [\"375 ml wine\"]\n}",
                {
                    "Amount": [
                        "375 ml"
                    ],
                    "Extraction process": [
                        "wine"
                    ],
                    "Parameter": [
                        "thrombin times (TTs)"
                    ],
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            610,
            "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Antioxidant activity\", \"Nitric oxide production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole herb\", \"Extract\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Nitric oxide synthase (NOS)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Ginkgo biloba",
                        "Dong quai"
                    ]
                }
            ]
        ],
        [
            611,
            "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Gouqizi\"],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients taking warfarin in China\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            612,
            "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"descriptive\",\n  \"PARAMETER\": [\"percentage of patients with atrial fibrillation taking warfarin in China\"],\n  \"FREQUENCY\": [\"no more than 10%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"patients with atrial fibrillation in China\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"patients in China\"],\n  \"PATHOLOGY\": [\"risk of bleeding during treatment with warfarin\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "bleeding",
                        "atrial fibrillation"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            613,
            "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Gouqizi\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"for 3 days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"three patients with prosthetic heart values\"],\n  \"DURATION\": [\"did not enhance the effects of warfarin\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"6 g\", \"daily Gouqizi dose\", \"for 3 days\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"prosthetic heart values\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Amount": [
                        "6 g"
                    ],
                    "Ethnic group": [
                        "Chinese"
                    ],
                    "Duration": [
                        "for 3 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Pathology": [
                        "prosthetic heart"
                    ]
                }
            ]
        ],
        [
            614,
            "Go to: Conflict of interests  There is no conflict of interests.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Glucose-6-phosphate dehydrogenase (G6PD)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            615,
            "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Lycium barbarum L.\"],\n  \"STUDY\": \"interaction study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Fujian Medical University Union Hospital ethics committee\",\n  \"DURATION\": [\"NO: 2015KY002\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "Lycium barbarum L.",
                        "Lycium barbarum L."
                    ]
                }
            ]
        ],
        [
            616,
            "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"Animal studies\",\n  \"PARAMETER\": [\"blood pressure\"],\n  \"FREQUENCY\": [\"reduces\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"HS extract\"]\n}",
                {
                    "Study": [
                        "Animal studies"
                    ],
                    "Herb name": [
                        "HS extract"
                    ],
                    "Parameter": [
                        "blood pressure"
                    ]
                }
            ]
        ],
        [
            617,
            "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": [\"believed to be responsible\", \"possibly because\"],\n  \"PARAMETER\": [\"antihypertensive\", \"antioxidant\", \"hypocholesterolemic\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"aqueous extracts\"]\n}",
                {
                    "Herb name": [
                        "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside",
                        "HS"
                    ],
                    "Pathology": [
                        "antihypertensive, antioxidant, and hypocholesterolemic"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ]
                }
            ]
        ],
        [
            618,
            "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"antioxidant activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe HS varieties with deeper red calyxes showed greater antioxidant activity compared to lighter red or white varieties. [\n\nNo additional information was provided in the text that could be parsed into the given fields.",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Herb part": [
                        "calyxes"
                    ],
                    "Pathology": [
                        "antioxidant activity"
                    ]
                }
            ]
        ],
        [
            619,
            "7.2.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            620,
            "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.",
            [
                " {\n  \"DRUGS\": [\"statins\", \"rosuvastatin\", \"simvastatin\", \"pravastatin\", \"atorvastatin\"],\n  \"STUDY\": \"Randomized Controlled Trials (RCTs)\",\n  \"PARAMETER\": [\"total cholesterol\", \"HDL-C (high-density lipoprotein cholesterol)\", \"LDL-C (low-density lipoprotein cholesterol)\", \"triglycerides\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"8 weeks\", \"12 weeks\", \"24 weeks\", \"52 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"LDL-C\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Cholesterol",
                        "cholesterol",
                        "total cholesterol",
                        "HDL-C",
                        "LDL-C",
                        "triglycerides"
                    ],
                    "Study": [
                        "RCT",
                        "RCT"
                    ]
                }
            ]
        ],
        [
            621,
            "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].",
            [
                " {\n  \"DRUGS\": [\"HS\"],\n  \"STUDY\": \"15 day study\",\n  \"PARAMETER\": [\"total cholesterol\"],\n  \"COHORT\": \"hypertensive patients\",\n  \"DURATION\": [\"15 days\"]\n}",
                {
                    "Duration": [
                        "15 day"
                    ],
                    "Parameter": [
                        "total cholesterol"
                    ],
                    "Pathology": [
                        "hypertensive"
                    ],
                    "Herb name": [
                        "HS"
                    ]
                }
            ]
        ],
        [
            622,
            "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "RCT"
                    ]
                }
            ]
        ],
        [
            623,
            "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS extracts\"],\n  \"STUDY\": [\"in vitro studies\", \"in vivo studies\"],\n  \"PARAMETER\": [\"hypotensive activity\", \"vasodilation\", \"calcium influx\", \"new vessel formation\", \"myocardial mass\", \"blood viscosity\", \"PI3-K/Akt pathway\", \"ERK pathway\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"endothelium-derived relaxant pathways\", \"calcium channels\", \"ACE\", \"anthocyanins\", \"cyclooxygenase\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vitro and in vivo studies"
                    ],
                    "Herb name": [
                        "HS extracts",
                        "anthocyanins"
                    ],
                    "Pathology": [
                        "hypotensive activity,",
                        "vasodilation"
                    ],
                    "Parameter": [
                        "calcium influx",
                        "myocardial mass",
                        "blood viscosity",
                        "cyclooxygenase inhibitory activity",
                        "adipocyte differentiation",
                        "PI3-K/Akt",
                        "ERK"
                    ],
                    "Target": [
                        "ACE"
                    ]
                }
            ]
        ],
        [
            624,
            "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": [\"demonstrates\"],\n  \"PARAMETER\": [\"liver function\", \"kidney function\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatotoxic\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Pathology": [
                        "hepatotoxic"
                    ]
                }
            ]
        ],
        [
            625,
            "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"HS\"],\n  \"STUDY\": \"In vitro and in vivo studies\",\n  \"PARAMETER\": [\"electrolyte levels\"],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "electrolyte levels"
                    ],
                    "Herb name": [
                        "HS extracts"
                    ],
                    "Pathology": [
                        "diuretic effects"
                    ]
                }
            ]
        ],
        [
            626,
            "As a service to our customers we are providing this early version of the manuscript.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 30)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young\"],\n  \"AMOUNT\": [\"500 mg celecoxib\", \"400 mg ibuprofen\", \"1000 mg acetaminophen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\", \"IL-6\", \"TNF-\u03b1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            627,
            "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.",
            [
                " {\n  \"DRUGS\": [\"imatinib\"],\n  \"HERB NAME\": [\"Schisandra lignans\"],\n  \"STUDY\": \"Interaction study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "imatinib"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ]
                }
            ]
        ],
        [
            628,
            "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.",
            [
                " {\n  \"DRUGS\": [\"bosutiniab\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacology\",\n  \"PARAMETER\": [\"systemic exposure\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"clinically-relevant dose\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "S. sphenanthera"
                    ],
                    "Drug": [
                        "bosutinib"
                    ]
                }
            ]
        ],
        [
            629,
            "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Predicting clinically meaningful pharmacokinetic drug interactions using PBPK modelling approaches and in vitro to in vivo extrapolation techniques\",\n  \"PARAMETER\": [\"pharmacokinetic\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "modelling approaches combined with in vitro to in vivo extrapolation techniques"
                    ]
                }
            ]
        ],
        [
            630,
            "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50 values\", \"Inhibition percentage\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            631,
            "Go to: 2.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"at baseline\", \"after 1 week\", \"after 4 weeks\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"1 week\", \"4 weeks\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            632,
            "2.1.2.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg celecoxib/day\", \"200 mg ibuprofen/day\", \"1000 mg acetaminophen/day\", \"150 mg diclofenac/day\", \"500 mg naproxen/day\", \"20 mg piroxicam/day\", \"10 mg tenoxicam/day\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            633,
            "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.",
            [
                " {\n  \"DRUGS\": [\"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\"],\n  \"STUDY\": \"extensive in vitro study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C8 enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Parameter": [
                        "recombinant CYP2C8 enzyme (supersomes)",
                        "human liver microsomes (HLM)"
                    ]
                }
            ]
        ],
        [
            634,
            "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"NADPH\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Addition of NADPH\", \"Placing on cooling block (Selleckchem, Houston, TX, USA)\"]\n}",
                {
                    "Parameter": [
                        "NADPH"
                    ]
                }
            ]
        ],
        [
            635,
            "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Theoretical analysis\",\n  \"PARAMETER\": [\"competitive, noncompetitive and mixed-inhibition models\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            636,
            "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Theoretical discussion\",\n  \"PARAMETER\": [\"concentrations of substrates\", \"K m values\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"substrates\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "concentrations of substrates",
                        "K m values"
                    ]
                }
            ]
        ],
        [
            637,
            "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [\"Partition coefficients (log P)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Partition coefficients (log P)"
                    ]
                }
            ]
        ],
        [
            638,
            "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"tissue composition\", \"log P\", \"K p (tissue-to-plasma partition coefficients)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "log P",
                        "K p (tissue\u2010to\u2010plasma partition coefficients)"
                    ]
                }
            ]
        ],
        [
            639,
            "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"PBPK model prediction\", \"clinically-reported parameter values\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "lignans"
                    ]
                }
            ]
        ],
        [
            640,
            "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"tacrolimus\"],\n  \"STUDY\": \"PBPK simulations\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [\"Schisandra lignans\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Drug": [
                        "midazolam",
                        "tacrolimus"
                    ],
                    "Study": [
                        "trial designs"
                    ]
                }
            ]
        ],
        [
            641,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            642,
            "MBI, mechanism\u2010based inhibition Go to: 4.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"MBI\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"mechanism-based inhibition\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            643,
            "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.",
            [
                " {\n  \"DRUGS\": [\"carbamazepine\", \"phenytoin\"],\n  \"HERB NAME\": [\"Schisandra lignans\"],\n  \"STUDY\": \"chronic exposure\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"chronic exposure\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "carbamazepine",
                        "phenytoin"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            644,
            "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.",
            [
                " {\n  \"DRUGS\": [\"CYP substrates\"],\n  \"HERB NAME\": [\"Schisandra\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            645,
            "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"S. sphenanthera\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Anti-cancer activity\"],\n  \"FREQUENCY\": [\"In different cancer cell lines\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "S. sphenanthera extract"
                    ],
                    "Pathology": [
                        "anti\u2010cancer activity"
                    ]
                }
            ]
        ],
        [
            646,
            "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.",
            [
                " {\n  \"DRUGS\": [\"Ginkgo biloba\", \"antiplatelet agents\"],\n  \"HERB NAME\": [\"Ginkgo biloba\"],\n  \"STUDY\": \"Report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"when coadministered\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"haemorrhage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Ginkgo biloba"
                    ],
                    "Pathology": [
                        "haemorrhage"
                    ],
                    "Drug": [
                        "antiplatelet agents"
                    ]
                }
            ]
        ],
        [
            647,
            "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Sixty Sprague\u2013Dawley rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"0.2 mg/kg\", \"240 mg/kg\", \"240 mg/kg\", \"480 mg/kg\", \"480 mg/kg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Amount": [
                        "0.2\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ]
                }
            ]
        ],
        [
            648,
            "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"mRNA expression\", \"protein expression\", \"CYP\", \"VKOR\", \"TM\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP\", \"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": [\"Microsomes incubation\", \"Real Time-Polymerase Chain Reaction\", \"Western blot\"]\n}",
                {
                    "Target": [
                        "CYP",
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            649,
            "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).",
            [
                " {\n  \"DRUGS\": [\"Danshen\", \"Gegen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacodynamic analysis\",\n  \"PARAMETER\": [\"activities and mRNA and protein expression levels of VKOR and TM\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            650,
            "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Chinese skullcap\", \"Scutellaria baicalensis\"],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Root\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Morphologically authenticated\", \"Chemically authenticated using thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            651,
            "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).",
            [
                " {\n  \"DRUGS\": [\"Racemic warfarin\", \"Diclofenac sodium\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"Inhibition of cytochrome P450 2C9 (CYP2C9) enzyme activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "warfarin",
                        "diclofenac sodium"
                    ],
                    "Herb name": [
                        "naringin"
                    ]
                }
            ]
        ],
        [
            652,
            "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatography method description\",\n  \"PARAMETER\": [\"solvent A\", \"running time\", \"percentages\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"90 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"linear gradient elution\", \"solvent A\", \"5 % for the first 5 min\", \"increased to 10, 17, 35 and 90 %\", \"returned to 5 %\", \"equilibrated for 15 min before the next injection\"]\n}",
                {}
            ]
        ],
        [
            653,
            "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.",
            [
                " {\n  \"DRUGS\": [\"CYP2C6\"],\n  \"STUDY\": \"mRNA expression ratio study\",\n  \"PARAMETER\": [\"mRNA expression ratio of CYP2C6\"],\n  \"FREQUENCY\": [\"significant increase\"],\n  \"P value\": [\"P < 0.001\"]\n}",
                {
                    "Target": [
                        "CYP2C6"
                    ]
                }
            ]
        ],
        [
            654,
            "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"mRNA expression level of CYP2C6\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C6"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            655,
            "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"ibuprofen\", \"indomethacin\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled, parallel-group\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"fever\", \"body temperature\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"2 weeks\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg acetaminophen\", \"200 mg celecoxib\", \"400 mg ibuprofen\", \"50 mg indomethacin\", \"500 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\", \"Pain and inflammation\"],\n  \"TARGET\": [\"COX-1 and COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            656,
            "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.",
            [
                " {\n  \"DRUGS\": [\"Danshen\", \"Gegen\", \"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"elicit their effects\"],\n  \"PARAMETER\": [\"microcirculation\", \"platelet aggregation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"VKOR\", \"TM\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            657,
            "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"DFG\"],\n  \"STUDY\": \"previous study\",\n  \"PARAMETER\": [\"warfarin plasma concentration\", \"PT time\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DFG"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Parameter": [
                        "PT time"
                    ]
                }
            ]
        ],
        [
            658,
            "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Gegen\"],\n  \"STUDY\": \"Taken together with the results of the current study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Gegen",
                        "DFG"
                    ]
                }
            ]
        ],
        [
            659,
            "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"Gegen\", \"Danshen\"],\n  \"STUDY\": \"case reports\",\n  \"PATHOLOGY\": [\"interactions\"],\n  \"TARGET\": []\n}",
                {
                    "Study": [
                        "clinical reports",
                        "case reports"
                    ],
                    "Herb name": [
                        "Gegen",
                        "Danshen"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            660,
            "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparison of CYP enzymes across different species\",\n  \"PARAMETER\": [\"CYP enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP enzymes",
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            661,
            "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Comparison of gene sequences\",\n  \"PARAMETER\": [\"catalytic specificity\", \"activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"isoforms\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            662,
            "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"STUDY\": \"predictive models\",\n  \"TARGET\": [\"warfarin dose\"]\n}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            663,
            "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A-\", \"CYP2C-\", \"CYP3A-\"],\n  \"EXTRACTION PROCESS\": [\"ethyl acetate extract\", \"aqueous extract\"]\n}",
                {
                    "Target": [
                        "CYP1A-",
                        "CYP2C-",
                        "CYP3A-"
                    ],
                    "Extraction process": [
                        "ethyl acetate extract",
                        "aqueous extract"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            664,
            "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [\"Danshen\"],\n  \"STUDY\": [\"in vitro\", \"in vivo\"],\n  \"PARAMETER\": [\"warfarin hydroxylation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": [\"major tanshinone components\", \"aqueous extract\"]\n}",
                {
                    "Herb name": [
                        "tanshinone",
                        "Danshen"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Study": [
                        "in vitro and in vivo"
                    ]
                }
            ]
        ],
        [
            665,
            "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SAB\", \"Danshen\"],\n  \"STUDY\": \"In vivo vs in vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe article mentions \"SAB\" (Salvia miltiorrhiza bungeana) and \"Danshen\" (Radix Salviae Miltiorrhizae) as the herb name. It describes that the in vivo effects of SAB were different from those observed in cells due to its poor absorption and bioavailability. No other entities were mentioned in the provided text.",
                {
                    "Herb name": [
                        "SAB",
                        "Danshen",
                        "SAB"
                    ],
                    "Study": [
                        "in vivo effects"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            666,
            "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo\",\n  \"PARAMETER\": [\"discrepancies\", \"results\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ]
                }
            ]
        ],
        [
            667,
            "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.",
            [
                " {\n  \"DRUGS\": [\"phenobarbital\", \"beta-naphthoflavone\", \"cyclophosphamide\"],\n  \"HERB NAME\": [\"Danshen\u2013Gegen Formula\"],\n  \"STUDY\": \"designed the study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"liver cytochrome P450\", \"vitamin K epoxide reductase\", \"vitamin K\", \"thrombomodulin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "liver cytochrome P450",
                        "vitamin K epoxide reductase",
                        "vitamin K",
                        "vitamin K",
                        "thrombomodulin"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen",
                        "salvianolic acid B"
                    ],
                    "Drug": [
                        "phenobarbital",
                        "cyclophosphamide"
                    ]
                }
            ]
        ],
        [
            668,
            "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.",
            [
                " {\n  \"DRUGS\": [\"hormone therapy\"],\n  \"HERB NAME\": [\"ginkgo biloba\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"women with early stage breast cancer\",\n  \"DURATION\": [],\n  \"SEX\": [\"women\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "hormone therapy"
                    ],
                    "Herb name": [
                        "ginkgo biloba"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Pathology": [
                        "early stage breast cancer"
                    ]
                }
            ]
        ],
        [
            669,
            "Sample preparation was based on the publication by (Beer et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Activity of hERG channel\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"hERG channel\"],\n  \"EXTRACTION PROCESS\": [\"Based on the publication by Beer et al.\"]\n}",
                {}
            ]
        ],
        [
            670,
            "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"recovery\", \"analyte\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"mean recovery\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            671,
            "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatography analysis\",\n  \"PARAMETER\": [\"extracted ion chromatograms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            672,
            "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.",
            [
                " {\n  \"DRUGS\": [\"adjuvant chemotherapy\"],\n  \"PARAMETER\": [\"mean of 37 months\", \"range 4\u2013113\"],\n  \"DURATION\": [\"mean of 37 months\", \"range 4\u2013113\"]\n}",
                {
                    "Drug": [
                        "adjuvant chemotherapy"
                    ]
                }
            ]
        ],
        [
            673,
            "Competing interests          The authors have declared no conflicts of interests.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"MIC\", \"LD50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"5-HT1A receptors\", \"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            674,
            "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Mangifera indica\"],\n  \"STUDY\": [\"research\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"chronically ill patients\", \"patients with terminal diseases\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes",
                        "hypertension",
                        "hyperlipidemia",
                        "malaria fever"
                    ],
                    "Study": [
                        "In vitro"
                    ],
                    "Herb name": [
                        "Mangifera indica"
                    ]
                }
            ]
        ],
        [
            675,
            "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"],\n  \"STUDY\": \"References\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"chronic diseases\", \"as antimalarials and antimicrobials\", \"minor ailments\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"sub-Saharan Africa\", \"India\"],\n  \"PATHOLOGY\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Alstonia boonei",
                        "Bauhinia monandra",
                        "Picralima nitida"
                    ],
                    "Pathology": [
                        "hypertension",
                        "diabetes",
                        "asthma",
                        "peptic ulcer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            676,
            "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).",
            [
                " {\n  \"DRUGS\": [\"prescription medications\", \"over-the-counter medications\"],\n  \"STUDY\": \"research article\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            677,
            "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Literature review\",\n  \"PARAMETER\": [\"metabolic capacity of CYP isoenzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            678,
            "Each mixture was filtered, concentrated, and freeze\u2010dried.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study type mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"No description provided\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"mixture\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"filtered\", \"concentrated\", \"freeze-dried\"]\n}",
                {}
            ]
        ],
        [
            679,
            "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Acetic acid\", \"HPLC-grade acetonitrile\"],\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            680,
            "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Validation of methods\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            681,
            "Multiple reaction monitoring (MRM) mode using positive ion mode.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"MRM mode\", \"positive ion mode\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            682,
            "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herb\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"fifty percent inhibitory concentration (IC50)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"aqueous extract\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"aqueous extract\"]\n}",
                {
                    "Parameter": [
                        "Fifty percent inhibitory concentration"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ]
                }
            ]
        ],
        [
            683,
            "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herbs\"],\n  \"STUDY\": \"in vitro herb\u2013drug interactions studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vitro herb\u2013drug interactions studies",
                        "in vivo herb\u2013drug interaction studies"
                    ]
                }
            ]
        ],
        [
            684,
            "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Musa sapientum unripe fruits\", \"Tetracarpidium conophorum seeds\", \"Allium sativum bulbs\"],\n  \"STUDY\": \"Pharmacology study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"unripe fruits\", \"seeds\", \"bulbs\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"eight major human CYP isoenzymes\"],\n  \"EXTRACTION PROCESS\": [\"aqueous extracts\"]\n}\n\nThis study investigated the inhibitory potential of three plant extracts on eight major human CYP isoenzymes. The plants found to have no inhibitory potential were Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs. The extracts were prepared through an aqueous process. No information was provided regarding the study design, parameters measured, frequency of events, cohort demographics, duration of events, sex, age, amount of extract used, or any potential pathologies or side effects.",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ],
                    "Herb name": [
                        "Musa sapientum",
                        "Tetracarpidium conophorum",
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "unripe fruits",
                        "seeds",
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            685,
            "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"Research study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"extraction procedure\", \"assay method\", \"concentration\", \"type of extract\", \"enzyme sources\"]\n}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ]
                }
            ]
        ],
        [
            686,
            "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"bulbs\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"aqueous extract\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"oven-dried\", \"aqueous extract\"]\n}",
                {
                    "Extraction process": [
                        "aqueous extract of oven\u2010dried"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            687,
            "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Moringa oleifera\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C9\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Leaves\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C9\"],\n  \"EXTRACTION PROCESS\": [\"Aqueous extract\"]\n}",
                {
                    "Extraction process": [
                        "Aqueous extract"
                    ],
                    "Herb name": [
                        "Moringa oleifera"
                    ],
                    "Herb part": [
                        "leaves"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            688,
            "Strandell et\u00a0al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"half-maximal inhibitory concentration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Aldehyde oxidase\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nStrandell et al. conducted an in vitro study to determine the IC50 values of Aldehyde oxidase inhibitors. No information about drugs, herbs, study population, duration, frequency, herb parts, cohort, amounts, ethnic groups, or pathologies was provided in the given text.",
                {}
            ]
        ],
        [
            689,
            "(2000).",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"etodolac\", \"tenoxicam\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled trials\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"leukotriene B4\", \"prostaglandin E2\", \"interleukin-6\", \"interleukin-8\", \"tumor necrosis factor-alpha\", \"cyclooxygenase-2\", \"prostaglandin E2 synthesis\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\", \"three times daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers and patients with osteoarthritis or rheumatoid arthritis\",\n  \"DURATION\": [\"4-6 weeks\", \"12 weeks\", \"24 weeks\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"adults\", \"elderly\"],\n  \"AMOUNT\": [\"50-1200 mg\", \"200-400 mg\", \"100-200 mg\", \"25-50 mg\", \"10-20 mg\", \"50 mg\", \"10 mg\", \"20 mg\", \"5 mg\", \"10 mg\", \"5 mg\", \"10 mg\"],\n  \"ETHNIC GROUP\": [\"Caucasian\", \"Asian\", \"African\"],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammation\", \"pain\", \"fever\"],\n  \"TARGET\": [\"cyclooxygenase-2\", \"prostaglandin E2 synthesis\", \"interleukin-6\", \"interleukin-",
                {}
            ]
        ],
        [
            690,
            "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Gongronema latifolium\", \"Alstonia boonei\"],\n  \"STUDY\": \"in vivo\",\n  \"PARAMETER\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\", \"CYP2C19\", \"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Gongronema latifolium",
                        "Alstonia boonei"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C19",
                        "CYP3A4"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Parameter": [
                        "IC"
                    ]
                }
            ]
        ],
        [
            691,
            "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"patented polyherbal formulation\"],\n  \"STUDY\": \"Description of a product\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"menopause symptoms\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"patented\"]\n}",
                {
                    "Pathology": [
                        "menopause symptoms"
                    ]
                }
            ]
        ],
        [
            692,
            "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"transition to menopause\", \"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n(2020; 81:XXX\u2013XXX) In this study, we investigated the effects of a standardized extract of Salvia miltiorrhiza (danshen) on menopausal symptoms in a multi-ethnic population.\n\n{\n  \"DRUGS\": [\"Salvia miltiorrhiza\", \"danshen\"],\n  \"HERB NAME\": [\"Salvia miltiorrhiza\", \"danshen\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"menopausal symptoms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"multi-ethnic population\",\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"600 mg/day\"],\n  \"ETHNIC GROUP\": [\"multi-ethnic\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\n(2020; 81:XXX\u2013XXX) The study included 120 participants, aged 45\u201365 years, who had experienced menopause for at least 1 year.\n\n{\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"participants\", \"aged",
                {
                    "Pathology": [
                        "menopause",
                        "hot flashes",
                        "night sweats",
                        "sleep disturbances",
                        "sexual dysfunction",
                        "mood disorders",
                        "weight gain",
                        "cognitive declines"
                    ]
                }
            ]
        ],
        [
            693,
            "34860-2.5L-R) and ammonium acetate (catalog No.",
            [
                " {\n  \"DRUGS\": [\"34860-2.5L-R\", \"ammonium acetate\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"catalog No.\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme activity\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            694,
            "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.",
            [
                " {\n\"DRUGS\": [\"phenylephrine\", \"phentolamine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"HERB NAME\": [],\n\"STUDY\": \"experimental\",\n\"PARAMETER\": [\"intraocular pressure\", \"pupil diameter\", \"heart rate\"],\n\"FREQUENCY\": [],\n\"HERB PART\": [],\n\"COHORT\": \"healthy rabbits\",\n\"DURATION\": [\"30 minutes\", \"1 hour\", \"2 hours\"],\n\"SEX\": [],\n\"AGE\": [],\n\"AMOUNT\": [\"10% w/v\", \"0.1% w/v\", \"0.5% w/v\", \"1% w/v\", \"2% w/v\"],\n\"ETHNIC GROUP\": [],\n\"PATHOLOGY\": [],\n\"TARGET\": [\"\u03b11-adrenergic receptors\", \"\u03b2-adrenergic receptors\", \"\u03b22-adrenergic receptors\"],\n\"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            695,
            "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Volunteers were recruited for this randomized, double-blind, placebo-controlled, crossover study.\",\n  \"PARAMETER\": [\"clinically significant history or presence\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"
                    ]
                }
            ]
        ],
        [
            696,
            "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.",
            [
                " {\n  \"COHORT\": \"Female volunteers\",\n  \"SEX\": [\"Female\"],\n  \"PREGNANCY\": [\"Pregnant\", \"positive test for serum human chorionic gonadotropin\"],\n  \"BREASTFEEDING\": [\"Breastfeeding\"],\n  \"PLANNING TO CONCEIVE\": [\"Planning to conceive a child\"]\n}",
                {
                    "Sex": [
                        "Female"
                    ],
                    "Parameter": [
                        "serum human chorionic gonadotropin"
                    ],
                    "Duration": [
                        "30 days"
                    ]
                }
            ]
        ],
        [
            697,
            "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.",
            [
                " {\n  \"DRUGS\": [\"MenoAct851\"],\n  \"STUDY\": \"clinical trial\",\n  \"FREQUENCY\": [\"14 days\"],\n  \"DOSE\": [\"500 mg BID\"],\n  \"HERB NAME\": [],\n  \"COHORT\": \"volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "placebo"
                    ],
                    "Herb name": [
                        "MenoAct851"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Duration": [
                        "14 days"
                    ]
                }
            ]
        ],
        [
            698,
            "Double-blinded treatments were allocated using sequentially numbered drug containers.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"double-blinded\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            699,
            "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.",
            [
                " {\n  \"DRUGS\": [\"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"],\n  \"STUDY\": \"The study described in the text is not explicitly stated, but it can be inferred that it is a research study based on the presence of Figure 4.\",\n  \"PARAMETER\": [\"plasma concentrations\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"mean (SD)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "simvastatin",
                        "simvastatin hydroxy acid",
                        "lovastatin"
                    ]
                }
            ]
        ],
        [
            700,
            "Values are expressed as mean (SD).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n},\n{\n  \"DRUGS\": [\"diclofenac\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pain intensity\", \"WOMAC score\"],\n  \"FREQUENCY\": [\"daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"120 patients with osteoarthritis\"],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [\"both males and females\"],\n  \"AGE\": [\"50-75 years\"],\n  \"AMOUNT\": [\"150 mg\"],\n  \"ETHNIC GROUP\": [\"not specified\"],\n  \"PATHOLOGY\": [\"osteoarthritis\"],\n  \"TARGET\": [\"not specified\"],\n  \"EXTRACTION PROCESS\": []\n},\n{\n  \"DRUGS\": [\"acetaminophen\"],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"pain intensity\", \"global improvement\"],\n  \"FREQUENCY\": [\"twice daily\"],\n  \"HERB PART\": [\"root\"],\n  \"COHORT\": [\"135 patients with knee osteoarthritis\"],\n  \"DUR",
                {}
            ]
        ],
        [
            701,
            "A difference was considered significant at P < 0.05.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"platelet aggregation\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"COX-2\", \"COX-1\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            702,
            "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.",
            [
                " {\n  \"DRUGS\": [\"simvastatin\"],\n  \"PARAMETER\": [\"plasma\"],\n  \"FREQUENCY\": [\"single\"],\n  \"AMOUNT\": [\"40 mg\"]\n}",
                {
                    "Frequency": [
                        "single oral dose"
                    ],
                    "Amount": [
                        "40 mg"
                    ],
                    "Drug": [
                        "simvastatin"
                    ]
                }
            ]
        ],
        [
            703,
            "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"prediction\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            704,
            "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.",
            [
                " {\n  \"DRUGS\": [\"ischemic heart disease\", \"stent\", \"multiple medications\", \"hypertension\", \"diabetes\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case Report\",\n  \"PARAMETER\": [\"severe fatigue\", \"bleeding\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"65-year-old man\"],\n  \"DURATION\": [],\n  \"SEX\": [\"man\"],\n  \"AGE\": [\"65-year-old\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"ischemic heart disease\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Case Report",
                        "case report"
                    ],
                    "Pathology": [
                        "Fatigue",
                        "Bleeding",
                        "severe fatigue",
                        "bleeding",
                        "ischemic heart disease",
                        "hypertension",
                        "diabetes"
                    ],
                    "Herb name": [
                        "Herbal Supplementations"
                    ],
                    "Age": [
                        "65-year-old"
                    ],
                    "Sex": [
                        "man"
                    ]
                }
            ]
        ],
        [
            705,
            "Drug interactions can be considered illnesses by themselves.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"diclofenac\", \"ibuprofen-naproxen\", \"naproxen\", \"phenylbutazone\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Retrospective cohort study\",\n  \"PARAMETER\": [\"risk of drug-induced acute kidney injury (AKI)\", \"AKI incidence\", \"AKI risk\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"A total of 1,021,281 patients\",\n  \"DURATION\": [\"median follow-up of 1 year\"],\n  \"SEX\": [\"male\", \"female\"],\n  \"AGE\": [\"mean age of 58.5 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"White\", \"Black\", \"Asian\", \"Hispanic\"],\n  \"PATHOLOGY\": [\"drug-induced acute kidney injury (AKI)\", \"kidney injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "illnesses"
                    ]
                }
            ]
        ],
        [
            706,
            "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Evaluating possible interactions between medication and lifestyle\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            707,
            "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.",
            [
                " {\n  \"DRUGS\": [\"personalized prescription software\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            708,
            "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.",
            [
                " {\n  \"DRUGS\": [\"warfarin\", \"echinacea\", \"policosanol\"],\n  \"HERB NAME\": [\"echinacea\", \"policosanol\"],\n  \"STUDY\": \"investigation\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea",
                        "policosanol"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            709,
            "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"CYP2C9 genotyping\",\n  \"PARAMETER\": [\"CYP2C9 polymorphisms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2C9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP2C9",
                        "VKORC1",
                        "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"
                    ]
                }
            ]
        ],
        [
            710,
            "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.",
            [
                " {\n  \"DRUGS\": [\"warfarin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"all subjects\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse events"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            711,
            "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"echinacea\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"platelet aggregation\", \"Ohms\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"n=12\",\n  \"DURATION\": [\"2 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe given text does not provide any information about drugs, herbs other than echinacea, type of study other than clinical trial, physiological or medical parameters other than platelet aggregation and Ohms, frequencies of events, parts of herb used, cohort size or demographics, durations of events, sexes, ages, quantities, ethnic groups, pathologies or side effects, enzymes, transporters, or herb preparation processes.",
                {
                    "Parameter": [
                        "Platelet aggregation"
                    ],
                    "Herb name": [
                        "echinacea",
                        "policosanol",
                        "Policosanol",
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            712,
            "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"echinacea\"],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"plasma concentrations\", \"Cmax\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"ranged from 1 to 23 ng ml\u22121\", \"ranged from 13 to 65 ng ml\u22121\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "echinacea alkamide tetraene"
                    ],
                    "Parameter": [
                        "Cmax"
                    ]
                }
            ]
        ],
        [
            713,
            "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.",
            [
                " {\n  \"DRUGS\": [\"(S)-warfarin\"],\n  \"PARAMETER\": [\"pharmacokinetics\", \"pharmacodynamics\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Drug": [
                        "(S)-warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            714,
            "Gorski et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nAccording to Gorski et al., an in vitro study was conducted to investigate the binding affinity of a novel compound towards the serotonin transporter. The IC50 value was determined. No information was provided about the drugs, herbs, frequency of events, herb parts, cohort, duration of events, sex, age, amount, ethnic group, or pathologies involved in the study. Additionally, no information was given about the extraction process of the compound used in the study.",
                {}
            ]
        ],
        [
            715,
            "The reason for the discrepancy with previous studies remains unclear.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            716,
            "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"herb-drug\"],\n  \"STUDY\": \"surveys\",\n  \"PARAMETER\": [\"levels of herb-drug use\", \"awareness of herb-drug use amongst health care professionals\"],\n  \"FREQUENCY\": [\"80%\", \"80%\", \"81%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies, Jamaican prescription drug users\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer"
                    ],
                    "Ethnic group": [
                        "Jamaican"
                    ]
                }
            ]
        ],
        [
            717,
            "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"],\n  \"STUDY\": \"Clinical studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "garlic (Allium sativum)",
                        "St. John\u2019s wort (Hypericum perforatum)",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ]
                }
            ]
        ],
        [
            718,
            "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP1A2 activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP1A2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "CYP1A2"
                    ]
                }
            ]
        ],
        [
            719,
            "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro CYP assays\",\n  \"PARAMETER\": [\"potential for herb-drug interactions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP assays\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "In vitro CYP assays"
                    ]
                }
            ]
        ],
        [
            720,
            "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"podophyllotoxin, lignans\"],\n  \"STUDY\": \"No specific study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"No specific part mentioned\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"No specific target mentioned\"],\n  \"EXTRACTION PROCESS\": [\"supplied\"]\n}",
                {
                    "Herb name": [
                        "\u03b2-Sitosterol",
                        "cadina-4,10(15)-dien-3-one",
                        "lignans",
                        "dehydropodophyllotoxin",
                        "deoxydehydropodophyllotoxin",
                        "4\u2032-demethyldesoxypodophyllotoxin",
                        "5\u2032-methoxydehydropodophyllotoxin",
                        "dehydro-b-peltatin methyl ether"
                    ]
                }
            ]
        ],
        [
            721,
            "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Not specified in given text\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified in given text\",\n  \"DURATION\": [\"stored\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"suction-filtered through type 1 Whatman filter paper\"]\n}",
                {
                    "Extraction process": [
                        "liquor"
                    ]
                }
            ]
        ],
        [
            722,
            "The following chromatographic methods were employed.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Chromatographic analysis\",\n  \"PARAMETER\": [\"chromatographic methods\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            723,
            "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"High resolution LC-MS analysis\",\n  \"PARAMETER\": [\"Mass spectrometry\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"High performance liquid chromatography (HPLC)\", \"Waters LCT Time of Flight Mass Spectrometer\", \"Waters Alliance 2690 HPLC\", \"Mass Lynx V4.1 software\"]\n}",
                {}
            ]
        ],
        [
            724,
            "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"screening\",\n  \"PARAMETER\": [\"cytochrome P450 inhibition potential\", \"CYPs 1A1, 1A2, 1B1, 3A4 and 2D6\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6\"]\n}",
                {
                    "Target": [
                        "cytochrome P450",
                        "P450 enzymes",
                        "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"
                    ]
                }
            ]
        ],
        [
            725,
            "[35].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 mg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"G6PD deficiency\"],\n  \"TARGET\": [\"G6PD\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            726,
            "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"free radical 2,2-diphenyl-1-picrylhydrazl (DPPH)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5L\", \"0.02% (w/v)\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"methanol\"]\n}",
                {}
            ]
        ],
        [
            727,
            "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"H. verticillata\"],\n  \"STUDY\": \"Phytochemical identification\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"aerial, dried\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"aqueous extract\"]\n}",
                {
                    "Extraction process": [
                        "the aqueous extract"
                    ],
                    "Herb name": [
                        "H. verticillata"
                    ],
                    "Herb part": [
                        "aerial"
                    ]
                }
            ]
        ],
        [
            728,
            "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.",
            [
                " {\n  \"DRUGS\": [\"curcumin\"],\n  \"PARAMETER\": [\"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"],\n  \"FREQUENCY\": [\"significantly (p \u2264 0.05)\"],\n  \"COHORT\": \"\",\n  \"DURATION\": \"\",\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": \"\",\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": \"\",\n  \"TARGET\": \"\",\n  \"EXTRACTION PROCESS\": \"\"\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Parameter": [
                        "area under the plasma concentration-time curve",
                        "area under the first moment of plasma drug concentration-time curve"
                    ]
                }
            ]
        ],
        [
            729,
            "Worse than the Disease?",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"Worse than the disease\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Patients with chronic pain\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Chronic pain\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "the Disease"
                    ]
                }
            ]
        ],
        [
            730,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            731,
            "Five days after presentation, her symptoms had completely resolved.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"symptoms\", \"resolution\"],\n  \"FREQUENCY\": [\"five days\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            732,
            "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Lomatium\"],\n  \"STUDY\": \"Naturopathic literature\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rashes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "rashes",
                        "the rash"
                    ],
                    "Herb name": [
                        "Lomatium",
                        "Lomatium"
                    ]
                }
            ]
        ],
        [
            733,
            "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.",
            [
                " {\n  \"DRUGS\": [\"glucocorticoids\", \"antihistamines\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"rash\"],\n  \"FREQUENCY\": [\"refractory\", \"ceased\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"our patient\"],\n  \"DURATION\": [\"once her exposure to the extract ceased\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"rash\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "the rash",
                        "pruritis"
                    ],
                    "Drug": [
                        "glucocorticoids",
                        "antihistamines"
                    ]
                }
            ]
        ],
        [
            734,
            "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Wen Bing Mixture\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"OS-induced apoptosis\", \"Cell viability\", \"Mitochondrial membrane potential\", \"ROS production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole herb\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"OS\"],\n  \"TARGET\": [\"Mitochondria\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {
                    "Drug": [
                        "OS"
                    ],
                    "Herb name": [
                        "Wen Bing formulas"
                    ]
                }
            ]
        ],
        [
            735,
            "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Radix Scutellariae\"],\n  \"STUDY\": \"Obtaining of a commercially available herb extract\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Root\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Commercially available\", \"Standardized\", \"Purified\", \"Obtained from Shanghai U-sea Biotech Co., Ltd.\", \"Batch number: 110208\", \"Quality of control standard number: WS-10001-(HD-0989)-2002\"]\n}",
                {
                    "Herb name": [
                        "Radix Scutellariae extract (RS)"
                    ]
                }
            ]
        ],
        [
            736,
            "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.",
            [
                " {\n  \"DRUGS\": [\"Albuterol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"No study mentioned\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"as internal standard\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            737,
            "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.",
            [
                " {\n  \"DRUGS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            738,
            "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.",
            [
                " {\n  \"DRUGS\": [\"dichlorvos\"],\n  \"PARAMETER\": [\"reaction\"],\n  \"FREQUENCY\": [\"terminated\"],\n  \"AMOUNT\": [\"5 \u03bcL\", \"8 mg/mL\"]\n}",
                {}
            ]
        ],
        [
            739,
            "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"antiviral activity\"],\n  \"FREQUENCY\": [\"30 min\", \"Day 5\", \"8PM\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [\"10 mL\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"about 10 mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            740,
            "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro incubation\",\n  \"PARAMETER\": [\"rat plasma\", \"reaction rate\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"for nearly all the studied herb/herbal components\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"1 \u03bcg/mL\", \"10%\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            741,
            "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"OSA\", \"herb/herbal components\"],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [\"formation rate of OSA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OSA"
                    ]
                }
            ]
        ],
        [
            742,
            "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro analysis\",\n  \"PARAMETER\": [\"ten marker components\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            743,
            "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"anti-influenza herbs/herbal components\"],\n  \"STUDY\": \"in-vitro experiments\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in-vitro experiments"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            744,
            "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.",
            [
                " {\n  \"DRUGS\": [\"RS\", \"OS\", \"OSA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"systemic exposure\", \"OS\", \"OSA\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "RS"
                    ],
                    "Drug": [
                        "OS",
                        "OSA"
                    ]
                }
            ]
        ],
        [
            745,
            "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.",
            [
                " {\n  \"DRUGS\": [\"RS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"OSA/OS ratio in rat urine samples\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"After co-administration\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"RS in rat urine samples\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OSA",
                        "OS"
                    ],
                    "Herb name": [
                        "RS"
                    ]
                }
            ]
        ],
        [
            746,
            "S8).",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\", \"200 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2 (COX-2)\", \"Prostaglandin E2 receptor (EP)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            747,
            "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"OS\", \"anti-influenza herb/herbal components\"],\n  \"STUDY\": \"screening platform development and utilization\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OS\", \"influenza viruses\", \"enzymes\", \"cells\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            748,
            "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"all the herbal extracts\", \"all the herbal components\"],\n  \"STUDY\": \"metabolic inhibition studies\",\n  \"PARAMETER\": [\"hydrolysis of OS\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 \u03bcg/mL\", \"100 \u03bcg/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OS\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "500\u202f\u03bcg/mL",
                        "100\u202f\u03bcg/mL"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            749,
            "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [\"hydrolase activities\", \"hydrolysis enzymes\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"hydrolysis enzymes\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Target": [
                        "hCE1"
                    ]
                }
            ]
        ],
        [
            750,
            "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"week 1\", \"week 2\", \"week 4\", \"week 8\", \"week 12\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers and patients with osteoarthritis\",\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [\"Male and Female\"],\n  \"AGE\": [\"Adults\"],\n  \"AMOUNT\": [\"400 mg\", \"200 mg\", \"100 mg\", \"25 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "OS",
                        "OS"
                    ]
                }
            ]
        ],
        [
            751,
            "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.",
            [
                " {\n  \"DRUGS\": [\"RS\", \"OS\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacokinetics\",\n  \"PARAMETER\": [\"elimination rate\", \"absorption rate\", \"systemic exposure (AUC)\", \"metabolic clearance (CL)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OS\"],\n  \"EXTRACTION PROCESS\": [\"in-vitro screening\", \"in-vivo pharmacokinetics in rats\", \"ex-vivo pharmacodynamic evaluation\"]\n}",
                {
                    "Herb name": [
                        "RS",
                        "RS",
                        "RS"
                    ],
                    "Parameter": [
                        "BIO",
                        "AUC"
                    ],
                    "Drug": [
                        "OS",
                        "OS"
                    ],
                    "Study": [
                        "in-vitro screening",
                        "in-vivo",
                        "ex-vivo"
                    ]
                }
            ]
        ],
        [
            752,
            "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Radix Isatidis\", \"Root of Isatis indigotica\"],\n  \"STUDY\": \"Pharmacological study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Root\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Radix Isatidis",
                        "Isatis indigotica Fort"
                    ],
                    "Herb part": [
                        "Root"
                    ]
                }
            ]
        ],
        [
            753,
            "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Fructus Arctii\", \"Fruit of Arctium lappa L.\", \"Niubangzi\"],\n  \"STUDY\": \"In vitro study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Fruit\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Fructus Arctii",
                        "Arctium lappa L."
                    ],
                    "Herb part": [
                        "Fruit"
                    ]
                }
            ]
        ],
        [
            754,
            "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"natural products\"],\n  \"STUDY\": \"estimate\",\n  \"PARAMETER\": [\"clinical breast cancer patients\", \"likelihood of drug interactions\"],\n  \"FREQUENCY\": [\"30%\u201370%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            755,
            "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.",
            [
                " {\n  \"DRUGS\": [\"TAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pre-clinical studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "natural products"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Study": [
                        "pre-clinical studies"
                    ]
                }
            ]
        ],
        [
            756,
            "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"cancer patients\", \"breast cancer patients\"],\n  \"FREQUENCY\": [\"are more likely\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"all the cancer patients, breast cancer patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"turn to complementary and alternative medicine (CAM) treatment\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "cancer",
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            757,
            "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"dried orange peel (Citrus aurantium L.)\", \"Anemarrhena (Anemarrhena asphodeloides Bunge)\", \"Phellodendron bark (Phellodendron amurense Rupr.)\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"dried orange peel\", \"Anemarrhena root\", \"Phellodendron bark\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"5-lipoxygenase (5-LOX)\"],\n  \"EXTRACTION PROCESS\": [\"ethanolic extract\", \"methanolic extract\"]\n}",
                {
                    "Herb name": [
                        "dried orange peel (Citrus aurantium L.)",
                        "Anemarrhena (Anemarrhena asphodeloides Bunge)",
                        "Phellodendron bark (Phellodendron amurense Rupr."
                    ]
                }
            ]
        ],
        [
            758,
            "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Licorice (Glycyrrhiza glabra L.)\", \"Ginger (Zingiber officinale Roscoe)\", \"Lilyturf (Ophiopogon japonicus (Thunb.))\"],\n  \"STUDY\": \"In vitro and in vivo studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"The extraction process was not specified in the given text\"]\n}",
                {
                    "Herb name": [
                        "Licorice (Glycyrrhiza glabra L.)",
                        "Ginger (Zingiber officinale Roscoe)",
                        "Lilyturf (Ophiopogon japonicus (Thunb.)"
                    ]
                }
            ]
        ],
        [
            759,
            "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"research articles\",\n  \"PARAMETER\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "anti-cancer",
                        "apoptosis, autophagy, and cell cycle arrest"
                    ]
                }
            ]
        ],
        [
            760,
            "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).",
            [
                " {\n  \"DRUGS\": [\"HES\", \"PIP\", \"BV\", \"TAM\"],\n  \"STUDY\": \"recent study\",\n  \"PARAMETER\": [\"anti-proliferative effect\", \"cell apoptosis\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HES",
                        "PIP",
                        "BV"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Pathology": [
                        "anti-proliferative effect",
                        "apoptosis"
                    ]
                }
            ]
        ],
        [
            761,
            "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).",
            [
                " {\n  \"DRUGS\": [\"combined with TAM\", \"TAM\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro study\",\n  \"PARAMETER\": [\"MCF-7 and T-47D cell growth\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "MCF-7 and T-47D cell growth"
                    ]
                }
            ]
        ],
        [
            762,
            "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Mistletoe\", \"Viscum album L.\"],\n  \"STUDY\": \"Descriptive\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Many European countries\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Mistletoe (Viscum album L.)"
                    ],
                    "Ethnic group": [
                        "European"
                    ]
                }
            ]
        ],
        [
            763,
            "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).",
            [
                " {\n  \"DRUGS\": [\"TAM\", \"TAM-resistant\"],\n  \"HERB NAME\": [\"Vitex negundo L.\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"cell viability\", \"cell growth\", \"apoptosis\"],\n  \"FREQUENCY\": [\"significantly reduces\", \"induces\", \"reverses\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 Evn-50\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"TAM resistance\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"ethyl acetate extract\"]\n}",
                {
                    "Drug": [
                        "TAM",
                        "TAM",
                        "TAM",
                        "TAM"
                    ],
                    "Herb name": [
                        "10 Evn-50",
                        "Vitex negundo L."
                    ],
                    "Extraction process": [
                        "ethyl acetate extract"
                    ],
                    "Parameter": [
                        "cell viability",
                        "cell growth"
                    ]
                }
            ]
        ],
        [
            764,
            "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Jaeumkanghwa soup\", \"JEKHT\"],\n  \"STUDY\": \"Publication\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe following text describes 12 herbs that compose Jaeumkanghwa soup (JEKHT):\n\n\"Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).\"\n\nSince no further information about the herbs or the study is provided, all fields except \"HERB NAME\" remain empty.",
                {
                    "Herb name": [
                        "Jaeumkanghwa soup (JEKHT)"
                    ]
                }
            ]
        ],
        [
            765,
            "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Jiawei Xiaoyao San (JWXYS)\"],\n  \"STUDY\": [\"research\", \"thousands of years\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"Chinese\"],\n  \"DURATION\": [\"thousands of years\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Chinese\"],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Jiawei Xiaoyao San (JWXYS)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            766,
            "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Rahate\", \"Rajasekaran\"],\n  \"STUDY\": \"The protective effect is described as a finding from a research study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"is dose-dependent\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "protective effect"
                    ]
                }
            ]
        ],
        [
            767,
            "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).",
            [
                " {\n  \"DRUGS\": [\"DDB\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"oxidative stress status\", \"antioxidant enzymes\", \"sGPT\", \"sGOT\", \"glutathione\", \"TBARS\", \"liver transaminases\"],\n  \"FREQUENCY\": [\"significant increase\", \"significant decrease\", \"reduction\", \"significant reduction\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"intoxicated\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"TAM-intoxicated liver injury\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "DDB"
                    ],
                    "Pathology": [
                        "the oxidative stress",
                        "liver injury"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "antioxidant enzymes",
                        "the activity of sGPT and sGOT",
                        "glutathione concomitant",
                        "TBARS",
                        "liver transaminases"
                    ]
                }
            ]
        ],
        [
            768,
            "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"research, shows\",\n  \"PARAMETER\": [\"protein expression levels\", \"transcription activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "protein expression levels"
                    ]
                }
            ]
        ],
        [
            769,
            "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.",
            [
                " {\n  \"DRUGS\": [\"GA\", \"PCA\", \"OAT1/3\", \"MDR1\", \"BCRP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vitro HDI\",\n  \"PARAMETER\": [\"OAT1/3\", \"MDR1\", \"BCRP\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"OAT1/3\", \"MDR1\", \"BCRP\"]\n}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Target": [
                        "OAT1/3",
                        "MDR1",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            770,
            "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"GBD Diseases and Injuries, 2020\",\n  \"PARAMETER\": [\"communicable diseases\", \"deaths\", \"disability\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Communicable diseases"
                    ]
                }
            ]
        ],
        [
            771,
            "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"P. capitatum\", \"Chinese herbal plant\"],\n  \"STUDY\": [\"Chinese Pharmacopoeia Commission, 2010\", \"Liao et al., 2011\"],\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"China\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"China\"],\n  \"PATHOLOGY\": [\"urinary tract infections\", \"pyelonephritis\", \"prostatitis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ex D. Don (P. capitatum)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Drug": [
                        "antibacterial agents"
                    ],
                    "Pathology": [
                        "urinary tract infections",
                        "pyelonephritis",
                        "prostatitis"
                    ]
                }
            ]
        ],
        [
            772,
            "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"pharmacokinetic- and tissue distribution-based HDIs studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThis text does not provide enough information to extract any specific entities related to drugs, herbs, study type, parameters, frequencies, herb parts, cohort, durations, sexes, ages, amounts, ethnic groups, pathologies, or target enzymes/transporters. The text only mentions that GA and PCA were used as tracer components in pharmacokinetic- and tissue distribution-based HDIs studies.",
                {
                    "Herb name": [
                        "GA",
                        "PCA",
                        "PCE"
                    ]
                }
            ]
        ],
        [
            773,
            "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).",
            [
                " {\n  \"DRUGS\": [\"CIP\"],\n  \"PARAMETER\": [\"60%\"],\n  \"FREQUENCY\": [\"Approximately 60%\"],\n  \"DURATION\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            774,
            "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"CIP\"],\n  \"STUDY\": [\"In vitro\", \"Animal studies\", \"Clinical studies\"],\n  \"PARAMETER\": [\"ATP-binding cassette transporters\", \"Intestinal secretion\", \"Biliary excretion\", \"Secretion into breast milk\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"ATP-binding cassette transporters\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            775,
            "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Liquid chromatography-mass spectrometry analysis\",\n  \"PARAMETER\": [\"gradient elution program\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            776,
            "The supernate was utilized for the quantification of GA, PCA, and CIP.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory\",\n  \"PARAMETER\": [\"GA\", \"PCA\", \"CIP\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"supernate\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"utilized for the quantification\"]\n}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            777,
            "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.",
            [
                " {\n  \"DRUGS\": [\"CIP\", \"ofloxacin\"],\n  \"PARAMETER\": [\"precursor-product ion transitions\"],\n  \"FREQUENCY\": []\n}",
                {
                    "Drug": [
                        "CIP",
                        "ofloxacin"
                    ]
                }
            ]
        ],
        [
            778,
            "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.",
            [
                " {\n  \"DRUGS\": [\"CIP\", \"PCE\", \"GA\", \"PCA\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetics\",\n  \"PARAMETER\": [\"PK\", \"Figures 3, 4\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP"
                    ],
                    "Herb name": [
                        "PCE",
                        "GA",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            779,
            "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.",
            [
                " {\n  \"DRUGS\": [\"ciprofloxacin\", \"PCE\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"tissue to plasma distribution coefficients (K)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "PCE",
                        "PCE",
                        "GA",
                        "PCE"
                    ],
                    "Drug": [
                        "ciprofloxacin (CIP)",
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            780,
            "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.",
            [
                " {\n  \"DRUGS\": [\"ciprofloxacin\", \"PCE\", \"gallic acid\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo study\",\n  \"PARAMETER\": [\"K tissue distribution profiles\", \"tissue to plasma distribution coefficients\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP",
                        "ciprofloxacin",
                        "CIP"
                    ],
                    "Herb name": [
                        "gallic acid (GA)",
                        "PCE",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            781,
            "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.",
            [
                " {\n  \"DRUGS\": [\"CIP\"],\n  \"STUDY\": \"Scientific article\",\n  \"PARAMETER\": [\"circulating CIP in humans\", \"liver metabolism\", \"biliary excretion\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            782,
            "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\", \"Dicentra formosa\", \"Scutellaria baicalensis\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"Cell viability\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\", \"Root\", \"Aerial part\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Cancer\", \"Cell lines\"],\n  \"TARGET\": [\"Mitochondria\", \"Mitochondrial complex I\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            783,
            "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Glucose-6-phosphate dehydrogenase (G6PD)\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in the text\"]\n}",
                {}
            ]
        ],
        [
            784,
            "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [\"daily\", \"twice daily\", \"once daily\"],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"male\"],\n  \"AGE\": [\"18-60 years\"],\n  \"AMOUNT\": [\"500 mg\", \"1000 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"pain and inflammation\"],\n  \"TARGET\": [\"cyclooxygenase-2 (COX-2)\", \"lipoxygenase (LOX)\"],\n  \"EXTRACTION PROCESS\": [\"standardized extract\"]\n}",
                {}
            ]
        ],
        [
            785,
            "Click here for additional data file.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [\"Young adults\"],\n  \"AMOUNT\": [\"400 mg celecoxib/day\", \"200 mg ibuprofen/day\", \"1000 mg acetaminophen/day\", \"150 mg diclofenac/day\", \"500 mg naproxen/day\", \"20 mg piroxicam/day\", \"10 mg tenoxicam/day\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            786,
            "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"All tests were performed\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"All tests were performed\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            787,
            "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Cross-Sectional\",\n  \"PARAMETER\": [\"pain intensity\", \"anxiety level\", \"depression level\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            788,
            "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).",
            [
                " {\n  \"DRUGS\": [\"CHO\", \"PLC\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"AUC (area under the curve)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC",
                        "CHO"
                    ],
                    "Herb name": [
                        "YM"
                    ]
                }
            ]
        ],
        [
            789,
            "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical trial\",\n  \"PARAMETER\": [\"Total Energy Expenditure (TEE)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"Treatment: YM vs. PLC\", \"Exercise time\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "Total Energy Expenditure (TEE)"
                    ],
                    "Herb name": [
                        "YM"
                    ],
                    "Drug": [
                        "PLC"
                    ]
                }
            ]
        ],
        [
            790,
            "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"previous study\",\n  \"PARAMETER\": [\"incremental protocol\", \"exercise intensities\", \"increase\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            791,
            "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"YM\"],\n  \"STUDY\": [\"human participants\", \"promising effects\", \"12 weeks of ingestion\"],\n  \"PARAMETER\": [\"metabolic rate\", \"RER\", \"blood lipid metabolites\"],\n  \"FREQUENCY\": [\"acutely\", \"after 12 weeks of ingestion\"],\n  \"HERB PART\": [],\n  \"COHORT\": [\"healthy obese participants\"],\n  \"DURATION\": [\"12 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Duration": [
                        "12 weeks"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            792,
            "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"coffee\", \"chlorogenic acids\", \"mono- and di-caffeolquinic acids\", \"hydroxycinnamic acids\", \"caffeic acid\", \"quinic acid\", \"terterpenic saponins\"],\n  \"STUDY\": \"description of metabolic effects\",\n  \"PARAMETER\": [\"adrenergic effects\", \"central nervous system\", \"lipolysis\", \"cholesterol\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"adrenergic system\", \"central nervous system\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "caffeine"
                    ]
                }
            ]
        ],
        [
            793,
            "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"YM\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Antioxidant activity\", \"Total phenolic content\", \"Total flavonoid content\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"The YM capsules were subjected to ultrasonic-assisted extraction\"]\n}",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            794,
            "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Discussion of expected outcomes\",\n  \"PARAMETER\": [\"mood state\", \"satiety\", \"fat and weight-loss\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            795,
            "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"YM\"],\n  \"STUDY\": \"single trials\",\n  \"PARAMETER\": [\"fat-loss outcomes\", \"exercise\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"females\",\n  \"DURATION\": [],\n  \"SEX\": [\"females\"],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Sex": [
                        "females"
                    ],
                    "Herb name": [
                        "YM",
                        "YM",
                        "YM"
                    ]
                }
            ]
        ],
        [
            796,
            "R.A. collected the data and contributed to data analysis and manuscript writing.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50 \u00b5g/mL\", \"100 \u00b5g/mL\", \"200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"iNOS\", \"NO synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            797,
            "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Seoul National University\", \"Prof. Yeong Bae Seo\"],\n  \"STUDY\": \"Confirmation of herb identity\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            798,
            "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Purchase of cell lines\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"purchased\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"
                    ]
                }
            ]
        ],
        [
            799,
            "Food and water were supplied ad libitum.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Food and water\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            800,
            "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.",
            [
                " {\n  \"DRUGS\": [\"isoflurane\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [\"anesthesia\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "anesthesia"
                    ],
                    "Drug": [
                        "isoflurane"
                    ]
                }
            ]
        ],
        [
            801,
            "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"LC-MS/MS system\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"Mass Hunter software\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            802,
            "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"38%\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"respondents\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            803,
            "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].",
            [
                " {\n  \"DRUGS\": [\"felodipine\"],\n  \"HERB NAME\": [\"grapefruit juice\"],\n  \"STUDY\": \"elucidated various mechanisms\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"juice\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"],\n  \"EXTRACTION PROCESS\": [\"juice\"]\n}",
                {
                    "Herb name": [
                        "grapefruit juice"
                    ],
                    "Drug": [
                        "felodipine"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP)",
                        "P-glycoprotein (P-gp)"
                    ]
                }
            ]
        ],
        [
            804,
            "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"],\n  \"STUDY\": \"\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "hydroxycut",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic",
                        "valerian"
                    ]
                }
            ]
        ],
        [
            805,
            "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"celery\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"DMEs\", \"CYP450 family\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"DMEs\", \"CYP450 family\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery"
                    ],
                    "Target": [
                        "DMEs",
                        "CYP450 family"
                    ]
                }
            ]
        ],
        [
            806,
            "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Anecdotal pieces of evidence\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"consequences of HDIs\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"consequences of HDIs\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            807,
            "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginkgo\"],\n  \"STUDY\": [\"controlled clinical studies\", \"review and meta-analysis\"],\n  \"PARAMETER\": [\"symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "Several controlled clinical studies"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Pathology": [
                        "cognition decline",
                        "memory loss",
                        "anxiety",
                        "mood disorders",
                        "fatigue",
                        "cardiovascular disorders"
                    ]
                }
            ]
        ],
        [
            808,
            "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.",
            [
                " {\n  \"DRUGS\": [\"both drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Toxicological autopsy\",\n  \"PARAMETER\": [\"serum levels\"],\n  \"FREQUENCY\": [\"before his death\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"seizure\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "seizure"
                    ]
                }
            ]
        ],
        [
            809,
            "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].",
            [
                " {\n  \"DRUGS\": [\"midazolam\"],\n  \"STUDY\": \"human studies\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"demonstrated\"],\n  \"TARGET\": [\"CYP3A4\"]\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "midazolam"
                    ],
                    "Study": [
                        "human studies"
                    ]
                }
            ]
        ],
        [
            810,
            "Chronic use of ginseng on its own has been associated with manic psychosis [90].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": [\"associated with\"],\n  \"PARAMETER\": [\"manic psychosis\"],\n  \"FREQUENCY\": [\"chronic use\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"manic psychosis\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "manic psychosis"
                    ]
                }
            ]
        ],
        [
            811,
            "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"kava\"],\n  \"STUDY\": \"Pharmacological activities\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": \"\",\n  \"AGE\": \"\",\n  \"AMOUNT\": \"\",\n  \"ETHNIC GROUP\": \"\",\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"kavalactones\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "kava",
                        "kavalactones"
                    ],
                    "Herb part": [
                        "rhizomes"
                    ]
                }
            ]
        ],
        [
            812,
            "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"kava\"],\n  \"STUDY\": \"Despite the general concern about its safety,\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Despite the general concern about its safety,\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "kava"
                    ]
                }
            ]
        ],
        [
            813,
            "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].",
            [
                " {\n  \"DRUGS\": [\"kava\", \"bromazepam\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"18 health volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Cohort": [
                        "18 health volunteers"
                    ],
                    "Herb name": [
                        "kava"
                    ],
                    "Drug": [
                        "bromazepam"
                    ]
                }
            ]
        ],
        [
            814,
            "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Kratom\"],\n  \"STUDY\": \"Descriptive\",\n  \"PARAMETER\": [\"diabetes\", \"diarrhea\", \"circulation\", \"alertness and concentration\", \"libido\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Kratom"
                    ],
                    "Pathology": [
                        "diabetes",
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            815,
            "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"SJW\"],\n  \"STUDY\": \"Description of study is missing\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonergic system\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW"
                    ]
                }
            ]
        ],
        [
            816,
            "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.",
            [
                " {\n  \"DRUGS\": [\"midazolam\", \"SJW\"],\n  \"STUDY\": \"2-way, open-label crossover study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"21 healthy subjects\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "SJW"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Study": [
                        "open-label crossover study"
                    ],
                    "Cohort": [
                        "21 healthy subjects"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            817,
            "This is important because the vast majority of herbal products are orally administered.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"G6PD deficiency\"],\n  \"TARGET\": [\"Dihydroartemisinic acid\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            818,
            "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.",
            [
                " {\n  \"DRUGS\": [\"Ibuprofen\", \"Acetaminophen\", \"Diclofenac\"],\n  \"HERB NAME\": [\"Turmeric\", \"Curcuma longa\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Inflammation\", \"Cytotoxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Inflammation\"],\n  \"TARGET\": [\"COX-2, LOX-2, iNOS\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            819,
            "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Descriptive study\",\n  \"PARAMETER\": [\"CYP3A4\", \"P-gp\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\", \"P-gp\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            820,
            "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"],\n  \"STUDY\": \"Review\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic mixture",
                        "valerian"
                    ],
                    "Herb part": [
                        "hydroxycut"
                    ],
                    "Drug": [
                        "neuropsychiatric drugs"
                    ]
                }
            ]
        ],
        [
            821,
            "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Narrative\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nMedicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.\n\n(No specific entities were identified and cited in the provided text.)",
                {}
            ]
        ],
        [
            822,
            "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.",
            [
                " {\n  \"DRUGS\": [\"Sirolimus\", \"calcineurin inhibitors\"],\n  \"STUDY\": \"description of interaction between drugs\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"kidney transplantation\"],\n  \"TARGET\": [\"calcineurin inhibitors\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "Sirolimus",
                        "calcineurin inhibitors",
                        "calcineurin inhibitors"
                    ]
                }
            ]
        ],
        [
            823,
            "This is especially important for drugs with a narrow therapeutic window.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"ibuprofen\", \"celecoxib\", \"diclofenac\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein\", \"interleukin-6\", \"tumor necrosis factor-alpha\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"300 mg acetaminophen\", \"200 mg ibuprofen\", \"100 mg celecoxib\", \"100 mg diclofenac\", \"500 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"pain and inflammation\"],\n  \"TARGET\": [\"cyclooxygenase-2\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            824,
            "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.",
            [
                " {\n  \"DRUGS\": [\"tacrolimus\", \"sirolimus\"],\n  \"PARAMETER\": [\"tremors\"],\n  \"DURATION\": [\"April 2016\"]\n}",
                {
                    "Drug": [
                        "tacrolimus",
                        "tacrolimus",
                        "sirolimus"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            825,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"serum creatinine level\"],\n  \"FREQUENCY\": [\"at that time\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            826,
            "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Discussion of herb-drug interactions and their potential adverse effects\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"serious adverse effects\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            827,
            "Author contributions: MK drafted the initial and final versions of the manuscript.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Artemisia annua\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"G6PD activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Whole plant\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"G6PD\"],\n  \"EXTRACTION PROCESS\": [\"Not specified in text\"]\n}",
                {}
            ]
        ],
        [
            828,
            "Sirolimus is an immunosuppressive drug used to prevent graft rejection.",
            [
                " {\n  \"DRUGS\": [\"Sirolimus\"],\n  \"STUDY\": \"Description of study not provided\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nSirolimus is an immunosuppressive drug. It is used to prevent graft rejection.",
                {
                    "Drug": [
                        "Sirolimus"
                    ],
                    "Pathology": [
                        "graft rejection"
                    ]
                }
            ]
        ],
        [
            829,
            "Therapeutic drug monitoring is required as with other immunosuppressive drugs.",
            [
                " {\n  \"DRUGS\": [\"immunosuppressive drugs\"],\n  \"STUDY\": \"Therapeutic drug monitoring\",\n  \"PARAMETER\": []\n}",
                {}
            ]
        ],
        [
            830,
            "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Parsley\", \"Petroselinum crispum\"],\n  \"STUDY\": \"Descriptive\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Parsley",
                        "Petroselinum crispum"
                    ]
                }
            ]
        ],
        [
            831,
            "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.",
            [
                " {\n  \"DRUGS\": [\"sirolimus\"],\n  \"STUDY\": \"Previous studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"metabolizing enzymes, transporter proteins\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            832,
            "Parsley is a food, spice, and also a medicinal herb.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Parsley\"],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Herb\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Parsley"
                    ]
                }
            ]
        ],
        [
            833,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"serum creatinine level\"],\n  \"FREQUENCY\": [\"at that time\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            834,
            "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.",
            [
                " {\n  \"DRUGS\": [\"sirolimus\"],\n  \"HERB NAME\": [\"parsley\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"juice\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"parsley juice\"]\n}",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            835,
            "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"apoptosis\", \"cell viability\", \"reactive oxygen species (ROS)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200, 400, and 800 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"cancer\", \"breast cancer\"],\n  \"TARGET\": [\"Bcl-2 protein\", \"Bax protein\", \"caspase-3\", \"caspase-9\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            836,
            "Data are expressed as mean \u00b1 S. D. (n = 6).",
            [
                " {\n  \"DRUGS\": [\"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"etodolac\", \"tenoxicam\", \"meloxicam\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"diclofenac sodium\", \"piroxicam sodium\", \"etodolac sodium\", \"tenoxicam sodium\", \"meloxicam sodium\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inhibitory effect\", \"inflammatory response\", \"cyclooxygenase-2 (COX-2) expression\", \"prostaglandin E2 (PGE2) production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 \u00b5M\", \"50 \u00b5M\", \"100 \u00b5M\", \"200 \u00b5M\", \"500 \u00b5M\", \"1 mM\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\", \"arthritis\"],\n  \"TARGET\": [\"cyclooxygenase-2 (COX-2)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            837,
            "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.",
            [
                " {\n  \"DRUGS\": [\"sildenafil\", \"Epimedium sagittatum extract\"],\n  \"HERB NAME\": [\"Epimedium sagittatum\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"statistically significant differences\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ],
                    "Drug": [
                        "sildenafil"
                    ]
                }
            ]
        ],
        [
            838,
            "et Zucc.)",
            [
                " {\n  \"DRUGS\": [\"phenylephrine\", \"diclofenac sodium\", \"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"indomethacin\", \"aspirin\", \"ibuprofen lysine\", \"diclofenac potassium\", \"celecoxib sodium\", \"naproxen sodium\", \"indomethacin sodium\", \"acetaminophen-caffeine-aspirin\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro and in vivo studies\",\n  \"PARAMETER\": [\"inflammation\", \"paw edema\", \"body temperature\", \"rectal temperature\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"24 hours\", \"7 days\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 mg/kg\", \"20 mg/kg\", \"40 mg/kg\", \"100 mg/kg\", \"200 mg/kg\", \"400 mg/kg\", \"10 mg/ml\", \"20 mg/ml\", \"40 mg/ml\", \"100 mg/ml\", \"200 mg/ml\", \"400 mg/ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammatory pain\", \"arthritis\"],\n  \"TARGET\": [\"cyclooxygenase-2 (COX-2)\", \"lipoxygenase (LOX)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            839,
            "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Epimedium sagittatum\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Activity of phosphodiesterase 5 (PDE5)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Phosphodiesterase 5 (PDE5)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            840,
            "The combined extraction solution was then evaporated to dryness.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Research article\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [\"combined extraction solution was then evaporated to dryness\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"combined extraction solution\"]\n}",
                {}
            ]
        ],
        [
            841,
            "Maxim extract are available from the authors.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers (n = 36)\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase (COX-1 and COX-2)\", \"Lipoxygenase (LOX)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Maxim"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            842,
            "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Review\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            843,
            "It most often means that we have less knowledge of benefits, as well as risks.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"aspirin\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\", \"PGE2 production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\", \"NO synthase\", \"PGE2 synthase\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            844,
            "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.",
            [
                " {\n  \"DRUGS\": [\"analgetic drugs\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"description of patient population\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"often over years\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [\"years\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "analgetic drugs"
                    ]
                }
            ]
        ],
        [
            845,
            "From the combined literature, a list of the most frequently occurring species was established.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"most frequently occurring species\"],\n  \"STUDY\": \"combined literature\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": \"not specified\"\n}",
                {}
            ]
        ],
        [
            846,
            "They found a prevalence of 56.6%.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"prevalence study\",\n  \"PARAMETER\": [\"prevalence\"],\n  \"FREQUENCY\": [\"56.6%\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            847,
            "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"complementary and alternative therapy\", \"supplement\"],\n  \"STUDY\": \"surveys\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}\n\nThe text does not provide enough information to extract details about specific drugs, herbs, studies, parameters, frequencies, herb parts, cohorts, durations, sexes, ages, amounts, ethnic groups, pathologies, or target enzymes/transporters. It only mentions that some surveys did not ask for the species used or were conducted outside of the geographical area of the review.",
                {}
            ]
        ],
        [
            848,
            "Thus, two studies from Canada and the USA were screened to find plants that patients might use.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"plants\", \"patients might use\"],\n  \"STUDY\": \"screened studies\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"patients\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            849,
            "A Spanish study reports Aloe vera [37].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Aloe vera\"],\n  \"STUDY\": \"Spanish study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Ethnic group": [
                        "Spanish"
                    ],
                    "Herb name": [
                        "Aloe vera"
                    ]
                }
            ]
        ],
        [
            850,
            "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"milk thistle\", \"silymarin\"],\n  \"STUDY\": \"Review\",\n  \"PARAMETER\": [\"hepatotoxicity\", \"liver function tests\", \"aspartate aminotransferase\", \"alanine aminotransferase\", \"gamma-glutamyl transferase\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"whole plant\", \"seeds\", \"fruit\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"hepatotoxicity\", \"liver damage\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"standardized extract\", \"dried and powdered\"]\n}",
                {
                    "Pathology": [
                        "hepatotoxic"
                    ],
                    "Frequency": [
                        "daily"
                    ]
                }
            ]
        ],
        [
            851,
            "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.",
            [
                " {\n  \"DRUGS\": [\"opioids\"],\n  \"PARAMETER\": [\"pain relief\"],\n  \"FREQUENCY\": [\"short-term use\"],\n  \"COHORT\": [\"patients who cannot reach pain relief otherwise\"],\n  \"DURATION\": [\"until surgical intervention\"]\n}",
                {
                    "Drug": [
                        "opioids"
                    ],
                    "Pathology": [
                        "pain"
                    ]
                }
            ]
        ],
        [
            852,
            "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].",
            [
                " {\n  \"DRUGS\": [\"500 mg leaf powder\"],\n  \"HERB NAME\": [\"None\"],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"Liver injury\"],\n  \"FREQUENCCY\": [\"After taking the drug every 2\u20133 days\"],\n  \"HERB PART\": [\"Leaf powder\"],\n  \"COHORT\": [\"Another patient\"],\n  \"DURATION\": [\"Not specified\"],\n  \"SEX\": [\"Not specified\"],\n  \"AGE\": [\"Not specified\"],\n  \"AMOUNT\": [\"500 mg\"],\n  \"ETHNIC GROUP\": [\"Not specified\"],\n  \"PATHOLOGY\": [\"Liver injury\"],\n  \"TARGET\": [\"Not specified\"],\n  \"EXTRACTION PROCESS\": [\"Not specified\"]\n}",
                {
                    "Pathology": [
                        "liver injury"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Herb part": [
                        "leaf"
                    ],
                    "Extraction process": [
                        "powder"
                    ],
                    "Frequency": [
                        "every 2\u20133 days"
                    ]
                }
            ]
        ],
        [
            853,
            "There are only food supplements available, with insufficiently defined product quality.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Curcuma longa\", \"turmeric\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"Antioxidant activity\", \"Cytotoxicity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200, 400, 800 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"Lipid peroxidation\", \"Protein denaturation\"],\n  \"EXTRACTION PROCESS\": [\"Methanolic extract\"]\n}",
                {}
            ]
        ],
        [
            854,
            "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Cannabis\"],\n  \"STUDY\": \"emerging as a promising option for co-treatment\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammatory diseases\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Cannabis"
                    ],
                    "Pathology": [
                        "inflammatory diseases"
                    ]
                }
            ]
        ],
        [
            855,
            "This is debated, and there are hints to possible beneficial effects [135].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"debated\"],\n  \"STUDY\": \"discussed\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"debated\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            856,
            "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].",
            [
                " {\n  \"DRUGS\": [\"Allium sativum\"],\n  \"HERB NAME\": [\"Allium sativum\"],\n  \"STUDY\": \"European pharmacopoeia monograph\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"bulbs\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"at least 0.45% allicin\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"pulverized dried\"]\n}",
                {
                    "Cohort": [
                        "European"
                    ],
                    "Herb part": [
                        "bulbs"
                    ],
                    "Herb name": [
                        "Allium sativum",
                        "allicin"
                    ],
                    "Amount": [
                        "0.45%"
                    ]
                }
            ]
        ],
        [
            857,
            "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"ginkgo\", \"Ginkgo biloba\"],\n  \"STUDY\": \"research\",\n  \"PARAMETER\": [\"ginkgolic acid content\"],\n  \"FREQUENCY\": [\"is limited to\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [\"for the refined quantified dry extract\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"5 ppm\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Extraction process": [
                        "refined quantified dry extract"
                    ],
                    "Herb name": [
                        "ginkgolic acid"
                    ],
                    "Amount": [
                        "5 ppm"
                    ]
                }
            ]
        ],
        [
            858,
            "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.",
            [
                " {\n  \"DRUGS\": [\"anticoagulant\", \"platelet inhibiting\"],\n  \"HERB NAME\": [\"ginkgo\"],\n  \"STUDY\": \"cases report\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"severe bleeding events\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"bleeding events\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "severe bleeding events",
                        "bleeding risk"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Drug": [
                        "anticoagulant or platelet inhibiting co-medication"
                    ]
                }
            ]
        ],
        [
            859,
            "There are in vitro experiments confirming thrombin inhibition [172].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro experiments\",\n  \"PARAMETER\": [\"Thrombin inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "in vitro experiments"
                    ],
                    "Target": [
                        "thrombin"
                    ]
                }
            ]
        ],
        [
            860,
            "The term \u201cginseng\u201d can be used for several drugs.",
            [
                " {\n  \"DRUGS\": [\n    \"ginseng\",\n    \"ginsenosides\",\n    \"acetylsalicylic acid\",\n    \"aspirin\",\n    \"ibuprofen\",\n    \"celecoxib\",\n    \"rofecoxib\",\n    \"naproxen\",\n    \"indomethacin\",\n    \"phenylbutazone\",\n    \"diclofenac\",\n    \"etodolac\",\n    \"tenoxicam\",\n    \"meloxicam\",\n    \"ibuprofen lysine\",\n    \"ketoprofen\",\n    \"tolmetin\",\n    \"piroxicam\",\n    \"nabumetone\",\n    \"etodolac sodium\",\n    \"diclofenac sodium\",\n    \"naproxen sodium\",\n    \"indomethacin sodium\",\n    \"phenylbutazone sodium\",\n    \"mefenamic acid\",\n    \"acetaminophen\",\n    \"ibuprofen potassium\",\n    \"ketorolac\",\n    \"tenoxicam sodium\",\n    \"meloxicam sodium\",\n    \"naproxen magnesium\",\n    \"diclofenac potassium\",\n    \"etodolac potassium\",\n    \"indomethacin potassium\",\n    \"phenylbutazone potassium\",\n    \"mefenamic acid sodium\",\n    \"acetaminophen potassium\"\n  ],\n  \"HERB NAME\": [\"ginseng\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inhibitory effect\", \"cyclooxygenase-2 (COX-2)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"ginseng root\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\",",
                {
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            861,
            "Seong et al.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}\n\nSeong et al. investigated the binding affinity of a novel compound towards the serotonin transporter using an in vitro approach. No specific drugs, herbs, or herb parts were mentioned in the text. No information was provided about the study cohort, duration of the study, sex, age, amount of compound used, or ethnic group. No pathologies or side effects were reported.",
                {}
            ]
        ],
        [
            862,
            "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"tea\"],\n  \"STUDY\": \"scientific opinion\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"HILI (Hepatotoxicity of Unknown Liver Injury)\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "HILI"
                    ],
                    "Herb name": [
                        "tea"
                    ]
                }
            ]
        ],
        [
            863,
            "HILI could occur more frequently in these groups because of the combination of risk factors.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Observational study\",\n  \"PARAMETER\": [\"HILI (Hepatotoxicity Induced Liver Injury)\"],\n  \"FREQUENCY\": [\"more frequently\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"This study included 10,000 patients\",\n  \"DURATION\": [\"over a period of 6 months\"],\n  \"SEX\": [\"Males and Females\"],\n  \"AGE\": [\"Ranges from 18 to 65 years\"],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [\"Diverse ethnic backgrounds\"],\n  \"PATHOLOGY\": [\"HILI\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "HILI"
                    ]
                }
            ]
        ],
        [
            864,
            "applied atorvastatin in rats after 3 weeks of drinking green tea or water.",
            [
                " {\n  \"DRUGS\": [\"atorvastatin\"],\n  \"HERB NAME\": [\"green tea\"],\n  \"STUDY\": \"Animal study\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"3 weeks\"],\n  \"HERB PART\": [\"none\"],\n  \"COHORT\": \"Rats\",\n  \"DURATION\": [\"3 weeks\"],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"none\"]\n}",
                {
                    "Drug": [
                        "atorvastatin"
                    ],
                    "Duration": [
                        "after 3 weeks"
                    ],
                    "Herb name": [
                        "green tea"
                    ]
                }
            ]
        ],
        [
            865,
            "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].",
            [
                " {\n  \"DRUGS\": [\"CYP\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Case report\",\n  \"PARAMETER\": [\"individual genotype\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            866,
            "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].",
            [
                " {\n  \"DRUGS\": [\"CY3A4\", \"2C9\"],\n  \"TARGET\": [\"CY3A4\", \"2C9\"],\n  \"STUDY\": \"in vitro\"\n}",
                {
                    "Herb name": [
                        "Curcuminoids"
                    ],
                    "Target": [
                        "CY3A4 and 2C9"
                    ]
                }
            ]
        ],
        [
            867,
            "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].",
            [
                " {\n  \"DRUGS\": [\"ASA\"],\n  \"PARAMETER\": [\"platelet aggregation\"],\n  \"FREQUENCY\": [\"in humans\"],\n  \"HERB NAME\": [\"Willow bark extract\"]\n}",
                {
                    "Herb name": [
                        "Willow bark extract"
                    ],
                    "Parameter": [
                        "platelet aggregation"
                    ],
                    "Drug": [
                        "ASA"
                    ]
                }
            ]
        ],
        [
            868,
            "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.",
            [
                " {\n  \"DRUGS\": [\"MTX\", \"ASA\"],\n  \"PARAMETER\": [\"AUC\"],\n  \"FREQUENCY\": [\"weekly\"],\n  \"AMOUNT\": [\"MTX doses between 7.5 and 15 mg\"]\n}",
                {
                    "Drug": [
                        "MTX",
                        "ASA"
                    ],
                    "Amount": [
                        "between 7.5 and 15 mg",
                        "+28%"
                    ],
                    "Frequency": [
                        "weekly"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            869,
            "The clinical significance of this phenomenon depends on individual susceptibility.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Clinical significance\",\n  \"PARAMETER\": [\"individual susceptibility\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"not specified\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Parameter": [
                        "individual susceptibility"
                    ]
                }
            ]
        ],
        [
            870,
            "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.",
            [
                " {\n  \"DRUGS\": [\"cephalexin\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"ibuprofen lysine\", \"celecoxib\", \"naproxen\", \"indomethacin\", \"aspirin\", \"ibuprofen sodium\", \"diclofenac sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"indomethacin sodium\", \"acetaminophen sodium\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"anti-inflammatory activity\", \"cytotoxicity\", \"inhibition of COX-1 and COX-2\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizome\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"100 \u00b5g/mL\", \"200 \u00b5g/mL\", \"300 \u00b5g/mL\", \"400 \u00b5g/mL\", \"500 \u00b5g/mL\", \"1000 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-1\", \"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            871,
            "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Valerian\"],\n  \"STUDY\": \"survey\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [\"proportion of consumption was not included in the survey by Garcia-Alvarez\"],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "HMP"
                    ]
                }
            ]
        ],
        [
            872,
            "This may result in translation errors or assigning mentions to the wrong species, in some cases.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\", \"diclofenac\", \"naproxen\", \"piroxicam\", \"tenoxicam\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Randomized Controlled Trial\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\", \"prostaglandin E2 (PGE2)\", \"leukotriene B4 (LTB4)\"],\n  \"FREQUENCY\": [\"baseline\", \"2 hours\", \"4 hours\", \"6 hours\", \"12 hours\", \"24 hours\"],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Male\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg\", \"100 mg\", \"200 mg\", \"400 mg\", \"600 mg\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Osteoarthritis\"],\n  \"TARGET\": [\"Cyclooxygenase-2 (COX-2)\", \"Prostaglandin E2 synthase (PGES)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            873,
            "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"piroxicam\", \"etodolac\", \"tenoxicam\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"diclofenac sodium\", \"piroxicam sodium\", \"etodolac sodium\", \"tenoxicam sodium\", \"meloxicob\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"IC50\", \"inhibitory effect\", \"anti-inflammatory activity\", \"cyclooxygenase-2 (COX-2) inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"10 \u00b5M\", \"20 \u00b5M\", \"30 \u00b5M\", \"40 \u00b5M\", \"50 \u00b5M\", \"100 \u00b5M\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\", \"pain\", \"arthritis\"],\n  \"TARGET\": [\"cyclooxygenase-2 (COX-2)\", \"cyclooxygenase (COX)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            874,
            "Diabetes is a complex condition with a variety of causes and pathophysiologies.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Description of a condition\",\n  \"PARAMETER\": [\"Diabetes\", \"complex condition\", \"variety of causes and pathophysiologies\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "Diabetes"
                    ]
                }
            ]
        ],
        [
            875,
            "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"discussion\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"herbal components\", \"drug molecules\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            876,
            "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"NO production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {}
            ]
        ],
        [
            877,
            "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"garlic\"],\n  \"STUDY\": \"descriptive\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"large number\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"suspected bioactive compounds called allyl thiosulfinates, mainly allicin\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "allyl thiosulfinates"
                    ]
                }
            ]
        ],
        [
            878,
            "This herb has been in use for diabetic treatment for almost two millennia [72].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"this herb\"],\n  \"STUDY\": \"historical use\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [\"almost two millennia\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetic\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            879,
            "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.",
            [
                " {\n  \"DRUGS\": [\"metformin\"],\n  \"HERB NAME\": [\"gymnema tea\"],\n  \"STUDY\": \"clinical trial\",\n  \"PARAMETER\": [\"blood sugar levels\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "diabetes"
                    ],
                    "Herb name": [
                        "gymnema"
                    ],
                    "Drug": [
                        "metformin"
                    ],
                    "Parameter": [
                        "blood sugar"
                    ]
                }
            ]
        ],
        [
            880,
            "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.",
            [
                " {\n  \"DRUGS\": [\"antidiabetics\"],\n  \"HERB NAME\": [\"Lycium\"],\n  \"STUDY\": \"Experimental\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            881,
            "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Lycium\"],\n  \"STUDY\": \"Suggests\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"Diabetes\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            882,
            "no interaction [98].",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"binding affinity\", \"IC50\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"serotonin transporter\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            883,
            "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"discussion of methodology\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            884,
            "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.",
            [
                " {\n  \"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetaminophen\"],\n  \"HERB NAME\": [\"turmeric\", \"curcumin\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"inflammation\", \"COX-2 expression\", \"PGE2 production\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"rhizomes\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"50, 100, 200 \u00b5g/mL\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"inflammation\"],\n  \"TARGET\": [\"COX-2\"],\n  \"EXTRACTION PROCESS\": [\"not specified\"]\n}",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            885,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\n  \"DRUGS\": [\"acetaminophen\", \"celecoxib\", \"diclofenac\", \"ibuprofen\", \"naproxen\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"randomized, double-blind, placebo-controlled\",\n  \"PARAMETER\": [\"pain\", \"inflammation\", \"C-reactive protein (CRP)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-alpha (TNF-\u03b1)\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy volunteers\",\n  \"DURATION\": [\"7 days\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"500 mg acetaminophen\", \"100 mg celecoxib\", \"100 mg diclofenac\", \"400 mg ibuprofen\", \"500 mg naproxen\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"osteoarthritis\", \"pain and inflammation\"],\n  \"TARGET\": [\"cyclooxygenase (COX-1 and COX-2)\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {}
            ]
        ],
        [
            886,
            "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"Folk medication\",\n  \"PARAMETER\": [\"Flatulence\", \"Cough\", \"Asthma\", \"Bronchitis\", \"Hysteria\", \"Convulsions\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Pathology": [
                        "flatulence",
                        "cough",
                        "asthma",
                        "bronchitis",
                        "hysteria",
                        "convulsions"
                    ]
                }
            ]
        ],
        [
            887,
            "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).",
            [
                " {\n  \"DRUGS\": [\"DEX\", \"dextrorphan (DOR)\"],\n  \"HERB NAME\": [],\n  \"STUDY\": [\"In vitro\", \"Study\"],\n  \"PARAMETER\": [\"O-demethylation\", \"CYP2D6\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            888,
            "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).",
            [
                " {\n  \"DRUGS\": [\"DEX\"],\n  \"STUDY\": [\"in vitro\", \"in vivo\"],\n  \"PARAMETER\": [\"CYP3A\", \"CYP2D6 activities\"],\n  \"FREQUENCY\": [],\n  \"HERB NAME\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A\", \"CYP2D6\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Parameter": [
                        "CYP3A",
                        "CYP2D6"
                    ],
                    "Study": [
                        "vivo in several studies"
                    ]
                }
            ]
        ],
        [
            889,
            "The internal standards codeine and betaxolol were of USP reference standard.",
            [
                " {\n  \"DRUGS\": [\"codeine\", \"betaxolol\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Pharmacokinetic study\",\n  \"PARAMETER\": [\"internal standards\", \"plasma concentration\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"Healthy volunteers\",\n  \"DURATION\": [\"24 hours\"],\n  \"SEX\": [\"Males\"],\n  \"AGE\": [],\n  \"AMOUNT\": [\"USP reference standard\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "codeine",
                        "betaxolol"
                    ]
                }
            ]
        ],
        [
            890,
            "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"HPLC determinations\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"GPR\", \"HPLC grade solvents\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"GPR\", \"HPLC grade solvents\"]\n}",
                {}
            ]
        ],
        [
            891,
            "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"Laboratory experiment\",\n  \"PARAMETER\": [\"Urine samples\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": [\"Urine samples were eluted on a Zorbax SB-CN column\"]\n}",
                {}
            ]
        ],
        [
            892,
            "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.",
            [
                " {\n  \"DRUGS\": [\"DEX\"],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Herb name": [
                        "Asafetida"
                    ]
                }
            ]
        ],
        [
            893,
            "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.",
            [
                " {\n  \"DRUGS\": [\"DEX\", \"DOR\"],\n  \"HERB NAME\": [\"Asafetida\", \"Asafetida resin\"],\n  \"STUDY\": \"in vitro\",\n  \"PARAMETER\": [\"formation of DOR from DEX\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [\"Asafetida resin\"],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"DOR from DEX\"],\n  \"EXTRACTION PROCESS\": [\"alcoholic extract\"]\n}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Extraction process": [
                        "Asafetida resin alcoholic extract"
                    ],
                    "Drug": [
                        "DEX"
                    ]
                }
            ]
        ],
        [
            894,
            "The activation was highest at 25\u00a0\u03bcg/ml concentration.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activation\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [\"25 \u03bcg/ml\"],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Amount": [
                        "25\u00a0\u03bcg/ml"
                    ]
                }
            ]
        ],
        [
            895,
            "The in vivo study was conducted on healthy human volunteers.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"in vivo\",\n  \"PARAMETER\": [\"healthy human volunteers\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"healthy human volunteers\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "vivo study"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            896,
            "Therefore, the clinical study was conducted to confirm the in vitro results.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical\",\n  \"PARAMETER\": [],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": \"\",\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            897,
            "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [\"Asafetida\"],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"CYP3A4 metabolic activity\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"CYP3A4\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            898,
            "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.",
            [
                " {\n  \"DRUGS\": [\"abemaciclib\"],\n  \"HERB NAME\": [],\n  \"STUDY\": \"clinical observation\",\n  \"PARAMETER\": [\"diarrhea\"],\n  \"FREQUENCY\": [\"may favor the occurrence\"],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [\"diarrhea\"],\n  \"TARGET\": [],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Drug": [
                        "abemaciclib"
                    ],
                    "Pathology": [
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            899,
            "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.",
            [
                " {\n  \"DRUGS\": [],\n  \"HERB NAME\": [],\n  \"STUDY\": \"In vitro\",\n  \"PARAMETER\": [\"activity\", \"inhibition\"],\n  \"FREQUENCY\": [],\n  \"HERB PART\": [],\n  \"COHORT\": [],\n  \"DURATION\": [],\n  \"SEX\": [],\n  \"AGE\": [],\n  \"AMOUNT\": [],\n  \"ETHNIC GROUP\": [],\n  \"PATHOLOGY\": [],\n  \"TARGET\": [\"enzyme-X\"],\n  \"EXTRACTION PROCESS\": []\n}",
                {
                    "Pathology": [
                        "fatigue",
                        "loose stools"
                    ]
                }
            ]
        ]
    ],
    "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. FInd every word refering to the described entities.\n\nThe following format must be followed:\n{\n  \"DRUGS\": [\"List of drugs found in text\"],\n  \"HERB NAME\": [\"List of herbs found in text\"],\n  \"STUDY\": Type of study described,\n  \"PARAMETER\": [\"List of physiological or medical parameters found in text\"],\n  \"FREQUENCY\": [frequences of events described in text],\n  \"HERB PART\": [\"List of parts of herb used found in text\"],\n  \"COHORT\": Description of the cohort,\n  \"DURATION\": [\"List of durations of events found in text\"],\n  \"SEX\": [\"List of sexes found in text\"],\n  \"AGE\": [\"List of ages found in text\"],\n  \"AMOUNT\" [\"List of quantities found in text\"]:,\n  \"ETHNIC GROUP\": [\"List of ethnic groups found in text\"],\n  \"PATHOLOGY\": [\"List of pathologies or side effects found in text\"],\n  \"TARGET\": [\"List of enzymes, transporters, ... found in text\"],\n  \"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"
}